Osimertinib or Platinumâ€“Pemetrexed in EGFR

New England Journal of Medicine
376, 629-640
DOI: 10.1056/nejmoa1612674

Citation Report

#	Article	IF	Citations
1	Les cancers bronchiques non Ã petites cellules EGFR-mutÃ©s. Revue Des Maladies Respiratoires Actualites, 2016, 8, 373-381.	0.0	1
2	Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 151-163.	0.9	10
3	Osimertinib for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 225-231.	0.9	4
4	Tackling the Next Generation of Resistance in EGFR -Mutant Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 419-421.	0.5	4
5	Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer, 2017, 17, 223-238.	12.8	1,786
7	Molecular mechanisms of therapy resistance in solid tumors: chasing â€œmovingâ€•targets. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 155-164.	1.4	12
8	Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells. Toxicology and Applied Pharmacology, 2017, 321, 18-26.	1.3	51
9	EGFR inhibition in NSCLC: New findingsâ€¦. and opened questions?. Critical Reviews in Oncology/Hematology, 2017, 112, 126-135.	2.0	22
10	A Neuro-oncologistâ€™s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer. Current Treatment Options in Oncology, 2017, 18, 22.	1.3	17
11	Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation. Lancet Respiratory Medicine,the, 2017, 5, 369-370.	5.2	0
12	Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing. International Journal of Oncology, 2017, 50, 1579-1589.	1.4	16
13	Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. Lung Cancer, 2017, 108, 238-241.	0.9	62
14	Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report. Molecular and Clinical Oncology, 2017, 6, 525-528.	0.4	11
15	Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Annals of Oncology, 2017, 28, 1532-1539.	0.6	239
16	Lung carcinogenesis and fibrosis taken together. Current Opinion in Pulmonary Medicine, 2017, 23, 290-297.	1.2	5
17	Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clinical Cancer Research, 2017, 23, 4716-4723.	3.2	102
18	The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M. MedChemComm, 2017, 8, 820-822.	3.5	33
19	Genomic Profiling of Advanced Nonâ€“Small Cell Lung Cancer in Community Settings: Gaps and Opportunities. Clinical Lung Cancer, 2017, 18, 651-659.	1.1	164

#	Article	IF	Citations
20	Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure. Lung Cancer, 2017, 109, 89-91.	0.9	16
21	Osimertinib administration via nasogastric tube in an EGFR-T790M-positive patient with leptomeningeal metastases. Respirology Case Reports, 2017, 5, e00241.	0.3	7
22	Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. Journal of Hematology and Oncology, 2017, 10, 100.	6.9	28
24	Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. Clinical Lung Cancer, 2017, 18, 698-705.e2.	1.1	29
25	Treatment of KRAS-Mutant Nonâ€“Small Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1835.	3.8	12
26	AJRCCM: 100-Y<scp>ear</scp> A<scp>nniversary</scp>.The Shifting Landscape for Lung Cancer: Past, Present, and Future. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1150-1160.	2.5	75
27	Efficacy and safety of osimertinib in a Japanese compassionate use program. Japanese Journal of Clinical Oncology, 2017, 47, 625-629.	0.6	12
28	Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer, 2017, 110, 7-13.	0.9	40
29	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. Targeted Oncology, 2017, 12, 563-569.	1.7	71
30	Osimertinib in EGFR T790Mâ€“Positive Lung Cancer. New England Journal of Medicine, 2017, 376, 1992-1994.	13.9	31
31	Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Nonâ€“Small-Cell Lung Cancer With Brain Metastases. JAMA Oncology, 2017, 3, 1274.	3.4	46
32	Successful Treatment with Gefitinib in Advanced Nonâ€“Small Cell Lung Cancer after Acquired Resistance to Osimertinib. Journal of Thoracic Oncology, 2017, 12, e78-e80.	0.5	27
33	A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusionâ€“Positive Solid Tumors. Cancer Discovery, 2017, 7, 963-972.	7.7	331
34	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies ofÂOsimertinib. Journal of Thoracic Oncology, 2017, 12, 1247-1256.	0.5	48
35	Plasma genotyping in patients with non-small-cell lung cancer: simplifying or confusing the diagnosis?. Lung Cancer Management, 2017, 6, 29-37.	1.5	0
36	Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clinical Cancer Research, 2017, 23, 5101-5111.	3.2	126
37	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutationâ€“Positive Nonsquamous Nonâ€“Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. Clinical Lung Cancer, 2017, 18, 719-723.	1.1	13
38	A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R. Journal of Thoracic Oncology, 2017, 12, 1368-1375.	0.5	79

#	Article	IF	Citations
39	Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer. Investigational New Drugs, 2017, 35, 848-850.	1.2	12
40	Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology, 2017, 12, 1183-1209.	0.5	40
41	Application of Plasma Genotyping Technologies in Nonâ€“Small Cell Lung Cancer: A Practical Review. Journal of Thoracic Oncology, 2017, 12, 1344-1356.	0.5	81
42	What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?. European Journal of Cancer, 2017, 81, 66-73.	1.3	56
43	Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 387-404.	1.4	30
44	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs, 2017, 77, 813-827.	4.9	42
45	Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. Handbook of Experimental Pharmacology, 2017, 249, 63-89.	0.9	10
46	Emerging concepts in liquid biopsies. BMC Medicine, 2017, 15, 75.	2.3	211
47	Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy. Patient, 2017, 10, 593-603.	1.1	9
48	The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR -mutant NSCLC Patients. EORTC 1613. Clinical Lung Cancer, 2017, 18, 583-588.	1.1	84
49	AURA3 magic reveals new standard. Nature Reviews Clinical Oncology, 2017, 14, 69-69.	12.5	5
50	Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews Cancer, 2017, 17, 637-658.	12.8	679
52	AZD3759 for CNS metastases in EGFR-mutant lung cancer. Lancet Respiratory Medicine,the, 2017, 5, 841-842.	5.2	3
53	Response to Osimertinib in Choroidal Metastases from EGFRmt T790Mâ€“Positive Nonâ€“Small Cell LungÂAdenocarcinoma. Journal of Thoracic Oncology, 2017, 12, e165-e167.	0.5	11
54	Novel Mutation Pair L858M/L861Q Caused Resistance to Both First- and Third-Generation EGFR Inhibitors, but Was Found to Be Sensitive to the Combination of Lapatinib and Erbitux. Journal of Thoracic Oncology, 2017, 12, e169-e170.	0.5	1
55	Osimertinib for EpidermalÂGrowth Factor Receptor Mutationâ€“Positive Lung Adenocarcinoma ThatÂTransformed to T790M-Positive SquamousÂCell Carcinoma. Journal of Thoracic Oncology, 2017, 12, e167-e169.	0.5	12
56	Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). Lung Cancer, 2017, 113, 79-84.	0.9	12
57	The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance. Molecular Cancer Therapeutics, 2017, 16, 2668-2676.	1.9	26

#	Article	IF	Citations
58	Osimertinib induced bullous dermatitis. Cancer Treatment and Research Communications, 2017, 13, 25-26.	0.7	1
59	Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors. Radiology and Oncology, 2017, 51, 241-251.	0.6	3
60	Treatment choice in EGFR-mutant non-small-cell lung cancer. Lancet Oncology, The, 2017, 18, 1425-1426.	5.1	6
61	Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO Open, 2017, 2, e000214.	2.0	30
62	Gefitinib: an â€œorphanâ€•drug for non-small cell lung cancer. Expert Opinion on Orphan Drugs, 2017, 5, 899-906.	0.5	2
65	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respiratory Medicine,the, 2017, 5, 891-902.	5.2	92
66	Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead. Annals of Oncology, 2017, 28, 2923-2931.	0.6	46
67	Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Annals of Oncology, 2017, 28, 2698-2706.	0.6	77
68	Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology, 2017, 80, 1179-1187.	1.1	24
69	Cancer: Towards a general theory of the target. BioEssays, 2017, 39, 1700059.	1.2	2
70	Targeted Therapy and Imaging Findings. Journal of Thoracic Imaging, 2017, 32, 313-322.	0.8	10
71	T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 2563-2571.	1.9	19
72	Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance. Molecular Cancer Therapeutics, 2017, 16, 2572-2585.	1.9	26
73	T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis. Journal of Thoracic Oncology, 2017, 12, e138-e139.	0.5	5
74	Precision Diagnosis and Treatment for Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 849-861.	13.9	578
75	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. Pharmacoeconomics, 2017, 35, 1195-1209.	1.7	16
76	Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1728-1732.	0.5	143
77	An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma. Expert Opinion on Emerging Drugs, 2017, 22, 213-222.	1.0	6

#	Article	IF	Citations
78	EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. Medical Oncology, 2017, 34, 175.	1.2	5
79	Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. Acta Pharmacologica Sinica, 2017, 38, 1512-1520.	2.8	56
80	Brain metastases in patients with EGFR -mutant non-small-cell lung cancer. Lancet Respiratory Medicine,the, 2017, 5, 669-671.	5.2	4
81	Programmed death-ligand 1 expression and T790M status in EGFR -mutant non-small cell lung cancer. Lung Cancer, 2017, 111, 182-189.	0.9	30
82	Epithelialâ€toâ€mesenchymal transition and its role in EGFRâ€mutant lung adenocarcinoma and idiopathic pulmonary fibrosis. Pathology International, 2017, 67, 379-388.	0.6	36
83	Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer. Targeted Oncology, 2017, 12, 555-562.	1.7	41
84	Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 296-303.	0.7	15
85	Liquid Biopsy in Cancer Patients. Current Clinical Pathology, 2017, , .	0.0	6
86	Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC). Current Clinical Pathology, 2017, , 103-115.	0.0	4
87	Large Cell Neuroendocrine Carcinoma Transformation and EGFR -T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. Mayo Clinic Proceedings, 2017, 92, 1304-1311.	1.4	24
88	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. Journal of Thoracic Oncology, 2017, 12, 1588-1594.	0.5	21
89	Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens. Journal of Thoracic Oncology, 2017, 12, 1503-1511.	0.5	49
90	Analysis of Plasma Epsteinâ€“Barr Virus DNA to Screen for Nasopharyngeal Cancer. New England Journal of Medicine, 2017, 377, 513-522.	13.9	531
91	Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. Expert Review of Respiratory Medicine, 2017, 11, 791-805.	1.0	4
92	Novel therapeutic agents in the management of brain metastases. Current Opinion in Oncology, 2017, 29, 395-399.	1.1	6
93	Current Landscape of Targeted Therapy in Lung Cancer. Clinical Pharmacology and Therapeutics, 2017, 102, 757-764.	2.3	134
95	Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 1997-1999.	13.9	17
96	Cardiac Dysfunction Caused by Osimertinib. Journal of Thoracic Oncology, 2017, 12, e159-e160.	0.5	24

#	Article	IF	Citations
97	Resistance in trans-ition. Journal of Thoracic Oncology, 2017, 12, 1608-1610.	0.5	2
98	Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1281-1288.	1.5	8
99	Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid. Lung Cancer, 2017, 114, 111-112.	0.9	7
100	EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. Cancer Letters, 2017, 403, 186-194.	3.2	27
101	Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations. Journal of Thoracic Oncology, 2017, 12, 1388-1397.	0.5	49
102	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. Expert Review of Anticancer Therapy, 2017, 17, 779-786.	1.1	27
105	Recent advances in targeted advanced lung cancer therapy in the elderly. Expert Review of Anticancer Therapy, 2017, 17, 787-797.	1.1	13
106	Osimertinib-related skin and mucosal adverse events. Cancer Treatment and Research Communications, 2017, 12, 53-55.	0.7	1
107	Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer. Future Oncology, 2017, 13, 1829-1833.	1.1	7
108	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens. European Respiratory Review, 2017, 26, 170007.	3.0	74
109	Les cancers bronchiques non Ã petites cellules EGFR-mutÃ©s. Revue Des Maladies Respiratoires Actualites, 2017, 9, 213-223.	0.0	0
110	Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden. Kidney Cancer, 2017, 1, 65-70.	0.2	36
111	Current progress and outcomes of clinical trials on using epidermal growth factor receptorâ€tyrosine kinase inhibitor therapy in nonâ€small cell lung cancer patients with brain metastases. Chronic Diseases and Translational Medicine, 2017, 3, 221-229.	0.9	4
113	EANOâ€“ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Annals of Oncology, 2017, 28, iv84-iv99.	0.6	331
114	Efficacy of osimertinib in a patient with nonâ€‘small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status. Molecular and Clinical Oncology, 2017, 8, 246-249.	0.4	6
116	Can intercalating chemotherapy with epidermal growth factor receptor inhibitors delay development of treatment resistance in advanced non-small cell lung cancer?. Expert Opinion on Pharmacotherapy, 2017, 18, 1899-1902.	0.9	1
118	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. Ecancermedicalscience, 2017, 11, 787.	0.6	34
119	Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib. The Application of Clinical Genetics, 2017, Volume 10, 49-56.	1.4	25

#	Article	IF	Citations
120	Circulating DNA in EGFR-mutated lung cancer. Annals of Translational Medicine, 2017, 5, 379-379.	0.7	24
121	Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective. Current Oncology, 2017, 24, 111-119.	0.9	19
122	ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers, 2017, 9, 33.	1.7	25
123	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Frontiers in Medicine, 2017, 4, 39.	1.2	18
124	Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 113.	1.3	46
125	Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: â€œMTDâ€•or â€œALARAâ€?. Frontiers in Oncology, 2017, 7, 205.	1.3	9
126	Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer. Internal Medicine, 2017, 56, 2325-2328.	0.3	12
127	Kinase-Centric Computational Drug Development. Annual Reports in Medicinal Chemistry, 2017, , 197-236.	0.5	9
128	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. BioMed Research International, 2017, 2017, 1-7.	0.9	13
129	Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. Journal of Oncology, 2017, 2017, 1-5.	0.6	20
130	Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature. Lung Cancer: Targets and Therapy, 2017, Volume 8, 241-247.	1.3	12
131	Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives. Lung Cancer: Targets and Therapy, 2017, Volume 8, 45-55.	1.3	25
132	Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC. OncoTargets and Therapy, 2017, Volume 10, 3307-3312.	1.0	11
133	AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?. Annals of Translational Medicine, 2017, 5, S14-S14.	0.7	5
134	Adenocarcinoma of the lung with EGFR gene mutation and subsequent resistance mechanisms exploration: case report. OncoTargets and Therapy, 2017, Volume 10, 4517-4525.	1.0	1
135	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer: Targets and Therapy, 2017, Volume 8, 109-125.	1.3	49
136	The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer. Oncotarget, 2017, 8, 71358-71370.	0.8	51
137	Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer. PLoS ONE, 2017, 12, e0183319.	1.1	26

#	Article	IF	Citations
138	Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma. PLoS ONE, 2017, 12, e0183331.	1.1	24
139	Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report. Case Reports in Oncology, 2017, 10, 666-670.	0.3	3
140	Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms. Tumori, 2017, 103, 325-337.	0.6	12
141	Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review. Journal of Hematology and Oncology, 2017, 10, 147.	6.9	18
142	Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. Journal of Experimental and Clinical Cancer Research, 2017, 36, 174.	3.5	70
143	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. Genome Medicine, 2017, 9, 89.	3.6	39
145	Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. Oncotarget, 2017, 8, 90557-90578.	0.8	34
146	Targeted therapy for leptomeningeal metastases in non-small cell lung cancer â€“ Changing treatment paradigms. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 535-542.	0.7	10
147	EGFR T790M: revealing the secrets of a gatekeeper. Lung Cancer: Targets and Therapy, 2017, Volume 8, 147-159.	1.3	23
148	Osimertinib â€“ effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors. Wspolczesna Onkologia, 2017, 3, 254-258.	0.7	8
149	PUMA mediates the anti-cancer effect of osimertinib in colon cancer cells. OncoTargets and Therapy, 2017, Volume 10, 5281-5288.	1.0	11
150	Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. OncoTargets and Therapy, 2017, Volume 10, 2289-2295.	1.0	19
151	EGFR G796D mutation mediates resistance to osimertinib. Oncotarget, 2017, 8, 49671-49679.	0.8	90
152	Recent advances in the biology and therapy of medullary thyroid carcinoma. F1000Research, 2017, 6, 2184.	0.8	18
153	Future Genetic/Genomic Biomarker Testing in Nonâ€“Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 12-17.	1.8	3
154	Managing Resistance to EFGR- and ALK-Targeted Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 607-618.	1.8	16
155	Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. Journal of Clinical Oncology, 2017, 35, 4027-4034.	0.8	141
156	Systemic Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. Journal of Oncology Practice, 2017, 13, 832-837.	2.5	70

#	Article	IF	Citations
157	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNAâ€“Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. JCO Precision Oncology, 2017, 1, 1-15.	1.5	31
158	Liquid biopsies in lung cancerâ€”time to implement research technologies in routine care?. Annals of Translational Medicine, 2017, 5, 278-278.	0.7	27
159	EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget, 2017, 8, 75712-75726.	0.8	119
160	Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget, 2017, 8, 114371-114392.	0.8	96
161	Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naÃ¯ve patients with nonâ€“small cell lung cancer harboring EGFR mutations. Oncotarget, 2017, 8, 68123-68130.	0.8	63
162	Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration. Journal of Thoracic Disease, 2017, 9, S405-S409.	0.6	11
163	Cell free DNA analysis by SiReÂ® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. Journal of Thoracic Disease, 2017, 9, S1383-S1390.	0.6	39
164	Possible application of circulating free tumor DNA in non-small cell lung cancer patients. Journal of Thoracic Disease, 2017, 9, S1364-S1372.	0.6	13
165	Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapyâ€”opportunities and challenges. Journal of Thoracic Disease, 2017, 9, 3385-3393.	0.6	13
166	EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome. Journal of Thoracic Disease, 2017, 9, 4208-4211.	0.6	10
167	Blood-based tumor biomarkers in lung cancer for detection and treatment. Translational Lung Cancer Research, 2017, 6, 648-660.	1.3	51
168	The rapidly evolving treatment landscape for patients with brain metastases from epidermal growth factor receptor mutated non-small cell lung cancer. Translational Lung Cancer Research, 2017, 6, S55-S57.	1.3	0
169	Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI. Journal of Thoracic Disease, 2017, 9, 470-473.	0.6	2
170	New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA. Journal of Thoracic Disease, 2017, 9, S1332-S1345.	0.6	13
171	Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, S1359-S1363.	0.6	3
172	Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer. Translational Lung Cancer Research, 2017, 6, S62-S66.	1.3	10
173	Urine test for EGFR analysis in patients with non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, S1323-S1331.	0.6	19
174	Prof. Yun Fan: persistence guarantees expertise, patience conquers difficulties. Journal of Thoracic Disease, 2017, 9, S1162-S1167.	0.6	0

#	Article	IF	Citations
175	Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. Translational Lung Cancer Research, 2017, 6, S21-S34.	1.3	9
176	Raising the bar: the future of EGFR inhibition in non-small lung cancer. Translational Lung Cancer Research, 2017, 6, S58-S61.	1.3	0
177	Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. Lung Cancer, 2018, 118, 105-110.	0.9	53
178	Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treatment Reviews, 2018, 65, 1-10.	3.4	225
179	Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer. Annals of Oncology, 2018, 29, i28-i37.	0.6	95
180	Genetic profiling of cancer with circulating tumor DNA analysis. Journal of Genetics and Genomics, 2018, 45, 79-85.	1.7	26
181	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2018, 17, 740-750.	1.9	27
182	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Archives of Pathology and Laboratory Medicine, 2018, 142, 1242-1253.	1.2	120
183	Case sharing of a patient reâ€challenged with afatinib for EGFRâ€mutated advanced nonâ€“small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 4-6.	0.7	2
184	PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy. Bioorganic and Medicinal Chemistry, 2018, 26, 1609-1613.	1.4	7
185	Imaging on Lung Cancer and Treatment with Targeted Therapy. Seminars in Ultrasound, CT and MRI, 2018, 39, 308-313.	0.7	1
186	EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib. Journal of Thoracic Oncology, 2018, 13, 727-731.	0.5	39
187	Management of acquired resistance to EGFR TKIâ€“targeted therapy in advanced non-small cell lung cancer. Molecular Cancer, 2018, 17, 38.	7.9	489
188	A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations. Medical Oncology, 2018, 35, 34.	1.2	10
189	Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment. Cancer Letters, 2018, 423, 9-15.	3.2	38
190	Osimertinib in patients with epidermal growth factor receptor T790M advanced nonâ€small cell lung cancer selected using cytology samples. Cancer Science, 2018, 109, 1177-1184.	1.7	10
191	Treatment of Advanced Nonâ€“Small Cell Lung Cancer in 2018. JAMA Oncology, 2018, 4, 569.	3.4	82
192	Cell-Free Plasma DNA-Guided Treatment WithÂOsimertinib in Patients With Advanced EGFR-Mutated NSCLC. Journal of Thoracic Oncology, 2018, 13, 821-830.	0.5	53

#	Article	IF	Citations
193	The Evolving Landscape of Brain Metastasis. Trends in Cancer, 2018, 4, 176-196.	3.8	194
194	Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Nonâ€“Small Cell Lung Cancer Patients. Clinical Cancer Research, 2018, 24, 3097-3107.	3.2	357
195	How to Design Phase I Trials in Oncology. , 2018, , 165-187.		0
196	First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Nonâ€“Small CellÂLung Cancer: Safety, Efficacy, and PotentialÂMechanism of Resistance. Journal of Thoracic Oncology, 2018, 13, 968-977.	0.5	50
197	Osimertinib for an older de novo T790M patient with chronic kidney disease. Geriatrics and Gerontology International, 2018, 18, 503-504.	0.7	5
199	Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors. Biochemical Pharmacology, 2018, 152, 327-337.	2.0	27
200	Targeted Therapy and Immunotherapy in the Treatment of Nonâ€“Small Cell Lung Cancer. Radiologic Clinics of North America, 2018, 56, 485-495.	0.9	61
201	Cell-Free DNA Utility and Value of Recommendation. Archives of Pathology and Laboratory Medicine, 2018, 142, 785-786.	1.2	0
202	Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1079-1086.	1.2	7
203	Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring. Lab on A Chip, 2018, 18, 1320-1329.	3.1	48
204	Improving therapy for patients with epidermal growth factor receptorâ€mutant lung cancer. Cancer, 2018, 124, 2272-2275.	2.0	1
205	Molecular Testing for Stage IV Nonâ€“Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression. Archives of Pathology and Laboratory Medicine, 2018, 142, 799-800.	1.2	0
206	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. Oncologist, 2018, 23, 1199-1209.	1.9	42
207	Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. Oncologist, 2018, 23, 891-899.	1.9	36
209	Clinical utility of non-EpCAM based circulating tumor cell assays. Advanced Drug Delivery Reviews, 2018, 125, 132-142.	6.6	26
210	Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?. Lung Cancer, 2018, 117, 27-31.	0.9	13
211	Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib. Lung Cancer, 2018, 118, 1-5.	0.9	63
212	Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival. Pathology Research and Practice, 2018, 214, 335-342.	1.0	11

#	Article	IF	Citations
213	Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. Critical Reviews in Oncology/Hematology, 2018, 123, 149-161.	2.0	50
214	Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Annals of Oncology, 2018, 29, i10-i19.	0.6	449
215	Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Annals of Oncology, 2018, 29, i20-i27.	0.6	159
216	Targeting EGFR^{L858R/T790M} and EGFR^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry. Medicinal Research Reviews, 2018, 38, 1550-1581.	5.0	113
217	The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. British Journal of Clinical Pharmacology, 2018, 84, 1156-1169.	1.1	47
218	Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401775333.	1.4	41
219	Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. Future Oncology, 2018, 14, 1477-1486.	1.1	14
220	Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. International Journal of Clinical Oncology, 2018, 23, 443-451.	1.0	10
221	Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?. Future Oncology, 2018, 14, 1117-1132.	1.1	89
222	Established, emerging and elusive molecular targets in the treatment of lung cancer. Journal of Pathology, 2018, 244, 565-577.	2.1	15
223	MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. Scientific Reports, 2018, 8, 1955.	1.6	34
224	Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC. Annals of Oncology, 2018, 29, 789-791.	0.6	9
225	Heterogeneityâ€based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report. Thoracic Cancer, 2018, 9, 498-501.	0.8	3
226	Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer. Targeted Oncology, 2018, 13, 141-156.	1.7	17
227	Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Letters, 2018, 420, 242-246.	3.2	102
228	Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. European Journal of Cancer, 2018, 91, 92-98.	1.3	30
229	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.4	
230	Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Lung Cancer, 2018, 117, 14-19.	0.9	63

#	Article	IF	Citations
231	Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas. Pancreas, 2018, 47, 142-157.	0.5	19
232	The biology and management of non-small cell lung cancer. Nature, 2018, 553, 446-454.	13.7	2,877
233	Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for nonâ€“small cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 267-276.	1.1	14
234	Molecular Imaging in Cancer Drug Development. Journal of Nuclear Medicine, 2018, 59, 726-732.	2.8	50
235	Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) â€“ Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy. Pathology and Oncology Research, 2018, 24, 723-731.	0.9	21
236	Second-Line Treatment Options in Nonâ€“Small-CellÂLung Cancer: Report From anÂInternational Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2018, 19, 301-314.	1.1	7
237	Network science in clinical trials: A patient-centered approach. Seminars in Cancer Biology, 2018, 52, 135-150.	4.3	9
239	Progress in the Management of Advanced Thoracic Malignancies in 2017. Journal of Thoracic Oncology, 2018, 13, 301-322.	0.5	43
240	Changing health care costs for NSCLC, what does it mean?. Lung Cancer, 2018, 117, 62-63.	0.9	2
241	Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma. Respiratory Medicine Case Reports, 2018, 23, 68-70.	0.2	15
242	Response to Stephane Renaud et al.. Radiotherapy and Oncology, 2018, 129, 188-189.	0.3	0
243	Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncology, The, 2018, 19, e43-e55.	5.1	201
244	Cost-Effectiveness of Osimertinib for EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy. Journal of Thoracic Oncology, 2018, 13, 184-193.	0.5	56
245	Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clinical Drug Investigation, 2018, 38, 319-331.	1.1	14
246	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews, 2018, 118, 1599-1663.	23.0	64
247	Will liquid biopsies become our fluid transition to personalized immunotherapy?. Annals of Oncology, 2018, 29, 11-13.	0.6	7
248	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774501.	1.4	101
249	High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. Lung Cancer, 2018, 117, 1-6.	0.9	46

#	Article	IF	Citations
250	Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration. Advanced Drug Delivery Reviews, 2018, 125, 122-131.	6.6	21
251	Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. Cancer Letters, 2018, 418, 1-9.	3.2	61
252	KEYNOTE-024: Unlocking a pathway to lung cancer cure?. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1777-1780.	0.4	10
253	Osimertinib as First-Line Treatment in EGFR-Mutated Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 192-193.	13.9	47
254	Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma. Journal of Molecular Diagnostics, 2018, 20, 184-194.	1.2	35
255	CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Annals of Oncology, 2018, 29, 687-693.	0.6	193
256	Targeting HER2 Aberrations in Nonâ€“Small Cell Lung Cancer with Osimertinib. Clinical Cancer Research, 2018, 24, 2594-2604.	3.2	85
257	Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report. Investigational New Drugs, 2018, 36, 952-954.	1.2	13
258	Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies. Oncologist, 2018, 23, 1063-1075.	1.9	10
259	Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib. Medicine (United States), 2018, 97, e0650.	0.4	13
260	Recent progress in systemic treatment for lung cancer. Current Opinion in Pulmonary Medicine, 2018, 24, 355-366.	1.2	10
261	Simple Determination of Plasma Ponatinib Concentration Using HPLC. Biological and Pharmaceutical Bulletin, 2018, 41, 254-258.	0.6	17
262	Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. Lung Cancer, 2018, 121, 12-17.	0.9	23
263	Efficacy of thoracic radiotherapy in patients with stage IIIBâ€“IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment. Radiotherapy and Oncology, 2018, 129, 52-60.	0.3	32
264	Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology. Journal of Visualized Experiments, 2018, , .	0.2	3
265	Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease. Targeted Oncology, 2018, 13, 269-285.	1.7	46
266	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Journal of Thoracic Oncology, 2018, 13, 810-820.	0.5	29
267	Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas. Cancer, 2018, 124, 2399-2406.	2.0	19

#	Article	IF	Citations
268	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. Lung Cancer, 2018, 119, 36-41.	0.9	7
269	Exosome-Based Detection of EGFR T790M in Plasma from Nonâ€“Small Cell Lung Cancer Patients. Clinical Cancer Research, 2018, 24, 2944-2950.	3.2	157
270	A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy. Clinical Cancer Research, 2018, 24, 3583-3592.	3.2	151
271	Subjecting appropriate lung adenocarcinoma samples to nextâ€generation sequencingâ€based molecular testing: challenges and possible solutions. Molecular Oncology, 2018, 12, 677-689.	2.1	20
272	Circulating tumor DNA testing in advanced non-small cell lung cancer. Lung Cancer, 2018, 119, 42-47.	0.9	31
273	Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. Lab on A Chip, 2018, 18, 1174-1196.	3.1	234
274	Management of epidermal growth factor receptor tyrosine kinase inhibitorâ€related cutaneous and gastrointestinal toxicities. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 23-31.	0.7	43
275	Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. Journal of Oncology Pharmacy Practice, 2018, 24, 379-388.	0.5	46
276	An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. Clinical Lung Cancer, 2018, 19, 42-50.	1.1	6
277	Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Nonâ€“Small-Cell Lung CancerÂ(NSCLC). Clinical Lung Cancer, 2018, 19, e19-e28.	1.1	17
278	Retreatment With Osimertinib Following Pneumonitis. Clinical Lung Cancer, 2018, 19, e53-e55.	1.1	16
279	Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review. Clinical Lung Cancer, 2018, 19, e63-e66.	1.1	50
280	Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment. PET Clinics, 2018, 13, 33-42.	1.5	2
281	Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discovery Today, 2018, 23, 745-753.	3.2	99
282	Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790ÂM Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment. Pathology and Oncology Research, 2018, 24, 843-851.	0.9	15
283	Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. Journal of Medical Economics, 2018, 21, 113-121.	1.0	30
284	First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790Mâ€“Mutant Metastatic NSCLC. Journal of Thoracic Oncology, 2018, 13, e3-e5.	0.5	14
285	Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. Lung Cancer, 2018, 115, 21-27.	0.9	87

#	Article	IF	Citations
286	The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Nonâ€Smallâ€Cell Lung Cancer and in Healthy Volunteers. Journal of Clinical Pharmacology, 2018, 58, 474-484.	1.0	41
287	Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. Immunotherapy, 2018, 10, 93-105.	1.0	86
288	Molecular Diagnosis and Targeting for Lung Cancer. Current Human Cell Research and Applications, 2018, , 1-32.	0.1	0
289	Pharmacogenomic Biomarkers for Improved Drug Therapyâ€"Recent Progress and Future Developments. AAPS Journal, 2018, 20, 4.	2.2	106
290	An oligoclonal antibody durably overcomes resistance of lung cancer to thirdâ€generation <scp>EGFR</scp> inhibitors. EMBO Molecular Medicine, 2018, 10, 294-308.	3.3	46
291	Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study. Journal of Clinical Pharmacology, 2018, 58, 504-513.	1.0	20
292	Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respiratory Medicine,the, 2018, 6, 107-116.	5.2	121
293	FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. Oncologist, 2018, 23, 353-359.	1.9	52
294	Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. British Journal of Cancer, 2018, 118, 32-37.	2.9	71
295	Personalized medicine for non-small cell lung cancer: where are we now and where can we go?. Expert Review of Respiratory Medicine, 2018, 12, 81-82.	1.0	5
296	Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance. Journal of Cell Communication and Signaling, 2018, 12, 133-141.	1.8	47
297	Giant steps and stumbling blocks. Nature Reviews Clinical Oncology, 2018, 15, 71-72.	12.5	18
299	Thoracic Immunotherapy. Current Cancer Research, 2018, , 281-305.	0.2	0
300	Detection and monitoring of driver mutations by nextâ€generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation <scp>EGFRâ€tyrosine kinase inhibitors</scp>. Thoracic Cancer, 2018, 9, 181-184.	0.8	1
301	Osimertinib in UntreatedEGFR-Mutated Advanced Nonâ€"Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 113-125.	13.9	3,530
302	Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing. Clinical Lung Cancer, 2018, 19, 163-169.e4.	1.1	11
303	Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Nonâ€"small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e247-e252.	1.1	41
304	Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. JCO Precision Oncology, 2018, 2, 1-12.	1.5	60

#	Article	IF	Citations
305	Have We Really MET a New Target?. Journal of Clinical Oncology, 2018, 36, 3069-3071.	0.8	7
306	Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer. Oncotarget, 2018, 9, 37520-37533.	0.8	7
307	Sequencing Therapy for Genetically Defined Subgroups of Nonâ€“Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 726-739.	1.8	13
308	Precision Medicine in Nonâ€“Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 708-715.	1.8	30
309	CNS Metastases in Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer: Impact on Health Resource Utilization. Journal of Oncology Practice, 2018, 14, e612-e620.	2.5	8
310	Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 873-880.	1.8	6
311	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of Clinical Oncology, 2018, 36, 1631-1641.	0.8	668
312	Liquid Biopsy to Identify Actionable Genomic Alterations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 978-997.	1.8	54
313	Osimertinib As First-Line Treatment of EGFR Mutationâ€“Positive Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 841-849.	0.8	423
314	Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer: The AURA3 Trial. Journal of Clinical Oncology, 2018, 36, 1853-1860.	0.8	32
315	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Nonâ€“Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). Journal of Clinical Oncology, 2018, 36, 2702-2709.	0.8	359
316	Hemorrhage of a pancreatic metastasis from lung adenocarcinoma after osimertinib therapy. Journal of Thoracic Disease, 2018, 10, E686-E689.	0.6	5
317	The continued EGFR-TKI with cytotoxic chemotherapy at progressionâ€”poison or medicine?. Translational Lung Cancer Research, 2018, 7, S176-S178.	1.3	2
318	Lung cancer in never smokersâ€”the East Asian experience. Translational Lung Cancer Research, 2018, 7, 450-463.	1.3	104
319	Combined exosomal RNA and circulating tumor DNA for epidermal growth factor mutation detection in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S4023-S4027.	0.6	6
320	Circulating tumor DNA analysis in patients with EGFR mutant lung cancer. Journal of Thoracic Disease, 2018, 10, S4061-S4064.	0.6	2
321	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. Journal of Thoracic Disease, 2018, 10, 3909-3921.	0.6	35
322	Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients. Journal of Thoracic Disease, 2018, 10, 5904-5912.	0.6	17

#	Article	IF	Citations
323	Immunotherapy in tyrosine kinase inhibitor-naÃ¯ve advanced epidermal growth factor receptor-mutant non-small cell lung cancerâ€"driving down a precarious road in driver-mutated lung cancer. Translational Lung Cancer Research, 2018, 7, S377-S380.	1.3	3
324	Oncogene-addicted non-small cell lung cancer and immunotherapy. Journal of Thoracic Disease, 2018, 10, S1547-S1555.	0.6	25
325	Moving osimertinib to first-line: the right â€œstrategyâ€•in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?. Journal of Thoracic Disease, 2018, 10, S1076-S1080.	0.6	5
326	Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine. Journal of Thoracic Disease, 2018, 10, 1364-1369.	0.6	6
327	First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC. Translational Lung Cancer Research, 2018, 7, S127-S130.	1.3	2
328	Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S165-S170.	1.3	14
329	Osimertinib in first line setting: preventive or delayed T790M occurrence?. Translational Lung Cancer Research, 2018, 7, S187-S190.	1.3	5
330	EGFR targeted therapy for lung cancer: are we almost there?. Translational Lung Cancer Research, 2018, 7, S142-S145.	1.3	7
331	Liquid biopsy guided precision therapy for lung cancers. Journal of Thoracic Disease, 2018, 10, S4173-S4175.	0.6	3
332	Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine. Translational Lung Cancer Research, 2018, 7, S312-S317.	1.3	1
333	A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors. Journal of Thoracic Disease, 2018, 10, E739-E743.	0.6	1
334	Choosing the Best EGFR TKI in the Era of Precision Medicine. Journal of Oncology Translational Research, 2018, 04, .	0.2	0
335	Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. Cancer Biotherapy and Radiopharmaceuticals, 2018, 33, 421-426.	0.7	3
336	Targeting the miR-630/YAP1/ERK feedback loop in epidermal growth factor receptor-mutated lung adenocarcinomas. Journal of Thoracic Disease, 2018, 10, S4017-S4020.	0.6	0
337	Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial. Journal of Thoracic Disease, 2018, 10, S3071-S3077.	0.6	4
338	Single-cell analysis of tumors: Creating new value for molecular biomarker discovery of cancer stem cells and tumor-infiltrating immune cells. World Journal of Stem Cells, 2018, 10, 160-171.	1.3	12
339	Discrepancies between ALK protein disruption and occurrence of ALK gene rearrangement in Polish NSCLC patients. Journal of Thoracic Disease, 2018, 10, 4994-5009.	0.6	7
340	A Patient with a Massive Single Cardiac Metastasis of Lung Adenocarcinoma, Diagnosed via a Biopsy. Internal Medicine, 2018, 57, 1637-1640.	0.3	0

#	Article	IF	Citations
341	Safety and Efficacy of Osimertinib in the Treatment of a Patient With Metastatic Lung Cancer and Concurrent Somatic EGFR L858R and Germline EGFR T790M Mutations. JCO Precision Oncology, 2018, 2, 1-7.	1.5	2
342	Fundamental Concepts in the Application of Plasma Genotyping (Liquid Biopsy) to EGFR Mutation Detection in Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2018, 2, 1-12.	1.5	1
343	Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide. JCO Precision Oncology, 2018, 2, 1-14.	1.5	21
344	EGFR Primary T790M and L858R Double Mutation Confers Clinical Benefit to Erlotinib and Resistance to Osimertinib in One Lung Adenocarcinoma Patient: A Case Report. Journal of Cancer Science & Therapy, 2018, 10, .	1.7	2
346	Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors. Journal of Hematology and Oncology, 2018, 11, 129.	6.9	27
347	Receptor Tyrosine Kinase-Targeted Cancer Therapy. International Journal of Molecular Sciences, 2018, 19, 3491.	1.8	187
348	Exploration of resistance mechanisms for epidermal growth factor receptorâ€tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and nextâ€generation sequencing. Cancer Science, 2018, 109, 3921-3933.	1.7	27
349	Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells, 2018, 7, 212.	1.8	190
351	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS ONE, 2018, 13, e0208097.	1.1	17
352	Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR. BMC Cancer, 2018, 18, 1136.	1.1	12
353	Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. OncoTargets and Therapy, 2018, Volume 11, 7513-7519.	1.0	6
354	Afatinib in Advanced Pretreated Non-Small-Cell Lung Cancerâ€"A Canadian Experience. Current Oncology, 2018, 25, 385-390.	0.9	4
355	Safety of osimertinib in EGFR-mutated non-small cell lung cancer. Expert Opinion on Drug Safety, 2018, 17, 1239-1248.	1.0	25
356	Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790ÂM mutation. BMC Cancer, 2018, 18, 1070.	1.1	5
357	The Changing Paradigm of Treatment for Non-Small Cell Lung Cancer Intracranial Metastases. Current Pulmonology Reports, 2018, 7, 203-213.	0.5	2
358	The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. British Journal of Cancer, 2018, 119, 1252-1258.	2.9	39
359	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018, 9, 4655.	5.8	107
360	Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence. OncoTargets and Therapy, 2018, Volume 11, 9033-9047.	1.0	3

#	Article	IF	Citations
361	Nile Tilapia Derived TP4 Shows Broad Cytotoxicity Toward to Non-Small-Cell Lung Cancer Cells. Marine Drugs, 2018, 16, 506.	2.2	17
362	Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. BioScience Trends, 2018, 12, 537-552.	1.1	20
363	Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFRâ€'mutant Ba/F3 cells. Oncology Reports, 2018, 41, 1059-1066.	1.2	6
364	Mechanisms of acquired resistance to afatinib clarified with liquid biopsy. PLoS ONE, 2018, 13, e0209384.	1.1	25
365	The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. BMC Cancer, 2018, 18, 1241.	1.1	1
367	Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance. Oncotarget, 2018, 9, 15418-15434.	0.8	21
368	Les addictions oncogÃ©niques : du diagnostic au suivi. Revue Des Maladies Respiratoires Actualites, 2018, 10, 358-368.	0.0	0
369	Prise en charge thÃ©rapeutique des cancers bronchiques non Ã petites cellules de stades avancÃ©s mutÃ©s pour lâ€™EGFR. Revue Des Maladies Respiratoires Actualites, 2018, 10, 425-439.	0.0	1
371	Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC. Cancers, 2018, 10, 486.	1.7	11
372	Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer. Scientific Reports, 2018, 8, 14896.	1.6	31
373	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. OncoTargets and Therapy, 2018, Volume 11, 6189-6196.	1.0	47
374	Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discovery, 2018, 8, 1529-1539.	7.7	342
375	Early Detection and Chemoprevention of Lung Cancer. F1000Research, 2018, 7, 61.	0.8	19
376	A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Review of Anticancer Therapy, 2018, 18, 1249-1270.	1.1	164
377	Novel Systemic Treatments for Brain Metastases From Lung Cancer. Current Treatment Options in Neurology, 2018, 20, 48.	0.7	6
378	Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2018, 19, 58.	1.3	41
379	Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression. OncoTargets and Therapy, 2018, Volume 11, 5601-5605.	1.0	7
380	Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2457-2463.	1.2	8

#	Article	IF	Citations
383	Pulmonary Toxicities of Anticancer Treatment. , 2018, , 201-215.		0
384	Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?. Journal of Clinical Oncology, 2018, 36, 483-491.	0.8	151
385	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. BMJ Open, 2018, 8, e017240.	0.8	20
387	A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. Cancer Chemotherapy and Pharmacology, 2018, 82, 1031-1038.	1.1	18
388	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv192-iv237.	0.6	1,571
389	Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy. Journal of Physical Education and Sports Management, 2018, 4, a003269.	0.5	11
390	Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells. BMC Cancer, 2018, 18, 1028.	1.1	7
391	Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers. International Journal of Pharmaceutics, 2018, 553, 483-509.	2.6	54
392	EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer, 2018, 126, 133-138.	0.9	33
393	Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. Lung Cancer, 2018, 126, 149-155.	0.9	40
395	Efficacy of nanoâ€particulated, waterâ€soluble erlotinib against intracranial metastases of EGFR â€mutant lung cancer. Molecular Oncology, 2018, 12, 2182-2190.	2.1	9
396	Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. Journal of Thoracic Oncology, 2018, 13, 1625-1637.	0.5	10
397	Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661880865.	1.0	22
398	A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation. Medicine (United States), 2018, 97, e11569.	0.4	20
399	An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. Medicine (United States), 2018, 97, e12660.	0.4	0
401	Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death and Differentiation, 2018, 25, 1885-1904.	5.0	31
402	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. Cancer Treatment Reviews, 2018, 71, 47-58.	3.4	37
403	Biologie molÃ©culaire des carcinomes bronchiques : standards actuels et perspectives. Revue Francophone Des Laboratoires, 2018, 2018, 46-51.	0.0	1

#	Article	IF	Citations
404	Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncology, 2018, 14, 2861-2874.	1.1	90
405	Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis. Advances in Therapy, 2018, 35, 1905-1919.	1.3	9
406	Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors. Cancer Treatment Reviews, 2018, 71, 59-67.	3.4	39
407	Strategies to Preserve Cognition in Patients With Brain Metastases: A Review. Frontiers in Oncology, 2018, 8, 415.	1.3	24
408	Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada. Lung Cancer, 2018, 125, 1-7.	0.9	30
409	The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations. Translational Lung Cancer Research, 2018, 7, S134-S137.	1.3	7
410	T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas HarboringEGFRMutations. In Vivo, 2018, 32, 1199-1204.	0.6	9
411	Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma. Cancer Science, 2018, 109, 3326-3335.	1.7	32
412	Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFRâ€mutant nonâ€“small cell lung cancer: Multicenter, singleâ€arm, phase 2 trial (ABC Study). Cancer, 2018, 124, 3830-3838.	2.0	37
413	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. Scientific Reports, 2018, 8, 13379.	1.6	66
415	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clinical Cancer Research, 2018, 24, 6195-6203.	3.2	292
416	Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining. Lung Cancer, 2018, 124, 241-247.	0.9	5
417	The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1705-1716.	0.5	38
418	Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma. Journal of Clinical Pathology, 2018, 71, 1108-1115.	1.0	33
419	Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study. Clinical Lung Cancer, 2018, 19, e871-e874.	1.1	10
420	Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment. Anticancer Research, 2018, 38, 5231-5237.	0.5	20
421	Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation. Anticancer Research, 2018, 38, 5409-5415.	0.5	8
422	Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations. Internal Medicine, 2018, 57, 3643-3645.	0.3	9

#	Article	IF	Citations
423	Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan. Oncology and Therapy, 2018, 6, 203-215.	1.0	47
424	Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. Clinical Drug Investigation, 2018, 38, 983-987.	1.1	14
425	The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy. Annals of Translational Medicine, 2018, 6, 168-168.	0.7	1
426	Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. Cell Metabolism, 2018, 28, 848-865.e6.	7.2	184
427	EGFR TKIs and Immune Checkpoint Inhibitors: Is This an Optimal Combination?. Journal of Thoracic Oncology, 2018, 13, 1245-1247.	0.5	1
428	Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients. Analytical Chemistry, 2018, 90, 11203-11209.	3.2	24
429	Effect of multipleâ€dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. British Journal of Clinical Pharmacology, 2018, 84, 2877-2888.	1.1	20
430	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. CNS Drugs, 2018, 32, 527-542.	2.7	10
431	Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelialâ€“mesenchymal transition phenotype. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1413-1422.	1.2	16
432	Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment. Journal of Thoracic Oncology, 2018, 13, 915-925.	0.5	22
433	Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers. Oncologist, 2018, 23, 1054-1062.	1.9	14
434	Consensus on Molecular Testing in Lung Cancer. Current Pulmonology Reports, 2018, 7, 49-55.	0.5	2
435	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. Pharmacogenomics, 2018, 19, 727-740.	0.6	20
436	Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients. Journal of Thoracic Oncology, 2018, 13, 1213-1216.	0.5	22
437	The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clinical Cancer Research, 2018, 24, 3528-3538.	3.2	288
438	Comments on Cost-Effectiveness of Osimertinib for EGFR Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer after Progression during First-Line EGFRÂTyrosine Kinase Inhibitor Therapy. Journal of Thoracic Oncology, 2018, 13, e83-e84.	0.5	3
439	Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer. Anticancer Research, 2018, 38, 3587-3592.	0.5	9
440	Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. Oncology and Therapy, 2018, 6, 45-58.	1.0	5

#	Article	IF	Citations
441	Osimertinib in Japanese patients with <scp>EGFR</scp> T790M mutationâ€positive advanced nonâ€smallâ€cell lung cancer: <scp>AURA</scp>3 trial. Cancer Science, 2018, 109, 1930-1938.	1.7	53
442	Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report. Journal of Clinical Pathology, 2018, 71, 754-756.	1.0	3
443	Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer. Targeted Oncology, 2018, 13, 389-398.	1.7	2
444	A Convergence-Based Framework for Cancer Drug Resistance. Cancer Cell, 2018, 33, 801-815.	7.7	181
445	A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. Clinical Cancer Research, 2018, 24, 5610-5621.	3.2	43
446	Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer. Lung Cancer, 2018, 122, 100-106.	0.9	11
447	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. BioMed Research International, 2018, 2018, 1-8.	0.9	24
448	Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. PLoS ONE, 2018, 13, e0194730.	1.1	18
449	Analytical Validation of a Hybrid Captureâ€"Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. Journal of Molecular Diagnostics, 2018, 20, 686-702.	1.2	149
450	Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications. Cancer Chemotherapy and Pharmacology, 2018, 82, 171-183.	1.1	17
451	Can We Prevent Resistance to Osimertinib? Combination or Sequential. Journal of Thoracic Oncology, 2018, 13, 877-879.	0.5	2
452	Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. Current Oncology, 2018, 25, 73-82.	0.9	24
453	Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients. Lung Cancer, 2018, 123, 60-69.	0.9	58
454	Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment. British Journal of Cancer, 2018, 119, 558-564.	2.9	43
455	Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Current Oncology, 2018, 25, 68-76.	0.9	11
456	Liquid Biopsy for Advanced Non-Small Cell LungÂCancer (NSCLC): A Statement Paper from theÂIASLC. Journal of Thoracic Oncology, 2018, 13, 1248-1268.	0.5	515
457	Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers, 2018, 10, 248.	1.7	258
458	Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine, 2018, 7, 192.	1.0	27

#	Article	IF	Citations
459	Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790Mâ€“Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncology, 2018, 4, 1527.	3.4	522
460	Small Molecules in Oncology. Recent Results in Cancer Research, 2018, , .	1.8	5
461	MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R. Biomedicine and Pharmacotherapy, 2018, 106, 1357-1363.	2.5	44
462	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 1021-1030.	1.1	21
463	A comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients. Cancer Management and Research, 2018, Volume 10, 115-121.	0.9	16
464	Brain Metastases in Non-Small-Cell Lung Cancer: Are Tyrosine Kinase Inhibitors and Checkpoint Inhibitors Now Viable Options?. Current Oncology, 2018, 25, 103-114.	0.9	42
465	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, T790M, and Clinical Trials. Current Oncology, 2018, 25, 28-37.	0.9	23
466	Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. Journal of Thoracic Oncology, 2018, 13, 1363-1372.	0.5	140
467	Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. Lung Cancer, 2018, 124, 65-70.	0.9	13
468	Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR nonâ€T790M mutations after progression on firstâ€line EGFRâ€tyrosine kinase inhibitors. Thoracic Cancer, 2018, 9, 1151-1155.	0.8	7
469	Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA. Cancer Management and Research, 2018, Volume 10, 1209-1218.	0.9	26
470	Novel Indications for Brutonâ€™s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. Journal of Clinical Medicine, 2018, 7, 62.	1.0	43
471	Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors. Targeted Oncology, 2018, 13, 501-507.	1.7	38
472	Overview of precision oncology trials: challenges and opportunities. Expert Review of Clinical Pharmacology, 2018, 11, 797-804.	1.3	31
473	Efficacy of pemetrexed-based regimens in advanced non–small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. OncoTargets and Therapy, 2018, Volume 11, 2121-2129.	1.0	15
474	Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. Lung Cancer, 2018, 124, 31-39.	0.9	34
475	The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients. OncoTargets and Therapy, 2018, Volume 11, 2637-2646.	1.0	8
476	Osimertinib. Recent Results in Cancer Research, 2018, 211, 257-276.	1.8	24

#	Article	IF	Citations
478	Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs. Anticancer Research, 2018, 38, 4699-4704.	0.5	6
479	Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. Lung Cancer, 2018, 124, 293-297.	0.9	12
480	Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment. Frontiers in Oncology, 2018, 8, 88.	1.3	57
481	First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?. Frontiers in Oncology, 2018, 8, 94.	1.3	20
482	Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification. Frontiers in Oncology, 2018, 8, 176.	1.3	5
483	Acquired resistance in oncogene-addicted non-small-cell lung cancer. Future Oncology, 2018, 14, 29-40.	1.1	18
484	Oncogene addicted non-small-cell lung cancer: current standard and hot topics. Future Oncology, 2018, 14, 3-17.	1.1	18
485	The Significance of MMP-1 in EGFR-TKIâ€“Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting. International Journal of Molecular Sciences, 2018, 19, 609.	1.8	21
486	Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?. Journal of Clinical Medicine, 2018, 7, 144.	1.0	54
487	Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA). Micromachines, 2018, 9, 100.	1.4	70
488	EGFR: How Important Is EGFR Mutation Status in the Management of Lung Cancer?. Respiratory Disease Series, 2018, , 275-293.	0.1	0
489	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respiratory Medicine,the, 2018, 6, 681-690.	5.2	166
490	Nonâ€“Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutationâ€“positive Cancer. Radiology, 2018, 289, 227-237.	3.6	19
491	Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Pharmaceutical Research, 2018, 35, 177.	1.7	53
492	Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2018, 8, 208.	1.3	62
493	Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2018, 78, 5094-5106.	0.4	47
494	A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. Cancers, 2018, 10, 236.	1.7	31
495	Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes. International Journal of Biological Sciences, 2018, 14, 204-216.	2.6	75

#	Article	IF	Citations
496	A systematic review of targeted agents for non-small cell lung cancer. Acta OncolÃ³gica, 2018, 57, 176-186.	0.8	54
497	Irreversible Tyrosine Kinase Inhibition of Epidermal Growth Factor Receptor with Afatinib in Egfr Activating Mutationâ€“Positive Advanced Non-Small-Cell Lung Cancer. Current Oncology, 2018, 25, 9-17.	0.9	15
498	Effective osimertinib treatment in a patient with discordant T790ÂM mutation detection between liquid biopsy and tissue biopsy. BMC Cancer, 2018, 18, 314.	1.1	6
499	Third generation EGFR TKIs: current data and future directions. Molecular Cancer, 2018, 17, 29.	7.9	205
500	EGFR-TKIs resistance via EGFR-independent signaling pathways. Molecular Cancer, 2018, 17, 53.	7.9	223
501	Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. Acta Pharmaceutica Sinica B, 2018, 8, 530-538.	5.7	43
503	Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. Expert Opinion on Pharmacotherapy, 2018, 19, 851-864.	0.9	6
504	Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. BMC Cancer, 2018, 18, 6.	1.1	7
505	Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFRâ€“TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. Cancer Chemotherapy and Pharmacology, 2018, 82, 119-127.	1.1	5
507	EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors. Diagnostic Pathology, 2018, 13, 49.	0.9	18
508	Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada. Current Oncology, 2018, 25, 163-169.	0.9	28
509	Treatment of Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapy. Current Pulmonology Reports, 2018, 7, 79-91.	0.5	6
510	Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. Clinical Lung Cancer, 2018, 19, 518-530.e7.	1.1	48
511	Treatment of advanced non-small cell lung cancer in the elderly. Expert Review of Respiratory Medicine, 2018, 12, 783-792.	1.0	9
512	The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. OncoTargets and Therapy, 2018, Volume 11, 4739-4745.	1.0	23
513	Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening. Journal of Molecular Diagnostics, 2018, 20, 836-848.	1.2	15
514	Circulating tumor DNA â€“ Current state of play and future perspectives. Pharmacological Research, 2018, 136, 35-44.	3.1	31
515	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. Nature Reviews Clinical Oncology, 2018, 15, 694-708.	12.5	255

#	Article	IF	Citations
516	Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors. Chemotherapy, 2018, 63, 181-189.	0.8	4
517	Characterization of Factors Affecting the Detection Limit of EGFR p.T790M in Circulating Tumor DNA. Technology in Cancer Research and Treatment, 2018, 17, 153303381879365.	0.8	3
518	An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases. Internal Medicine, 2018, 57, 3423-3427.	0.3	3
519	The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. Drugs and Aging, 2018, 35, 819-834.	1.3	16
520	High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation. Lung Cancer, 2018, 124, 205-210.	0.9	19
521	Development and validation of a UPLCâ€“MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma. Biomedical Chromatography, 2018, 32, e4365.	0.8	19
522	Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib. Journal of Thoracic Oncology, 2018, 13, e137-e139.	0.5	7
523	Osimertinib Depletes EGFRÂT790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M. Journal of Thoracic Oncology, 2018, 13, e140-e142.	0.5	6
524	Multidisciplinary Management of Metastatic Brain Tumors. Japanese Journal of Neurosurgery, 2018, 27, 539-547.	0.0	0
525	Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries. Current Cancer Therapy Reviews, 2018, 14, 120-136.	0.2	0
526	A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment. Cancer Letters, 2018, 431, 171-181.	3.2	96
527	Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression. Expert Opinion on Pharmacotherapy, 2018, 19, 1049-1056.	0.9	0
528	BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review. Targeted Oncology, 2018, 13, 517-523.	1.7	23
529	Penetration of the bloodâ€“brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. Lung Cancer, 2018, 122, 1-6.	0.9	17
530	The Role of Osimertinib in Treatment NaÃ¯ve Epidermal Growth Factor Receptorâ€“Mutated Stage IIIB or IV Nonâ€“Small-Cell Lung Cancer Patients. Clinical Medicine Insights: Oncology, 2018, 12, 117955491877958.	0.6	1
531	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. International Journal of Clinical Oncology, 2018, 23, 1052-1059.	1.0	27
532	Targeting EGFR in Lung Cancer: Current Standards and Developments. Drugs, 2018, 78, 893-911.	4.9	61
533	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine, 2019, 29, 29-39.	2.3	43

#	Article	IF	Citations
534	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clinical Cancer Research, 2019, 25, 1063-1069.	3.2	257
535	Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Nonâ€“Small Cell Lung Cancer. Therapeutic Innovation and Regulatory Science, 2019, 53, 324-331.	0.8	0
536	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30.		49
537	Characterising acquired resistance to erlotinib in non-small cell lung cancer patients. Expert Review of Respiratory Medicine, 2019, 13, 1019-1028.	1.0	8
538	Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR. International Journal of Molecular Sciences, 2019, 20, 4020.	1.8	7
539	Osimertinib for Japanese patients with T790Mâ€positive advanced nonâ€smallâ€cell lung cancer: A pooled subgroup analysis. Cancer Science, 2019, 110, 2884-2893.	1.7	22
540	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology, 2019, 293, 15-29.	3.6	45
541	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences, 2019, 20, 3821.	1.8	116
542	Coâ€mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 6812-6821.	1.6	12
543	Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib. Journal of Thoracic Disease, 2019, 11, 2664-2668.	0.6	3
544	Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFRâ€mutated nonâ€“small cell lung cancer. Thoracic Cancer, 2019, 10, 1928-1935.	0.8	10
545	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. International Journal of Molecular Sciences, 2019, 20, 3951.	1.8	62
546	Co-occurring genomic alterations inÂnon-small-cell lung cancer biology and therapy. Nature Reviews Cancer, 2019, 19, 495-509.	12.8	573
547	ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. Future Oncology, 2019, 15, 3003-3014.	1.1	42
548	Next-generation sequencing in liquid biopsy: cancer screening and early detection. Human Genomics, 2019, 13, 34.	1.4	302
549	Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Thoracic Disease, 2019, 11, 2350-2360.	0.6	34
550	Determination of osimertinib in human plasma, urine and cerebrospinal fluid. Bioanalysis, 2019, 11, 987-1001.	0.6	12
551	Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. Acta OncolÃ³gica, 2019, 58, 1634-1639.	0.8	10

#	Article	IF	Citations
552	Prognostic significance of molecular characteristics of cerebrospinal fluid for nonâ€small cell lung cancer patients with leptomeningeal metastasis. Thoracic Cancer, 2019, 10, 1673-1682.	0.8	11
553	Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncology, 2019, 15, 2905-2914.	1.1	71
554	Nonâ€“Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings, 2019, 94, 1623-1640.	1.4	1,153
555	Realâ€world outcomes of NSCLC patients receiving tissue or circulating tumor DNAâ€guided osimertinib treatment. Cancer Medicine, 2019, 8, 5939-5947.	1.3	12
556	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. Journal of Clinical Medicine, 2019, 8, 998.	1.0	28
557	Opportunities of circulating tumor DNA in lung cancer. Cancer Treatment Reviews, 2019, 78, 31-41.	3.4	16
558	Treatment of Non-small Cell Lung Cancer with <i>EGFR</i>-mutations. Journal of UOEH, 2019, 41, 153-163.	0.3	65
559	Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient. Targeted Oncology, 2019, 14, 369-374.	1.7	12
560	Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer. Toxicology and Applied Pharmacology, 2019, 379, 114662.	1.3	27
561	Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR^{L858R/T790M}Âmutation . International Journal of Nanomedicine, 2019, Volume 14, 4503-4515.	3.3	14
562	An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer. Biomedicine and Pharmacotherapy, 2019, 118, 109169.	2.5	28
564	Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. Cancers, 2019, 11, 947.	1.7	26
565	Challenges for realâ€time intraoperative diagnosis of high risk histology in lung adenocarcinoma: A necessity for sublobar resection. Thoracic Cancer, 2019, 10, 1663-1668.	0.8	23
566	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer, 2019, 135, 66-72.	0.9	22
567	Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Frontiers in Pharmacology, 2019, 10, 732.	1.6	35
568	Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients. Lung Cancer, 2019, 135, 138-144.	0.9	13
569	Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. Targeted Oncology, 2019, 14, 433-440.	1.7	9
570	Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2555-2564.	1.2	6

#	Article	IF	Citations
571	Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance. BioMed Research International, 2019, 2019, 1-10.	0.9	14
572	Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease . OncoTargets and Therapy, 2019, Volume 12, 5545-5549.	1.0	4
573	Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. Molecular Cancer Therapeutics, 2019, 18, 1593-1601.	1.9	4
574	Osimertinib Administration as the Primary Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy for Brain Metastasis of <i>De Novo</i> T790M-positive Lung Cancer. Internal Medicine, 2019, 58, 3029-3031.	0.3	3
575	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). Tumori, 2019, 105, 3-14.	0.6	9
576	Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?. Anticancer Research, 2019, 39, 3923-3929.	0.5	24
577	Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers, 2019, 11, 923.	1.7	124
578	Development of an LCâ€“MS/MS-based method for quantitation of osimertinib in human plasma and cerebrospinal fluid. Bioanalysis, 2019, 11, 847-854.	0.6	13
579	EGFR Targeted Therapy. Current Cancer Research, 2019, , 1-30.	0.2	2
580	Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort. Experimental Hematology and Oncology, 2019, 8, 24.	2.0	14
581	Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Nonâ€“Small Cell Lung Cancer in China. Clinical Therapeutics, 2019, 41, 2308-2320.e11.	1.1	25
582	Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. Cancers, 2019, 11, 1550.	1.7	13
583	Essentials of Bioinformatics, Volume II. , 2019, , .		1
584	Untapped potential: recognising CNS opportunities in early oncology drug development. Lancet Oncology, The, 2019, 20, 1620-1622.	5.1	0
585	Complete Resolution of Sellar Metastasis in a Patient With NSCLC Treated With Osimertinib. Journal of the Endocrine Society, 2019, 3, 1887-1891.	0.1	3
586	Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study. Lung Cancer, 2019, 137, 149-156.	0.9	63
587	Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer. Journal of Thoracic Disease, 2019, 11, S1831-S1834.	0.6	5
588	Metforminâ€sensitized NSCLC cells to osimertinib via AMPKâ€dependent autophagy inhibition. Clinical Respiratory Journal, 2019, 13, 781-790.	0.6	17

#	Article	IF	Citations
589	Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing?. Journal of Thoracic Disease, 2019, 11, S1837-S1840.	0.6	2
590	FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. Biomolecules, 2019, 9, 668.	1.8	80
591	Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses. Global & Regional Health Technology Assessment, 2019, 2019, 228424031987789.	0.2	1
592	Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology, 2019, 51, 673-680.	0.3	8
594	Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 10272-10293.	2.9	89
595	CAR-T â€œthe living drugsâ€, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. Journal of Hematology and Oncology, 2019, 12, 113.	6.9	69
596	Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma. Molecular Diagnosis and Therapy, 2019, 23, 773-779.	1.6	10
597	Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. Trends in Cancer, 2019, 5, 677-692.	3.8	43
598	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. Cancers, 2019, 11, 1782.	1.7	53
599	A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. Journal of Thoracic Oncology, 2019, 14, 1982-1988.	0.5	27
600	A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases. Journal of Thoracic Disease, 2019, 11, 3909-3919.	0.6	2
601	Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation. Journal of Thoracic Disease, 2019, 11, S1847-S1851.	0.6	0
602	Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers. Journal of Thoracic Disease, 2019, 11, S1844-S1846.	0.6	1
603	The Factors Predicting Concordant Epidermal Growth Factor Receptor (EGFR) Mutation Detected in Liquid/Tissue Biopsy and the Related Clinical Outcomes in Patients of Advanced Lung Adenocarcinoma with EGFR Mutations. Journal of Clinical Medicine, 2019, 8, 1758.	1.0	8
604	Realâ€world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced nonâ€small cell lung cancer. Cancer Medicine, 2019, 8, 7542-7555.	1.3	14
605	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. Cancer Control, 2019, 26, 107327481987054.	0.7	16
606	Selecting short length nucleic acids localized in exosomes improves plasma EGFR mutation detection in NSCLC patients. Cancer Cell International, 2019, 19, 251.	1.8	17
607	Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Nonâ€“Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results. JCO Precision Oncology, 2019, 3, 1-9.	1.5	8

#	Article	IF	Citations
608	Postâ€progression survival is highly linked to overall survival in patients with nonâ€smallâ€cell lung cancer harboring sensitive EGFR mutations treated with firstâ€line epidermal growth factor receptorâ€tyrosine kinase inhibitors. Thoracic Cancer, 2019, 10, 2200-2208.	0.8	8
609	Systemic Therapy for Locally Advanced and Metastatic Nonâ€“Small Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2019, 322, 764.	3.8	720
610	DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wildâ€type NSCLC cells to AZD9291. Journal of Cellular and Molecular Medicine, 2019, 23, 7427-7437.	1.6	39
611	Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates. Future Oncology, 2019, 15, 2983-2997.	1.1	27
612	Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan. International Journal of Clinical Oncology, 2019, 24, 1549-1557.	1.0	4
613	Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study. PLoS ONE, 2019, 14, e0221575.	1.1	11
615	EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of nonâ€small cell lung cancer. Clinical and Translational Medicine, 2019, 8, 4.	1.7	15
616	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 1259.	1.7	18
617	Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer . OncoTargets and Therapy, 2019, Volume 12, 6535-6548.	1.0	26
618	Towards Circulating-Tumor DNA-Based Precision Medicine. Journal of Clinical Medicine, 2019, 8, 1365.	1.0	8
619	EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice. Lung Cancer, 2019, 136, 86-93.	0.9	7
620	TAS6417/CLN-081 Is a Pan-Mutationâ€“Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Molecular Cancer Research, 2019, 17, 2233-2243.	1.5	49
621	Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion. Targeted Oncology, 2019, 14, 619-626.	1.7	33
622	Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients. Oncology Letters, 2019, 18, 4153-4159.	0.8	4
623	Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 6644-6652.	3.2	100
624	Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor. Journal of Thoracic Oncology, 2019, 14, 1766-1783.	0.5	30
625	Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer. Anticancer Research, 2019, 39, 4817-4828.	0.5	14
626	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987465.	1.4	27

#	Article	IF	Citations
627	Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer: controversy, causes, and solutions. Translational Lung Cancer Research, 2019, 8, 524-531.	1.3	9
628	Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Molecular Cancer, 2019, 18, 139.	7.9	156
629	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. Seminars in Oncology, 2019, 46, 271-283.	0.8	61
630	Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. British Journal of Cancer, 2019, 121, 725-737.	2.9	702
631	Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives . Drug Design, Development and Therapy, 2019, Volume 13, 3187-3198.	2.0	39
632	Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report. Frontiers in Oncology, 2019, 9, 819.	1.3	12
633	Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice. Lung Cancer, 2019, 137, 85-93.	0.9	24
634	Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer, 2019, 137, 113-122.	0.9	154
635	Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy. Lung Cancer, 2019, 137, 76-84.	0.9	30
636	OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Translational Lung Cancer Research, 2019, 8, 352-366.	1.3	38
637	A sulfated glucan from Antrodia cinnamomea reduces Slug expression through regulation of TGFÎ²/AKT/GSK3Î² axis in lung cancer. Carbohydrate Polymers, 2019, 210, 175-184.	5.1	14
638	Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review. BMC Cancer, 2019, 19, 105.	1.1	8
639	Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. Journal of Thoracic Oncology, 2019, 14, 193-202.	0.5	104
640	Practical Considerations for Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials. Statistics in Biopharmaceutical Research, 2019, 11, 407-418.	0.6	8
641	Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma. Journal of Cancer, 2019, 10, 61-71.	1.2	29
642	YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 2575-2587.	3.2	71
643	The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Research and Treatment, 2019, 175, 5-15.	1.1	48
644	Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients. Journal of Clinical Medicine, 2019, 8, 112.	1.0	7

#	Article	IF	Citations
645	Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Nonâ€“small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2). Clinical Lung Cancer, 2019, 20, 222-230.	1.1	3
646	Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds toÂBrigatinib and Anti-EGFR Antibody CombinationÂTherapy. Journal of Thoracic Oncology, 2019, 14, e85-e88.	0.5	44
647	Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib. Internal Medicine, 2019, 58, 1625-1627.	0.3	3
648	Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. Oncologist, 2019, 24, 593-e170.	1.9	17
649	Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncology, 2019, 15, 805-816.	1.1	32
650	The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. Oncology and Therapy, 2019, 7, 1-32.	1.0	19
651	Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treatment and Research, 2019, 178, 3-43.	0.2	16
652	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. Journal of Cancer, 2019, 10, 1985-1990.	1.2	11
653	Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study . Cancer Management and Research, 2019, Volume 11, 4883-4892.	0.9	17
654	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. ESMO Open, 2019, 4, e000498.	2.0	38
655	Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease. Journal of Thoracic Disease, 2019, 11, 1756-1764.	0.6	8
656	Osimertinibâ€induced severe interstitial lung disease: A case report. Thoracic Cancer, 2019, 10, 1657-1660.	0.8	7
657	Advanced-Stage Nonâ€“Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. Journal of Thoracic Oncology, 2019, 14, 1134-1155.	0.5	61
658	The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clinical Cancer Research, 2019, 25, 6382-6391.	3.2	39
659	Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib. Targeted Oncology, 2019, 14, 335-342.	1.7	28
660	Real-World Analysis of the Efficacy of Rebiopsy andEGFRMutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer. Yonsei Medical Journal, 2019, 60, 525.	0.9	23
661	Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. Journal of Experimental and Clinical Cancer Research, 2019, 38, 222.	3.5	45
662	Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer. European Journal of Clinical Pharmacology, 2019, 75, 1193-1200.	0.8	6

#	Article	IF	Citations
663	Targeting the evolution of drug resistance in lung cancer. Molecular and Cellular Oncology, 2019, 6, e1603092.	0.3	1
664	Cas clinique nÂ° 5 : Adaptation thÃ©rapeutique chez un patient atteint de cancer du poumon EGFR-mutÃ©. Revue Des Maladies Respiratoires Actualites, 2019, 11, 34-37.	0.0	0
665	A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. Lung Cancer, 2019, 134, 46-51.	0.9	24
666	Response to First-Line Osimertinib Treatment in Nonâ€“Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 2019, 20, e531-e533.	1.1	1
667	Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives. Cancer Letters, 2019, 459, 240-247.	3.2	19
668	Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. Lung Cancer, 2019, 135, 104-109.	0.9	5
669	Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer. Targeted Oncology, 2019, 14, 307-314.	1.7	7
670	Precision Medical Approaches to the Diagnoses and Management of Brain Metastases. Current Treatment Options in Oncology, 2019, 20, 49.	1.3	6
671	Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. Drugs, 2019, 79, 823-831.	4.9	35
672	Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 350-362.e4.	1.1	10
673	Biomarker Testing for Patients With Advanced Nonâ€“Small Cell Lung Cancer: Real-World Issues and Tough Choices. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 531-542.	1.8	210
674	A Career in Lung Cancer: Pushing Beyond Chemotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 583-589.	1.8	4
675	An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report. Journal of Medical Case Reports, 2019, 13, 144.	0.4	0
676	MSâ€275 potentiates the effect of YMâ€155 in lung adenocarcinoma via survivin downregulation induced by miRâ€138 and miRâ€195. Thoracic Cancer, 2019, 10, 1355-1368.	0.8	3
677	Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors. Clinical Cancer Research, 2019, 25, 6026-6034.	3.2	50
678	Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling. Cells, 2019, 8, 442.	1.8	27
679	Implementing Companion Diagnostic Testing in the Clinic. , 2019, , 413-427.		0
680	Osimertinib (TAGRISSOâ„¢) and the cobasÂ® EGFR Mutation Test v2. , 2019, , 429-443.		2

#	Article	IF	Citations
681	Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort. Clinical Lung Cancer, 2019, 20, e576-e583.	1.1	32
682	Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression. Molecular Cancer Therapeutics, 2019, 18, 1366-1373.	1.9	12
683	Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discovery, 2019, 9, 926-943.	7.7	220
684	Combination of Osimertinib with Durvalumab inÂEpidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small Cell Lung Cancer: Is There Room for Reinvestigation?. Journal of Thoracic Oncology, 2019, 14, 766-767.	0.5	13
685	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. CardioVascular and Interventional Radiology, 2019, 42, 1230-1239.	0.9	2
686	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	2.3	76
687	ProGRP as early predictive marker of nonâ€“small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment. Respiratory Medicine Case Reports, 2019, 27, 100837.	0.2	9
688	AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nature Communications, 2019, 10, 1812.	5.8	98
689	The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, S448-S452.	0.6	7
690	Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives. Journal of Thoracic Disease, 2019, 11, S249-S252.	0.6	2
691	Cell-free DNA diagnostics: current and emerging applications in oncology. Pharmacogenomics, 2019, 20, 357-380.	0.6	12
692	The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report. BMC Cancer, 2019, 19, 410.	1.1	16
693	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. International Journal of Clinical Oncology, 2019, 24, 731-770.	1.0	100
694	Precision oncology of lung cancer: genetic and genomic differences in Chinese population. Npj Precision Oncology, 2019, 3, 14.	2.3	31
695	Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. Molecular Medicine, 2019, 25, 15.	1.9	22
696	How can better identification of T790M help to inform treatment sequencing decisions in EGFR mutation-positive non-small-cell lung cancer?. Future Oncology, 2019, 15, 2895-2898.	1.1	2
697	Comparison of cobasEGFRMutation Test v2 and PANAMutyper-R-EGFRfor Detection and Semi-Quantification of Epidermal Growth Factor Receptor Mutations in Plasma and Pleural Effusion Supernatant. Annals of Laboratory Medicine, 2019, 39, 478-487.	1.2	11
698	Molecular and Morphological Profiling of Lung Cancer: A Foundation for â€œNext-Generationâ€• Pathologists and Oncologists. Cancers, 2019, 11, 599.	1.7	41

#	Article	IF	Citations
699	The efficacy of immune checkpoint inhibitors in advanced nonâ€‘small cell lung cancer harboring driver mutations. Molecular and Clinical Oncology, 2019, 10, 610-614.	0.4	4
700	Detection of NRG1 Gene Fusions in Solid Tumors. Clinical Cancer Research, 2019, 25, 4966-4972.	3.2	145
701	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the â€˜real-worldâ€™ clinical setting. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983637.	1.4	25
702	Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. EBioMedicine, 2019, 43, 180-187.	2.7	30
703	Leptomeningeal Disease in Solid Cancers. , 2019, , 1-19.		0
704	Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). Clinical Lung Cancer, 2019, 20, e492-e494.	1.1	8
705	Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 291-299.	1.3	13
706	Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. Cancers, 2019, 11, 365.	1.7	8
707	Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?. Cancers, 2019, 11, 366.	1.7	50
708	Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer. , 2019, , 115-131.		0
709	Recent Advances in Liquid Biopsy in Precision Oncology Research. Biological and Pharmaceutical Bulletin, 2019, 42, 337-342.	0.6	27
710	Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer. Cancers, 2019, 11, 298.	1.7	10
711	Rapid effect of osimertinib reâ€‘challenge on brain metastases developing during salvage cytotoxic chemotherapy after osimertinib treatment failure: A case report. Molecular and Clinical Oncology, 2019, 10, 451-453.	0.4	2
712	Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790â€‰M point mutation: a case report. BMC Cancer, 2019, 19, 186.	1.1	8
713	Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial). Japanese Journal of Clinical Oncology, 2019, 49, 554-558.	0.6	14
714	Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with nonâ€‘small cell lung cancer harboring an EGFR mutation: A prospective observational study. Thoracic Cancer, 2019, 10, 880-889.	0.8	14
715	Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. International Journal of Molecular Sciences, 2019, 20, 1431.	1.8	77
716	Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer. Cancer Letters, 2019, 452, 191-202.	3.2	48

#	Article	IF	Citations
717	Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. Oncologist, 2019, 24, e1070-e1081.	1.9	76
718	From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. Lung Cancer, 2019, 131, 78-85.	0.9	42
719	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2019, 19, 547-559.	1.1	22
720	From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC. Journal of Oncology, 2019, 2019, 1-12.	0.6	12
721	Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. Current Oncology, 2019, 26, 81-93.	0.9	38
723	Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Clinical and Translational Oncology, 2019, 21, 1287-1301.	1.2	73
724	Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis. Clinical and Translational Oncology, 2019, 21, 1424-1431.	1.2	19
725	Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing. Advances in Therapy, 2019, 36, 766-785.	1.3	16
726	Mutation Profile of Resected EGFR-Mutated Lung Adenocarcinoma by Next-Generation Sequencing. Oncologist, 2019, 24, 1368-1374.	1.9	15
727	Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790Mâ€“Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. Journal of Thoracic Oncology, 2019, 14, 933-939.	0.5	152
728	Synthetic Lethality in Lung Cancerâ€”From the Perspective of Cancer Genomics. Medicines (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	6
729	Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncology, The, 2019, 20, 625-635.	5.1	470
730	Discovery of a novel EGFR targeting antibody-drug conjugate, SHR-A1307, for the treatment of solid tumors resistant or refractory to anti-EGFR therapies. Molecular Cancer Therapeutics, 2019, 18, molcanther.0854.2018.	1.9	11
731	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer, 2019, 133, 10-19.	0.9	25
732	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. Oncologist, 2019, 24, 1270-1284.	1.9	21
733	Osimertinib for patients with EGFR T790M mutation-positive nonâ€“small-cell lung cancer and a poor performance status. Japanese Journal of Clinical Oncology, 2019, 49, 671-675.	0.6	17
734	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respiratory Medicine,the, 2019, 7, 387-401.	5.2	704
735	Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 39-41.	0.6	1

#	Article	IF	Citations
736	Ultra-sensitive EGFRT790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFRdel19 Mutations and Treated with First-generation TKIs. Clinical Cancer Research, 2019, 25, 4280-4289.	3.2	31
737	Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing. Frontiers in Pharmacology, 2019, 10, 230.	1.6	89
738	Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995â€“2017. Lung Cancer, 2019, 131, 69-77.	0.9	34
739	The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge. Science Bulletin, 2019, 64, 499-503.	4.3	6
740	Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases. Critical Reviews in Oncology/Hematology, 2019, 138, 190-206.	2.0	8
741	Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment. Advances in Therapy, 2019, 36, 1279-1290.	1.3	14
742	EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology, 2019, 37, 278-285.	0.8	286
743	ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2019, 37, 1370-1379.	0.8	282
744	Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC). Expert Review of Anticancer Therapy, 2019, 19, 431-435.	1.1	10
745	Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations. Investigational New Drugs, 2019, 37, 1207-1217.	1.2	6
746	Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. Journal of Thoracic Oncology, 2019, 14, 553-559.	0.5	123
747	Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Annals of Oncology, 2019, 30, 830-838.	0.6	88
748	Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Current Oncology Reports, 2019, 21, 21.	1.8	82
749	First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. Journal of Cancer, 2019, 10, 522-529.	1.2	43
750	Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. Lung Cancer, 2019, 130, 87-92.	0.9	39
751	Covalent Inhibition in Drug Discovery. ChemMedChem, 2019, 14, 889-906.	1.6	168
752	Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice. Translational Oncology, 2019, 12, 640-645.	1.7	10
753	EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR. Targeted Oncology, 2019, 14, 197-203.	1.7	33

#	Article	IF	Citations
754	Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification. Biochemical and Biophysical Research Communications, 2019, 511, 544-550.	1.0	11
755	Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harboring uncommon EGFR mutations: a case report and literature review . OncoTargets and Therapy, 2019, Volume 12, 745-748.	1.0	6
756	A case report of metastatic lung adenocarcinoma with long-term survival for over 11 years. Medicine (United States), 2019, 98, e14100.	0.4	9
758	Successful Osimertinib Rechallenge After Osimertinib-induced Interstitial Lung Disease in a Patient with Postoperative Recurrence of Lung Cancer. Japanese Journal of Lung Cancer, 2019, 59, 1184-1189.	0.0	2
759	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. Oncologist, 2019, 24, 1469-1478.	1.9	25
760	Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study. Translational Cancer Research, 2019, 8, S612-S617.	0.4	10
761	Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?. Annals of Translational Medicine, 2019, 7, S346-S346.	0.7	2
762	The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era. Translational Lung Cancer Research, 2019, 8, 1134-1151.	1.3	3
763	Improving outcomes for brain metastases in EGFR mutated NSCLC. Translational Lung Cancer Research, 2019, 8, S355-S359.	1.3	5
764	Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints. Translational Lung Cancer Research, 2019, 8, S334-S338.	1.3	1
765	Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy. Clinical Lung Cancer, 2019, 20, e597-e600.	1.1	1
767	Cardiac Risk-Informed Treatment ofÂEGFR-Mutant Lung Cancer WithÂOsimertinib. JACC: CardioOncology, 2019, 1, 179-181.	1.7	1
769	Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma. Scientific Reports, 2019, 9, 19909.	1.6	18
770	La rÃ©animation des patients cancÃ©reux Ã lâ€™heure de lâ€™immunothÃ©rapie et des thÃ©rapies ciblÃ©es. Revue Des Maladies Respiratoires Actualites, 2019, 11, 418-425.	0.0	0
771	Cancer du poumon. Revue Des Maladies Respiratoires Actualites, 2019, 11, S29-S35.	0.0	0
772	Osimertinib-Induced Cardiotoxicity. JACC: CardioOncology, 2019, 1, 172-178.	1.7	66
773	Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib. Journal of Thoracic Oncology, 2019, 14, e274-e275.	0.5	20
774	A view on drug resistance in cancer. Nature, 2019, 575, 299-309.	13.7	1,391

#	Article	IF	Citations
775	Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989028.	1.4	28
776	Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Respiratory Research, 2019, 20, 270.	1.4	30
777	Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Nonâ€“Small Cell Lung Cancer (NSCLC). American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 440-445.	0.6	25
778	A Repeated Biopsy by EBUS-TBNA Contributed to the Selection of an Appropriate Therapeutic Regimen for a Lung Cancer Patient. Journal of Bronchology and Interventional Pulmonology, 2019, 26, 129-131.	0.8	2
779	Treatment of oncogene-driven non-small cell lung cancer. Current Opinion in Pulmonary Medicine, 2019, 25, 300-307.	1.2	7
780	Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 845-850.	0.6	6
781	Should the Use of Biologic Agents in Patients With Renal and Lung Cancer Affect Our Surgical Management of Femoral Metastases?. Clinical Orthopaedics and Related Research, 2019, 477, 707-714.	0.7	8
782	Afatinib, an irreversible ErbB family blocker for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer. European Journal of Oncology Pharmacy, 2019, 2, e18.	0.5	1
783	From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. Cancer Journal (Sudbury, Mass), 2019, 25, 245-253.	1.0	4
784	Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management. Translational Lung Cancer Research, 2019, 8, S318-S320.	1.3	8
785	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S265-S279.	1.3	17
786	The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduction and Targeted Therapy, 2019, 4, 61.	7.1	436
787	Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer. Medicine (United States), 2019, 98, e17705.	0.4	4
788	Management of Brain Metastases in Nonâ€“Small-Cell Lung Cancer. Journal of Oncology Practice, 2019, 15, 563-570.	2.5	91
789	Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Journal of Hematology and Oncology, 2019, 12, 134.	6.9	296
790	Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a costâ€“effectiveness analysis. Journal of Comparative Effectiveness Research, 2019, 8, 853-863.	0.6	15
791	Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy. Journal of Thoracic Disease, 2019, 11, 4400-4403.	0.6	5
792	Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors . OncoTargets and Therapy, 2019, Volume 12, 9495-9504.	1.0	5

#	Article	IF	Citations
793	Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S247-S264.	1.3	59
794	Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study . Cancer Management and Research, 2019, Volume 11, 9243-9251.	0.9	16
795	Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. Oncologist, 2019, 24, 1022-1026.	1.9	16
796	Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review . OncoTargets and Therapy, 2019, Volume 12, 11305-11311.	1.0	15
797	Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. International Journal of Clinical Oncology, 2019, 24, 41-45.	1.0	5
798	Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases. Journal of Oncology Pharmacy Practice, 2019, 25, 623-637.	0.5	1
799	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). Lung Cancer, 2019, 129, 63-71.	0.9	25
800	Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Lung Cancer, 2019, 128, 33-39.	0.9	34
801	Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Japanese Journal of Clinical Oncology, 2019, 49, 29-36.	0.6	101
802	Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2019, 20, 124-133.e2.	1.1	21
803	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCOâ€“ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Annals of Oncology, 2019, 30, 171-210.	0.6	214
804	Early Noninvasive Detection of Response to Targeted Therapy in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2019, 79, 1204-1213.	0.4	75
805	Liquid Biopsy and Lung Cancer. Acta Cytologica, 2019, 63, 489-496.	0.7	75
806	Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers. Laryngoscope, 2019, 129, 1836-1843.	1.1	21
807	Emerging drugs for EGFR-mutated non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2019, 24, 5-16.	1.0	10
808	Different characteristics and survival in nonâ€small cell lung cancer patients with primary and acquired EGFR T790M mutation. International Journal of Cancer, 2019, 144, 2880-2886.	2.3	25
809	Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Lung Cancer, 2019, 127, 96-102.	0.9	31
810	Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. Journal of Thoracic Oncology, 2019, 14, 16-24.	0.5	100

#	Article	IF	Citations
811	Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncology, 2019, 15, 637-652.	1.1	80
812	From the Double Helix to Oncogenomics and Precision Cancer Medicine. , 2019, , 3-16.		0
813	EGFR Mutations. , 2019, , 477-486.		2
814	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clinical and Translational Oncology, 2019, 21, 3-17.	1.2	110
815	Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment inEGFR-Mutant Nonâ€“Small Cell Lung Cancer Cells. Molecular Cancer Research, 2019, 17, 499-507.	1.5	65
816	The role of circulating free DNA in the management of NSCLC. Expert Review of Anticancer Therapy, 2019, 19, 19-28.	1.1	20
817	Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Critical Reviews in Oncology/Hematology, 2019, 133, 171-182.	2.0	93
818	Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis. Cancer Biotherapy and Radiopharmaceuticals, 2019, 34, 128-133.	0.7	4
819	Hospital Volume and Mortality following Diagnostic Bronchoscopy in Lung Cancer Patients: Data from a National Inpatient Database in Japan. Respiration, 2019, 97, 264-272.	1.2	2
820	Brain metastases. Nature Reviews Disease Primers, 2019, 5, 5.	18.1	579
821	Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer. Future Oncology, 2019, 15, 181-191.	1.1	15
822	First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?. International Journal of Molecular Sciences, 2019, 20, 146.	1.8	118
823	Efficacy and safety of osimertinib in treating EGFRâ€mutated advanced NSCLC: A metaâ€analysis. International Journal of Cancer, 2019, 145, 284-294.	2.3	52
824	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. European Journal of Clinical Pharmacology, 2019, 75, 697-706.	0.8	3
825	Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. Clinical Lung Cancer, 2019, 20, e413-e417.	1.1	27
826	Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice. PLoS ONE, 2019, 14, e0210225.	1.1	19
827	Necitumumab for the treatment of advanced non-small-cell lung cancer. Future Oncology, 2019, 15, 705-716.	1.1	28
828	Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Journal of Thoracic Oncology, 2019, 14, 99-106.	0.5	82

#	Article	IF	Citations
829	Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. Oncologist, 2019, 24, 349-357.	1.9	41
830	KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR. Molecular Cancer Therapeutics, 2019, 18, 112-126.	1.9	39
831	Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy?. Current Opinion in Oncology, 2019, 31, 1-7.	1.1	19
832	A banner year for immunotherapy and targeted therapy. Nature Reviews Clinical Oncology, 2019, 16, 79-80.	12.5	24
833	Overcoming T790M mutant small cell lung cancer with the thirdâ€generation EGFRâ€TKI osimertinib. Thoracic Cancer, 2019, 10, 359-364.	0.8	11
834	Prospective exosomeâ€focused translational research for afatinib study of nonâ€small cell lung cancer patients expressing EGFR (EXTRA study). Thoracic Cancer, 2019, 10, 395-400.	0.8	10
835	Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib. Targeted Oncology, 2019, 14, 75-83.	1.7	102
836	Predictive value of oncogenic driver subtype, programmed deathâ€1 ligand (PDâ€L1) score, and smoking status on the efficacy of PDâ€1/PDâ€L1 inhibitors in patients with oncogeneâ€driven nonâ€“small cell lung cancer. Cancer, 2019, 125, 1038-1049.	2.0	66
837	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among firstâ€line gefitinib, erlotinib and afatinibâ€treated nonâ€small cell lung cancer patients with activating EGFR mutations. International Journal of Cancer, 2019, 144, 2887-2896.	2.3	56
838	Mutational activation of the epidermal growth factor receptor downâ€regulates major histocompatibility complex class I expression via the extracellular signalâ€regulated kinase in nonâ€“small cell lung cancer. Cancer Science, 2019, 110, 52-60.	1.7	31
839	Osimertinib in patients with T790M mutationâ€positive, advanced nonâ€“small cell lung cancer: Longâ€term followâ€up from a pooled analysis of 2 phase 2 studies. Cancer, 2019, 125, 892-901.	2.0	117
840	De Novo MET Amplification in Chinese Patients With Nonâ€“Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study. Clinical Lung Cancer, 2019, 20, e171-e176.	1.1	22
841	Treatment of older patients with advanced non-small cell lung cancer: A challenge. Journal of Geriatric Oncology, 2019, 10, 528-533.	0.5	13
842	Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respiratory Investigation, 2019, 57, 20-26.	0.9	46
843	Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. Oncologist, 2019, 24, 836-843.	1.9	34
844	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. Seminars in Cancer Biology, 2019, 54, 14-28.	4.3	51
845	A liquid biopsy in primary lung cancer. Surgery Today, 2019, 49, 1-14.	0.7	12
846	Absolute Bioavailability of Osimertinib in Healthy Adults. Clinical Pharmacology in Drug Development, 2019, 8, 198-207.	0.8	22

#	Article	IF	Citations
847	The effects of switching EGFRâ€TKI treatments for nonâ€small cell lung cancer because of adverse events. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e113-e117.	0.7	10
848	Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation. Investigational New Drugs, 2020, 38, 194-201.	1.2	5
849	The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis. Pathology and Oncology Research, 2020, 26, 1137-1143.	0.9	1
850	Genetic and Epigenetic Alterations in Cancer. , 2020, , 209-224.e2.		5
851	Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis. Clinical and Translational Oncology, 2020, 22, 892-899.	1.2	5
852	Real-world use of osimertinib in nonâ€“small cell lung cancer: ASTRIS study Korean subgroup analysis. Current Medical Research and Opinion, 2020, 36, 477-482.	0.9	9
853	Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clinical Lung Cancer, 2020, 21, 232-237.	1.1	24
854	Longitudinal monitoring of somatic genetic alterations in circulating cellâ€free DNA during treatment with epidermal growth factor receptorâ€“tyrosine kinase inhibitors. Cancer, 2020, 126, 219-227.	2.0	20
855	Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. Journal of Thoracic Oncology, 2020, 15, 138-143.	0.5	33
856	Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of cliniciansâ€™ attitudes. Clinical and Translational Oncology, 2020, 22, 844-851.	1.2	21
857	Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. Clinical Oncology, 2020, 32, e1-e9.	0.6	6
858	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Nonâ€“small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer, 2020, 21, 1-14.e3.	1.1	19
859	Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. Journal of Clinical Oncology, 2020, 38, 124-136.	0.8	295
860	Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010â€“2016 in Sweden: A nationwide observational study. International Journal of Cancer, 2020, 146, 2510-2517.	2.3	14
861	Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report. Investigational New Drugs, 2020, 38, 1192-1195.	1.2	8
862	Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. Critical Reviews in Oncology/Hematology, 2020, 146, 102820.	2.0	53
863	Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 2020, 139, 80-88.	0.9	9
864	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2020, 22, 989-1003.	1.2	59

#	Article	IF	Citations
865	Mechanisms of resistance to osimertinib. Journal of Thoracic Disease, 2020, 12, 2851-2858.	0.6	62
866	The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance. Case Reports in Oncology, 2020, 12, 765-776.	0.3	9
867	Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs. Journal of Cancer Research and Clinical Oncology, 2020, 146, 407-416.	1.2	7
868	Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Nonâ€“Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. Journal of Clinical Oncology, 2020, 38, 115-123.	0.8	327
869	Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer, 2020, 139, 185-194.	0.9	11
870	Impact of Disease and Treatment Response in Drugâ€“Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Nonâ€“Small Cell Lung Cancer. Clinical and Translational Science, 2020, 13, 41-46.	1.5	2
871	Development of an LCâ€“MS/MS method for quantifying two main metabolites of abivertinib in human plasma. Biomedical Chromatography, 2020, 34, e4704.	0.8	3
872	Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance. Molecular Diversity, 2020, 24, 933-947.	2.1	21
873	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. Journal of Thoracic Oncology, 2020, 15, 258-265.	0.5	53
874	Therapies after first-line afatinib in patients with EGFRm⁺ NSCLC in Japan: retrospective analysis of LUX-Lung 3. Future Oncology, 2020, 16, 49-60.	1.1	4
875	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. Expert Review of Respiratory Medicine, 2020, 14, 367-383.	1.0	21
876	Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review. Internal Medicine, 2020, 59, 823-828.	0.3	9
877	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	39
878	Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC â€” Tarring all Patients With the Same Brush?. Journal of Thoracic Oncology, 2020, 15, 12-14.	0.5	0
879	The Evolving Landscape of Resistance to Osimertinib. Journal of Thoracic Oncology, 2020, 15, 18-21.	0.5	37
880	Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Lung Cancer, 2020, 140, 71-79.	0.9	8
881	Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1. Pathology Research and Practice, 2020, 216, 152797.	1.0	9
882	Genomics and the History of Precision Oncology. Surgical Oncology Clinics of North America, 2020, 29, 35-49.	0.6	23

#	Article	IF	Citations
883	Combined treatment with Nâ€acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line. Cancer Medicine, 2020, 9, 1495-1502.	1.3	16
884	Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. Journal of Thoracic Oncology, 2020, 15, 637-648.	0.5	83
885	Twentyâ€five years of Respirology: Advances in lung cancer. Respirology, 2020, 25, 26-31.	1.3	2
886	Exosomes transmit T790M mutationâ€induced resistance in EGFRâ€mutant NSCLC by activating PI3K/AKT signalling pathway. Journal of Cellular and Molecular Medicine, 2020, 24, 1529-1540.	1.6	51
887	Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Nonâ€“Small-Cell Lung Cancer: A Clash of the Generations. Clinical Lung Cancer, 2020, 21, e216-e228.	1.1	89
888	Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. European Journal of Cancer, 2020, 125, 49-57.	1.3	45
889	HPV-related Sinonasal Carcinoma. American Journal of Surgical Pathology, 2020, 44, 305-315.	2.1	37
890	Novel molecular targets for the treatment of lung cancer. Current Opinion in Oncology, 2020, 32, 37-43.	1.1	20
891	Osimertinib for Patients With Nonâ€“Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). Journal of Clinical Oncology, 2020, 38, 488-495.	0.8	233
892	Validation of an analytical method using HPLCâ€“MS/MS to quantify osimertinib in human plasma and supplementary stability results. Biomedical Chromatography, 2020, 34, e4771.	0.8	16
893	Osimertinib in Patients With Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. Journal of Clinical Oncology, 2020, 38, 538-547.	0.8	221
894	Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Lung Cancer, 2020, 140, 19-26.	0.9	16
895	Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC. Lung Cancer, 2020, 139, 133-139.	0.9	16
896	Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 2020, 382, 41-50.	13.9	1,725
897	Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. European Journal of Cancer, 2020, 124, 110-122.	1.3	56
898	Stereotactic Radiosurgery to More Than 10 Brain Metastases: Evidence to Support the Role of Radiosurgery for Ideal Hippocampal Sparing in the Treatment of Multiple Brain Metastases. World Neurosurgery, 2020, 135, e174-e180.	0.7	19
899	P5 eHealth: An Agenda for the Health Technologies of the Future. , 2020, , .		21
900	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e191-e204.	1.1	26

#	Article	IF	Citations
901	Activation of insulinâ€like growth factorâ€1 receptor confers acquired resistance to osimertinib in nonâ€small cell lung cancer withEGFRT790M mutation. Thoracic Cancer, 2020, 11, 140-149.	0.8	34
902	Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinumâ€pemetrexed for T790M mutationâ€positive advanced nonâ€“small cell lung cancer. Cancer, 2020, 126, 373-380.	2.0	95
903	Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands. European Journal of Cancer Care, 2020, 29, e13210.	0.7	3
904	Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers. Frontiers in Pharmacology, 2019, 10, 1533.	1.6	12
905	Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation. Case Reports in Oncology, 2020, 12, 918-921.	0.3	1
906	Osimertinib induced cardiomyopathy. Medicine (United States), 2020, 99, e22301.	0.4	11
907	Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations. BMC Cancer, 2020, 20, 951.	1.1	6
908	Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations. Immunotherapy, 2020, 12, 1195-1207.	1.0	2
909	A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. Diagnostics, 2020, 10, 765.	1.3	7
910	Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. Lung Cancer, 2020, 148, 100-104.	0.9	6
911	Superior efficacy of immunotherapyâ€based combinations over monotherapy for EGFR â€mutant nonâ€small cell lung cancer acquired resistance to EGFRâ€TKIs. Thoracic Cancer, 2020, 11, 3501-3509.	0.8	9
912	Ramucirumab or placebo plus erlotinib in EGFRâ€mutated, metastatic nonâ€smallâ€cell lung cancer: East Asian subset of RELAY. Cancer Science, 2020, 111, 4510-4525.	1.7	17
913	Understanding EGFR heterogeneity in lung cancer. ESMO Open, 2020, 5, e000919.	2.0	32
914	Non-small cell lung cancer targetable mutations: present and future. Precision Cancer Medicine, 0, 3, 5-5.	1.8	3
915	Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants. Journal of Thoracic Disease, 2020, 12, 4057-4069.	0.6	9
916	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. Cancers, 2020, 12, 2658.	1.7	10
917	Osimertinib versus platinumâ€“pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Annals of Oncology, 2020, 31, 1536-1544.	0.6	149
918	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer, 2020, 149, 33-40.	0.9	12

#	Article	IF	Citations
919	MicroRNA â€200b is a potential biomarker of the expression of PDâ€L1 in patients with lung cancer. Thoracic Cancer, 2020, 11, 2975-2982.	0.8	12
920	Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data. Future Oncology, 2020, 16, 2569-2586.	1.1	2
921	Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives. Translational Lung Cancer Research, 2020, 9, 1000-1014.	1.3	9
922	The Role of Stereotactic Biopsy in Brain Metastases. Neurosurgery Clinics of North America, 2020, 31, 515-526.	0.8	6
923	Alternative splicing of HER2: a novel mediator of EGFR TKI resistance. Translational Lung Cancer Research, 2020, 9, 1606-1612.	1.3	1
924	Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study. Cancers, 2020, 12, 3002.	1.7	22
925	Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study. Lung Cancer, 2020, 150, 97-106.	0.9	4
926	Postoperative management for non-small cell lung cancer harboring EGFR mutations. Journal of Thoracic Disease, 2020, 12, 4556-4560.	0.6	0
927	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Critical Reviews in Oncology/Hematology, 2020, 156, 103119.	2.0	97
928	Traitement des cancers bronchiques non Ã petites cellules de stades avancÃ©s mutÃ©s EGFR : quels inhibiteurs ? Quelles sÃ©quences thÃ©rapeutiques ?. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S195-2S211.	0.0	2
930	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2020, 31, 1491-1505.	0.6	658
931	Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduction and Targeted Therapy, 2020, 5, 228.	7.1	120
932	Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. Targeted Oncology, 2020, 15, 503-512.	1.7	12
933	A self-powered bidirectional partition microfluidic chip with embedded microwells for highly sensitive detection of EGFR mutations in plasma of non-small cell lung cancer patients. Talanta, 2020, 220, 121426.	2.9	16
934	Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation. Future Oncology, 2020, 16, 1537-1547.	1.1	6
935	Successful osimertinib retreatment after extremely early onset severe pneumonitis in firstâ€line treatment of lung adenocarcinoma. Thoracic Cancer, 2020, 11, 2713-2716.	0.8	4
936	Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-MutantÂLung Adenocarcinoma Who Experienced Small-Cell Transformationâ"Mediated Erlotinib Resistance After Failure of Chemotherapy. JTO Clinical and Research Reports, 2020, 1, 100010.	0.6	0
937	Application of Zizao Yangrong Granules for Treating Targeted Drugsâ€"Related Skin Xerosis: A Randomized Double-Blinded Controlled Study. Integrative Cancer Therapies, 2020, 19, 153473542092483.	0.8	0

#	Article	IF	Citations
938	ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib. Translational Lung Cancer Research, 2020, 9, 532-540.	1.3	17
939	<scp>CDK4/6</scp> inhibitor palbociclib overcomes acquired resistance to thirdâ€generation <scp>EGFR</scp> inhibitor osimertinib in <scp>nonâ€small</scp> cell lung cancer (<scp>NSCLC</scp>). Thoracic Cancer, 2020, 11, 2389-2397.	0.8	36
940	Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer. Journal of Thoracic Disease, 2020, 12, 2883-2895.	0.6	19
941	Innovations in Metastatic Brain Tumor Treatment. , 2020, , .		1
942	A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report . OncoTargets and Therapy, 2020, Volume 13, 11177-11181.	1.0	10
943	Tyrosine Kinase Receptors in Oncology. International Journal of Molecular Sciences, 2020, 21, 8529.	1.8	46
944	How should molecular findings be integrated in the classification for lung cancer?. Translational Lung Cancer Research, 2020, 9, 2245-2254.	1.3	5
945	Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib. Translational Lung Cancer Research, 2020, 9, 1952-1962.	1.3	10
946	Finding chinks in the osimertinib resistance armor. Translational Lung Cancer Research, 2020, 9, 2173-2177.	1.3	3
947	Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib. Scientific Reports, 2020, 10, 20243.	1.6	21
948	Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study. ESMO Open, 2020, 5, e000864.	2.0	9
949	Osimertinib Resistance With a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient With Non-Small Cell Lung Cancer: A Case Report. Frontiers in Oncology, 2020, 10, 542277.	1.3	8
950	Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy. Diagnostics, 2020, 10, 1006.	1.3	7
951	A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy. Frontiers in Microbiology, 2020, 11, 583525.	1.5	4
952	Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way. Annals of Translational Medicine, 2020, 8, 1111-1111.	0.7	2
953	Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer, 2020, 20, 1186.	1.1	8
954	Liquid biopsy is a valuable tool in the diagnosis and management of lung cancer. Journal of Thoracic Disease, 2020, 12, 7048-7056.	0.6	9
955	Ceramide Pathway Regulators Predict Clinical Prognostic Risk and Affect the Tumor Immune Microenvironment in Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 562574.	1.3	4

#	Article	IF	Citations
956	Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis. Journal of Cancer, 2020, 11, 7283-7290.	1.2	5
957	Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs. Expert Review of Anticancer Therapy, 2020, 20, 743-753.	1.1	1
958	Molecular profiling of non-small cell lung cancer. PLoS ONE, 2020, 15, e0236580.	1.1	17
959	Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis. Future Oncology, 2020, 16, 1585-1595.	1.1	5
960	Cholangiocarcinoma: investigations into pathway-targeted therapies. Expert Review of Anticancer Therapy, 2020, 20, 765-773.	1.1	13
961	Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S : A case report and literature review. Thoracic Cancer, 2020, 11, 2743-2748.	0.8	4
962	Enhanced Anti-Brain Metastasis from Non-Small Cell Lung Cancer of Osimertinib and Doxorubicin Co-Delivery Targeted Nanocarrier . International Journal of Nanomedicine, 2020, Volume 15, 5491-5501.	3.3	19
963	Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAF^{V600E} Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report . OncoTargets and Therapy, 2020, Volume 13, 7933-7939.	1.0	16
964	Non-Small-Cell Lung Cancer-Sensitive Detection of the p.Thr790Met EGFR Alteration by Preamplification before PNA-Mediated PCR Clamping and Pyrosequencing. Diagnostics, 2020, 10, 527.	1.3	5
965	Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing. Biomedicines, 2020, 8, 273.	1.4	13
966	Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancer. Biochemical and Biophysical Research Communications, 2020, 529, 760-765.	1.0	5
967	A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Frontiers in Pharmacology, 2020, 11, 891.	1.6	48
968	Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer. BMC Cancer, 2020, 20, 699.	1.1	6
969	KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. Journal of Thoracic Disease, 2020, 12, 3836-3843.	0.6	47
970	An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib. Radiotherapy and Oncology, 2020, 152, 96-100.	0.3	29
971	Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study. EBioMedicine, 2020, 57, 102861.	2.7	21
972	Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Technology in Cancer Research and Treatment, 2020, 19, 153303382094042.	0.8	1
973	Effective inhibition of cancer cells by recombinant adenovirus expressing EGFR-targeting artificial microRNA and reversed-caspase-3. PLoS ONE, 2020, 15, e0237098.	1.1	7

#	Article	IF	Citations
974	Clinical implementation of plasma EGFR T790M testing using droplet digital PCR in TKI-resistant NSCLC patients. Experimental and Molecular Pathology, 2020, 116, 104515.	0.9	10
975	Lysocardiolipin Acyltransferase 1-Anaplastic Lymphoma Receptor Tyrosine Kinase: A Novel Crizotinib-Sensitive Fusion Gene in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2020, 15, e55-e57.	0.5	2
976	Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib. Journal of Thoracic Oncology, 2020, 15, e54-e55.	0.5	7
977	BRCA sequencing of tumors: understanding its implications in the oncology community. Chinese Clinical Oncology, 2020, 9, 66-66.	0.4	6
978	A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity . Lung Cancer: Targets and Therapy, 2020, Volume 11, 73-103.	1.3	4
979	Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC. Journal of Thoracic Oncology, 2020, 15, 1705-1708.	0.5	2
980	Tyrosine kinase inhibitors for solid tumors in the past 20Âyears (2001â€“2020). Journal of Hematology and Oncology, 2020, 13, 143.	6.9	226
981	Patient-Centered Approach to Benefitâ€“Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Nonâ€“Small-Cell Lung Cancer. JCO Clinical Cancer Informatics, 2020, 4, 769-783.	1.0	1
982	Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncology, 2020, 16, 2799-2808.	1.1	50
983	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Science Translational Medicine, 2020, 12, .	5.8	101
984	Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases. BMC Cancer, 2020, 20, 837.	1.1	6
985	Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore. Journal of Medical Economics, 2020, 23, 1330-1339.	1.0	11
986	Optimal sequencing strategies in the treatment of EGFR mutationâ€“positive nonâ€“small cell lung cancer: Clinical benefits and cost-effectiveness. American Journal of Health-System Pharmacy, 2020, 77, 1466-1476.	0.5	10
987	MET amplification results in heterogeneous responses to osimertinib in EGFRâ€mutant lung cancer treated with erlotinib. Cancer Science, 2020, 111, 3813-3823.	1.7	9
988	Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review. Annals of Palliative Medicine, 2020, 9, 3038-3047.	0.5	10
989	The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1149-1158.	1.3	17
990	EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes. Translational Lung Cancer Research, 2020, 9, 1084-1092.	1.3	5
991	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. Journal of Thoracic Oncology, 2020, 15, 1857-1870.	0.5	19

#	Article	IF	Citations
992	ctDNA as a cancer biomarker: A broad overview. Critical Reviews in Oncology/Hematology, 2020, 155, 103109.	2.0	128
993	Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. Cancer Chemotherapy and Pharmacology, 2020, 86, 517-525.	1.1	3
994	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. Journal of Thoracic Oncology, 2020, 15, 1907-1918.	0.5	85
995	Osimertinib in ResectedEGFR-Mutated Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2020, 383, 1711-1723.	13.9	1,042
996	Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I. Molecular Cancer Therapeutics, 2020, 19, 2298-2307.	1.9	30
997	Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma. Translational Lung Cancer Research, 2020, 9, 1225-1234.	1.3	14
998	Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations. Frontiers in Oncology, 2020, 10, 1494.	1.3	7
999	Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers, 2020, 12, 2394.	1.7	34
1000	The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease. Radiation Oncology, 2020, 15, 207.	1.2	16
1001	The efficacy and safety of osimertinib in treating nonsmall cell lung cancer. Medicine (United States), 2020, 99, e21826.	0.4	12
1002	Circulating Tumor DNA in Cancer Management: A Value Proposition. journal of applied laboratory medicine, The, 2020, 5, 1017-1026.	0.6	0
1003	Surgical resection of symptomatic brain metastases improves the clinical status and facilitates further treatment. Cancer Medicine, 2020, 9, 7503-7510.	1.3	33
1004	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nature Communications, 2020, 11, 4607.	5.8	69
1006	An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. Frontiers in Oncology, 2020, 10, 1481.	1.3	25
1007	Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Current Oncology Reports, 2020, 22, 119.	1.8	9
1008	Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression. Theranostics, 2020, 10, 10925-10939.	4.6	20
1009	The utility of transbronchial rebiopsy for peripheral pulmonary lesions in patients with advanced non-squamous non-small cell lung cancer. BMC Pulmonary Medicine, 2020, 20, 238.	0.8	5
1010	Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative. BMC Pulmonary Medicine, 2020, 20, 240.	0.8	16

#	Article	IF	Citations
1011	Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790Mâ€“positive Nonâ€“Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study. Clinical Cancer Research, 2020, 26, 6168-6175.	3.2	19
1012	Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutationâ€”A Case Report and a Review of the Literature. Medicina (Lithuania), 2020, 56, 403.	0.8	12
1014	Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. Current Medical Research and Opinion, 2020, 36, 1667-1675.	0.9	11
1015	erbB in NSCLC as a molecular target: current evidences and future directions. ESMO Open, 2020, 5, e000724.	2.0	22
1016	Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. Lung Cancer, 2020, 148, 69-78.	0.9	25
1017	JuBei Oral Liquid Induces Mitochondria-Mediated Apoptosis in NSCLC Cells . OncoTargets and Therapy, 2020, Volume 13, 7585-7598.	1.0	1
1018	Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. Frontiers in Oncology, 2020, 10, 602762.	1.3	59
1019	Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring EGFR G719A/V769M Complex Mutation . OncoTargets and Therapy, 2020, Volume 13, 12027-12031.	1.0	0
1020	What Is the Standard First-Line Treatment for Advanced Nonâ€“Small Cell Lung Cancer?. Cancer Journal (Sudbury, Mass), 2020, 26, 485-495.	1.0	5
1021	Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report. BMC Cancer, 2020, 20, 1177.	1.1	3
1022	Changing paradigm in advanced and metastatic non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 6992-7001.	0.6	3
1023	Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments . Cancer Management and Research, 2020, Volume 12, 12593-12602.	0.9	11
1024	Timing of Development of Symptomatic Brain Metastases from Non-Small Cell Lung Cancer: Impact on Symptoms, Treatment, and Survival in the Era of Molecular Treatments. Cancers, 2020, 12, 3618.	1.7	8
1025	Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis. Annals of Palliative Medicine, 2020, 9, 4233-4245.	0.5	10
1026	Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. ACS Medicinal Chemistry Letters, 2020, 11, 2484-2490.	1.3	26
1027	Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 587377.	1.3	1
1028	Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. Journal of Thoracic Disease, 2020, 12, 5096-5103.	0.6	0
1029	EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges. Tumori, 2020, 107, 030089162096813.	0.6	2

#	Article	IF	Citations
1030	PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clinical Cancer Research, 2020, 26, 4186-4197.	3.2	44
1031	Osimertinib in NSCLC: Real-World Data From NewÂZealand. JTO Clinical and Research Reports, 2020, 1, 100022.	0.6	3
1032	Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples. BMC Cancer, 2020, 20, 366.	1.1	3
1033	A phase II study of Osimertinib for patients with radiotherapy-naÃ¯ve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L). BMC Cancer, 2020, 20, 370.	1.1	8
1034	Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC. Lung Cancer Management, 2020, 9, LMT29.	1.5	5
1035	The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy. JTO Clinical and Research Reports, 2020, 1, 100008.	0.6	4
1036	EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib. Translational Lung Cancer Research, 2020, 9, 239-245.	1.3	24
1037	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. Investigational New Drugs, 2020, 38, 1854-1861.	1.2	18
1038	Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs, 2020, 80, 883-892.	4.9	5
1039	Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. JCO Precision Oncology, 2020, 4, 520-533.	1.5	9
1040	Osimertinib in EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 2020, 382, 1863-1865.	13.9	7
1041	Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2427-2433.	1.2	41
1042	Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 510.	1.3	3
1043	Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 2020, 11, 2220.	5.8	31
1044	The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 153-155.	0.6	2
1045	Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer. Journal of Controlled Release, 2020, 324, 482-492.	4.8	16
1046	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. Cancers, 2020, 12, 1196.	1.7	65
1047	TIDieR checklist evaluation of clinical trial intervention reporting for recent FDA-approved anticancer medications. BMJ Evidence-Based Medicine, 2020, 25, 97-101.	1.7	6

#	Article	IF	Citations
1048	Performance Characteristics of a Real-Time Polymerase Chain Reaction Assay for the Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Plasma Samples of Non-Small Cell Lung Cancer (NSCLC) Patients. Molecular Diagnosis and Therapy, 2020, 24, 451-460.	1.6	2
1049	Systemic treatment of brain metastases in non-small cell lung cancer. European Journal of Cancer, 2020, 132, 187-198.	1.3	61
1050	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E nonâ€“small cell lung cancer. European Journal of Cancer, 2020, 132, 211-223.	1.3	53
1052	Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2051-2066.	1.2	67
1053	EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature. Clinical Lung Cancer, 2020, 21, e597-e600.	1.1	15
1054	Current Landscape of Personalized Therapy. Thoracic Surgery Clinics, 2020, 30, 121-125.	0.4	2
1055	Detection of Meningeal Metastasis in the Cerebrospinal Fluid in Lung Adenocarcinoma: Case Report. Clinical Lung Cancer, 2020, 21, e493-e496.	1.1	1
1056	Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report. Clinical Lung Cancer, 2020, 21, e601-e606.	1.1	6
1057	AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation. Lung Cancer, 2020, 146, 70-77.	0.9	12
1058	Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab. Translational Cancer Research, 2020, 9, 1307-1310.	0.4	0
1059	Significance of a Liquid Biopsy on Lung Cancer. Japanese Journal of Lung Cancer, 2020, 60, 67-73.	0.0	0
1060	Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives. Expert Review of Anticancer Therapy, 2020, 20, 531-542.	1.1	6
1061	Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. PLoS ONE, 2020, 15, e0234302.	1.1	13
1062	A circulating tumor cell-based digital assay for the detection of EGFR T790M mutation in advanced non-small cell lung cancer. Journal of Materials Chemistry B, 2020, 8, 5636-5644.	2.9	13
1063	A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care. Journal of Oncology Pharmacy Practice, 2020, 26, 1452-1460.	0.5	9
1064	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. Journal of Clinical Medicine, 2020, 9, 1762.	1.0	10
1065	Detection of Low-level EGFR c.2369 Câ€‰›â€‰T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes. Pathology and Oncology Research, 2020, 26, 2371-2379.	0.9	4
1066	Chitooligosaccharides-modified PLGA nanoparticles enhance the antitumor efficacy of AZD9291 (Osimertinib) by promoting apoptosis. International Journal of Biological Macromolecules, 2020, 162, 262-272.	3.6	20

#	Article	IF	Citations
1067	Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. Current Oncology, 2020, 27, 146-155.	0.9	14
1068	Concomitant genetic alterations having greater impact on the clinical benefit of EGFRâ€TKIs in EGFR â€mutant advanced NSCLC than BIM deletion polymorphism. Clinical and Translational Medicine, 2020, 10, 337-345.	1.7	7
1069	Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 821-827.	0.7	5
1070	Glasgow prognostic score predicts efficacy and prognosis in patients with advanced nonâ€small cell lung cancer receiving EGFRâ€TKI treatment. Thoracic Cancer, 2020, 11, 2188-2195.	0.8	11
1071	Advances in Treatment of Locally Advanced or Metastatic Nonâ€“Small Cell Lung Cancer. Clinics in Chest Medicine, 2020, 41, 223-235.	0.8	18
1072	Targeted Therapy for Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 409-434.	0.8	11
1073	Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis. Targeted Oncology, 2020, 15, 337-345.	1.7	4
1074	Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study. Investigational New Drugs, 2020, 38, 1915-1920.	1.2	7
1075	Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC. Clinical Lung Cancer, 2020, 21, 562-567.	1.1	5
1076	Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan. Japanese Journal of Clinical Oncology, 2020, 50, 909-919.	0.6	19
1077	Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. Journal of Clinical Oncology, 2020, 38, 2926-2936.	0.8	107
1078	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. Journal of Clinical Medicine, 2020, 9, 1870.	1.0	16
1079	Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Nonâ€“Small Cell Lung Cancer. Cancer Research, 2020, 80, 3292-3304.	0.4	17
1080	Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a firstâ€line treatment for advanced EGFRâ€mutant nonâ€small cell lung cancer. Clinical and Translational Medicine, 2020, 10, e33.	1.7	13
1081	Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy. Journal of Thoracic Oncology, 2020, 15, 1369-1375.	0.5	68
1082	Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Journal of Oncology Pharmacy Practice, 2020, 26, 1461-1474.	0.5	61
1083	Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Thoracic Disease, 2020, 12, 2859-2876.	0.6	11
1084	Potential Procedural Efficiencies and Challenges of Combining Multiple Type II Variations into a Single EU-RMP. Pharmaceutical Medicine, 2020, 34, 1-5.	1.0	0

#	Article	IF	Citations
1085	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nature Reviews Urology, 2020, 17, 271-291.	1.9	32
1086	Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System. Scientific Reports, 2020, 10, 4803.	1.6	48
1087	Serum Has Higher Proportion of Janus Kinase 2 V617F Mutation Compared to Paired EDTA-Whole Blood Sample: A Model for Somatic Mutation Quantification Using qPCR and the 2-âˆ†âˆ†Cq Method. Diagnostics, 2020, 10, 153.	1.3	8
1088	Genomic landscape of acquired resistance to thirdâ€generation EGFR tyrosine kinase inhibitors in EGFR T790Mâ€mutant nonâ€“small cell lung cancer. Cancer, 2020, 126, 2704-2712.	2.0	26
1089	Integrative Omics Analysis Reveals Soluble Cadherin-3 as a Survival Predictor and an Early Monitoring Marker of EGFR Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Clinical Cancer Research, 2020, 26, 3220-3229.	3.2	13
1090	Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Journal of Cancer, 2020, 11, 2060-2067.	1.2	7
1091	TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Annals of Oncology, 2020, 31, 507-516.	0.6	289
1092	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. Journal of Thoracic Oncology, 2020, 15, 1015-1026.	0.5	58
1093	Managing the Isolated Central Nervous System Progression in Patients With Oncogene-Driven Metastatic NSCLC: Does Circulating Tumor DNA Add to Management?. Journal of Thoracic Oncology, 2020, 15, 314-316.	0.5	0
1094	The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis. Journal of Cancer, 2020, 11, 3106-3113.	1.2	3
1095	Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). Lung Cancer, 2020, 143, 27-35.	0.9	42
1096	Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report. Translational Lung Cancer Research, 2020, 9, 139-143.	1.3	7
1097	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Translational Lung Cancer Research, 2020, 9, 111-138.	1.3	27
1098	Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design. Cell Reports, 2020, 30, 3951-3963.e4.	2.9	17
1099	Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies. Biochemistry, 2020, 59, 1428-1441.	1.2	35
1100	Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report. Translational Lung Cancer Research, 2020, 9, 144-147.	1.3	4
1101	Advances in covalent kinase inhibitors. Chemical Society Reviews, 2020, 49, 2617-2687.	18.7	160
1102	Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. Expert Review of Respiratory Medicine, 2020, 14, 565-576.	1.0	9

#	Article	IF	Citations
1103	Aspirin sensitizes osimertinibâ€resistant NSCLC cells inÂvitro and inÂvivo via Bimâ€dependent apoptosis induction. Molecular Oncology, 2020, 14, 1152-1169.	2.1	20
1104	The lncRNA NORAD/miR-520a-3p Facilitates Malignancy in Non-Small Cell Lung Cancer via PI3k/Akt/mTOR Signaling Pathway . OncoTargets and Therapy, 2020, Volume 13, 1533-1544.	1.0	37
1105	The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 233-242.	1.0	7
1106	Osimertinib, a thirdâ€generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its realâ€world efficacy and safety in advanced/recurrent nonâ€small cell lung carcinoma. Thoracic Cancer, 2020, 11, 935-942.	0.8	24
1107	EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in nonâ€small cell lung cancer patients. Clinical and Translational Medicine, 2020, 9, 17.	1.7	19
1108	A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. Pharmacology Research and Perspectives, 2020, 8, e00613.	1.1	6
1109	Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung Cancer. Applied Sciences (Switzerland), 2020, 10, 3704.	1.3	1
1110	Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Lung Cancer, 2020, 146, 310-317.	0.9	46
1111	Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2020, 86, 211-219.	1.1	14
1112	Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients. Clinica Chimica Acta, 2020, 510, 88-96.	0.5	4
1113	Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer. Annals of Palliative Medicine, 2020, 9, 1681-1687.	0.5	7
1114	Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the <i>EGFR</i> T790M Mutation. Internal Medicine, 2020, 59, 2161-2164.	0.3	4
1115	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Advances in Cancer Research, 2020, 147, 1-57.	1.9	32
1116	Molecular therapeutic targets in non-small cell lung cancer. Expert Review of Anticancer Therapy, 2020, 20, 647-661.	1.1	46
1117	A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Annals of Oncology, 2020, 31, 1397-1404.	0.6	98
1118	Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma. Scientific Reports, 2020, 10, 10881.	1.6	9
1119	Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases . OncoTargets and Therapy, 2020, Volume 13, 647-656.	1.0	7
1120	Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 107, 62-71.	0.4	25

#	Article	IF	Citations
1121	Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature. In Vivo, 2020, 34, 315-319.	0.6	8
1122	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. Expert Opinion on Drug Safety, 2020, 19, 187-204.	1.0	5
1123	Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer. Translational Cancer Research, 2020, 9, 372-381.	0.4	4
1124	Elevated SLC2A1 Expression Correlates with Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics. DNA and Cell Biology, 2020, 39, 631-644.	0.9	15
1125	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respiratory Medicine,the, 2020, 8, 561-572.	5.2	47
1126	Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer. Lancet Respiratory Medicine,the, 2020, 8, 528-529.	5.2	4
1127	Current approaches to the management of brain metastases. Nature Reviews Clinical Oncology, 2020, 17, 279-299.	12.5	276
1128	Evolving use of liquid biopsy in non-small-cell-lung cancer patients. International Journal of Biological Markers, 2020, 35, 23-25.	0.7	3
1129	Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with nonâ€small cell lung cancer harboring EGFR mutation. Thoracic Cancer, 2020, 11, 1045-1051.	0.8	14
1130	Upfront osimertinib â€" winner takes it all?. Nature Reviews Clinical Oncology, 2020, 17, 202-203.	12.5	4
1131	The Value of Next-Generation Sequencing for Treatment in Non-Small Cell Lung Cancer Patients: The Observational, Real-World Evidence in China. BioMed Research International, 2020, 2020, 1-7.	0.9	3
1132	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell, 2020, 37, 104-122.e12.	7.7	267
1133	The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. Journal of Geriatric Oncology, 2020, 11, 369-379.	0.5	20
1134	Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. Lung Cancer, 2020, 141, 82-88.	0.9	23
1135	Temperature-Responsive Multilayer Films of Micelle-Based Composites for Controlled Release of a Third-Generation EGFR Inhibitor. ACS Applied Polymer Materials, 2020, 2, 741-750.	2.0	182
1136	Enabling Precision Oncology Through Precision Diagnostics. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 97-121.	9.6	50
1137	Front-line Therapy in Advanced Nonâ€"Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis. Clinical Therapeutics, 2020, 42, 338-350.e4.	1.1	13
1138	Molecular profiling for precision cancer therapies. Genome Medicine, 2020, 12, 8.	3.6	447

#	Article	IF	Citations
1139	Abivertinib in patients with T790Mâ€positive advanced NSCLC and its subsequent treatment with osimertinib. Thoracic Cancer, 2020, 11, 594-602.	0.8	14
1140	Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 2037-2046.	3.2	142
1141	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment inEGFR-Mutated Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 2244-2256.	3.2	75
1142	Precision Management of Advanced Nonâ€“Small Cell Lung Cancer. Annual Review of Medicine, 2020, 71, 117-136.	5.0	101
1143	IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. Molecular Cancer Research, 2020, 18, 549-559.	1.5	34
1144	Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Advances in Therapy, 2020, 37, 946-954.	1.3	15
1145	Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFRâ€mutated lung adenocarcinoma: a report of two cases. Respirology Case Reports, 2020, 8, e00521.	0.3	13
1146	Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib. Scientific Reports, 2020, 10, 691.	1.6	8
1147	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncology, The, 2020, 21, 373-386.	5.1	300
1148	Targeting MET in EGFR resistance in non-small-cell lung cancerâ€”ready for daily practice?. Lancet Oncology, The, 2020, 21, 320-322.	5.1	19
1149	Firstâ€line pembrolizumab for nonâ€“small cell lung cancer patients with PDâ€Ł1Ââ‰¥50% in a multicenter realâ€life cohort: The PEMBREIZH study. Cancer Medicine, 2020, 9, 2309-2316.	1.3	35
1150	Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790Mâ€“positive nonâ€“small cell lung cancer: West Japan Oncology Group 8815L/LPS study. Cancer, 2020, 126, 1940-1948.	2.0	18
1151	Targeting the Cardiotoxicity of EpidermalÂGrowth Factor ReceptorÂInhibitors. JACC: CardioOncology, 2020, 2, 11-12.	1.7	3
1152	Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. Journal of Clinical Medicine, 2020, 9, 1268.	1.0	42
1153	Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors. Infectious Disease Clinics of North America, 2020, 34, 257-270.	1.9	0
1154	Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Nonâ€“Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study. Clinical Lung Cancer, 2020, 21, e464-e473.	1.1	24
1155	Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer. Molecular Cancer Research, 2020, 18, 517-528.	1.5	60
1156	Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. Journal of Clinical Medicine, 2020, 9, 1047.	1.0	47

#	Article	IF	Citations
1157	Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease. JAMA Network Open, 2020, 3, e201617.	2.8	28
1158	Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127167.	1.0	34
1159	Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell, 2020, 37, 443-455.	7.7	444
1160	Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. Clinical Lung Cancer, 2020, 21, e488-e492.	1.1	5
1161	Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated WithÂOsimertinib. JACC: CardioOncology, 2020, 2, 1-10.	1.7	44
1162	Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacologica Sinica, 2020, 41, 1366-1376.	2.8	18
1163	Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC. Molecular and Cellular Proteomics, 2020, 19, 928-943.	2.5	9
1164	Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 589-599.	1.0	13
1165	Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer. Frontiers in Genetics, 2020, 11, 281.	1.1	50
1166	Biopsy on Progression in Patients with EGFR Mutationâ€“Positive Advanced Non-Small-Cell Lung Cancerâ€”A Canadian Experience. Current Oncology, 2020, 27, 27-33.	0.9	6
1167	Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations. European Journal of Health Economics, 2020, 21, 931-943.	1.4	7
1168	Identification of somatic copy number variations in plasma cell free DNA correlating with intrinsic resistances to EGFR targeted therapy in T790M negative non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 883-892.	0.6	5
1169	Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers. Clinical Cancer Drugs, 2020, 7, 3-15.	0.3	2
1170	Toward a More Precise Future for Oncology. Cancer Cell, 2020, 37, 431-442.	7.7	21
1171	Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?. Expert Opinion on Pharmacotherapy, 2020, 21, 1287-1298.	0.9	12
1172	The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer. Health Economics Review, 2020, 10, 10.	0.8	1
1173	Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation. Anticancer Research, 2020, 40, 2239-2246.	0.5	2
1174	Complete Remission of Multiple Brain Metastases in a Patient with EGFR-Mutated Non-Small-Cell Lung Cancer Treated with First-Line Osimertinib without Radiotherapy. Case Reports in Oncological Medicine, 2020, 2020, 1-6.	0.2	4

#	Article	IF	Citations
1175	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clinical Cancer Research, 2020, 26, 2654-2663.	3.2	230
1176	Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion. Journal of Thoracic Disease, 2020, 12, 159-164.	0.6	7
1177	Immunotherapy Combined with Chemotherapy as a Promising Therapy for a EGFR Exon 19 Deletion with MET Amplification Patient with Non-Small-Cell Lung Cancer: A Case Report . OncoTargets and Therapy, 2020, Volume 13, 3039-3044.	1.0	1
1178	Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020. Current Oncology, 2020, 27, 52-60.	0.9	13
1179	HeartÂFailure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib. JACC: CardioOncology, 2020, 2, 119-122.	1.7	16
1180	Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review. Clinical Lung Cancer, 2021, 22, e466-e469.	1.1	2
1181	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038240.	2.9	34
1182	Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data. Acta Clinica Belgica, 2021, 76, 224-231.	0.5	1
1183	Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer. Journal of Clinical Pathology, 2021, 74, 116-122.	1.0	5
1184	First-line osimertinib for leptomeningeal metastasis from lung adenocarcinoma with EGFR mutation as the initial and solitary site of postoperative recurrence. International Cancer Conference Journal, 2021, 10, 78-82.	0.2	0
1185	Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 415-423.	0.7	8
1186	Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Critical Reviews in Oncology/Hematology, 2021, 157, 103127.	2.0	8
1187	A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 213-222.	1.2	8
1188	TGFÎ²2-mediated epithelialâ€“mesenchymal transition and NF-Î°B pathway activation contribute to osimertinib resistance. Acta Pharmacologica Sinica, 2021, 42, 451-459.	2.8	33
1189	Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in nonâ€“smallâ€cell lung cancer patients: A network metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 310-318.	0.7	6
1190	Polypharmacy among older advanced lung cancer patients taking EGFR tyrosine kinase inhibitors. Journal of Geriatric Oncology, 2021, 12, 64-71.	0.5	14
1191	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 992-1002.	3.2	36
1192	Dysregulated miR-137 and its target EGFR contribute to the progression of pituitary adenomas. Molecular and Cellular Endocrinology, 2021, 520, 111083.	1.6	3

#	Article	IF	Citations
1193	Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population. Future Oncology, 2021, 17, 103-115.	1.1	1
1194	AZD9291 Resistance Reversal Activity of a pHâ€Sensitive Nanocarrier Dualâ€Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC. Advanced Science, 2021, 8, 2002922.	5.6	23
1195	Phase II openâ€label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA : Liquidâ€Lungâ€A. Thoracic Cancer, 2021, 12, 444-452.	0.8	2
1196	Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. Archives of Medical Research, 2021, 52, 261-269.	1.5	14
1197	Development of an LCâ€“MS/MS method for quantifying ASK120067, a novel mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) as well as its main metabolite in human plasma and its application in a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1162, 122488.	1.2	3
1198	Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. Trends in Cancer, 2021, 7, 410-429.	3.8	13
1199	Preâ€existing interstitial lung disease does not affect prognosis in nonâ€small cell lung cancer patients with <scp>PDâ€L1</scp> expression â‰¥50% on firstâ€line pembrolizumab. Thoracic Cancer, 2021, 12, 304-313.	0.8	17
1200	Impact of the generation of <scp>EGFRâ€TKIs</scp> administered as prior therapy on the efficacy of osimertinib in patients with nonâ€small cell lung cancer harboring <scp>EGFR T790M</scp> mutation. Thoracic Cancer, 2021, 12, 329-338.	0.8	2
1201	Osimertinib combined with bevacizumab for leptomeningeal metastasis from <scp>EGFRâ€mutation nonâ€small cell</scp> lung cancer: A phase <scp>II singleâ€arm</scp> prospective clinical trial. Thoracic Cancer, 2021, 12, 172-180.	0.8	20
1202	Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncology, 2021, 17, 965-977.	1.1	40
1203	EGFR-mutant NSCLC: emerging novel drugs. Current Opinion in Oncology, 2021, 33, 87-94.	1.1	11
1204	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. Journal of Thoracic Oncology, 2021, 16, 764-773.	0.5	128
1205	Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy. Lung Cancer, 2021, 151, 39-43.	0.9	14
1206	Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction. Lung Cancer, 2021, 153, 186-192.	0.9	16
1207	Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase InhibitorsÂFor Advanced EGFR+ NSCLC. Journal of Thoracic Oncology, 2021, 16, 740-763.	0.5	115
1208	Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity. Journal of Controlled Release, 2021, 329, 1249-1261.	4.8	27
1209	Comprehensive crossâ€platform comparison of methods for nonâ€invasive EGFR mutation testing: results of the RING observational trial. Molecular Oncology, 2021, 15, 43-56.	2.1	18
1210	Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. Future Oncology, 2021, 17, 471-486.	1.1	11

#	Article	IF	Citations
1211	Predicting osimertinibâ€treatment outcomes through EGFR mutantâ€fraction monitoring in the circulating tumor DNA of EGFR T790Mâ€positive patients with nonâ€small cell lung cancer (WJOG8815L). Molecular Oncology, 2021, 15, 126-137.	2.1	12
1212	Erlotinib and bevacizumab in elderly patients â‰¥75Âyears old with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Investigational New Drugs, 2021, 39, 210-216.	1.2	4
1213	Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. Investigational New Drugs, 2021, 39, 571-577.	1.2	20
1214	Brain metastases of lung cancer: comparison of survival outcomes among whole brain radiotherapy, whole brain radiotherapy with consecutive boost, and simultaneous integrated boost. Journal of Cancer Research and Clinical Oncology, 2021, 147, 569-577.	1.2	11
1215	When compared to plasmaâ€based detection, osimertinibâ€treated nonâ€small cell lung cancer (NSCLC) with tissue rebiopsyâ€confirmed acquired T790M mutation is associated with better survival. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e35-e39.	0.7	3
1216	Tumors: Non-small Cell Lung Cancer. , 2021, , 1-10.		0
1217	Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. BMC Cancer, 2021, 21, 57.	1.1	3
1218	Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199650.	1.4	24
1219	Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report. In Vivo, 2021, 35, 2941-2945.	0.6	5
1220	Liquid biopsy enters the clinic â€" implementation issues and future challenges. Nature Reviews Clinical Oncology, 2021, 18, 297-312.	12.5	609
1221	Trousseauâ€™s Syndrome Anticipating Lung Adenocarcinoma: A Combination of Novel Direct Oral Anticoagulant and Osimertinib to Treat It. , 2021, 02, .		0
1222	Olmutinib in T790Mâ€positive nonâ€“small cell lung cancer after failure of firstâ€line epidermal growth factor receptorâ€tyrosine kinase inhibitor therapy: A global, phase 2 study. Cancer, 2021, 127, 1407-1416.	2.0	17
1223	Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. JTO Clinical and Research Reports, 2021, 2, 100107.	0.6	15
1224	Exploring the Effect of Differentially Expressed Long Non-coding RNAs Driven by Copy Number Variation on Competing Endogenous RNA Network by Mining Lung Adenocarcinoma Data. Frontiers in Cell and Developmental Biology, 2020, 8, 627436.	1.8	8
1225	A Phase II Trial of Osimertinib as the First-Line Treatment of Nonâ€“Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1. Cancer Research and Treatment, 2021, 53, 93-103.	1.3	2
1226	The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy. OncoTargets and Therapy, 2020, Volume 13, 13425-13435.	1.0	5
1227	Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US. Journal of Medical Economics, 2021, 24, 328-338.	1.0	0
1228	A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases. Journal of Molecular Pathology, 2021, 2, 1-10.	0.5	5

#	Article	IF	Citations
1229	Osimertinib in EGFR-Mutant Non-Small Cell Lung Carcinoma: Clinical Activity and Mechanisms of Resistance. Current Cancer Research, 2021, , 65-73.	0.2	1
1230	Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study. Clinics, 2021, 76, e2251.	0.6	2
1231	The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden. Journal of Medical Economics, 2021, 24, 447-457.	1.0	3
1232	Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report. Respiratory Medicine Case Reports, 2021, 33, 101450.	0.2	2
1233	Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma. Frontiers in Oncology, 2020, 10, 603671.	1.3	8
1234	Radiomics signature of brain metastasis: prediction of EGFR mutation status. European Radiology, 2021, 31, 4538-4547.	2.3	48
1235	Almonertinib-induced interstitial lung disease. Medicine (United States), 2021, 100, e24393.	0.4	10
1236	Management of Brain Metastases. Current Cancer Research, 2021, , 115-137.	0.2	0
1237	Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Frontiers in Pharmacology, 2021, 12, 636324.	1.6	2
1238	Carcinoma de pulmÃ³n no microcÃtico. Medicine, 2021, 13, 1377-1387.	0.0	2
1239	BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Translational Oncology, 2021, 14, 100961.	1.7	1
1240	Secondâ€line therapy with firstâ€or secondâ€generation tyrosine kinase inhibitors in EGFR â€mutated nonâ€small cell lung cancer patients with T790M â€negative or unidentified mutation. Thoracic Cancer, 2021, 12, 1067-1073.	0.8	5
1241	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports, 2021, 2, 100114.	0.6	11
1242	Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists. Current Oncology, 2021, 28, 783-799.	0.9	29
1243	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 699-711.	1.3	12
1244	Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Targeted Oncology, 2021, 16, 165-176.	1.7	69
1245	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCOâ€"Friends of Cancer Research Prior Therapies Work Group. Clinical Cancer Research, 2021, 27, 2408-2415.	3.2	14
1246	Costâ€effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptorâ€mutated nonâ€smallâ€cell lung cancer. Experimental and Therapeutic Medicine, 2021, 21, 343.	0.8	6

#	Article	IF	Citations
1247	Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study. Translational Lung Cancer Research, 2021, 10, 839-854.	1.3	4
1248	In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO). Scientific Reports, 2021, 11, 4590.	1.6	6
1249	Cardiac Safety of Osimertinib: A Review of Data. Journal of Clinical Oncology, 2021, 39, 328-337.	0.8	44
1250	An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update. Expert Opinion on Pharmacotherapy, 2021, 22, 809-819.	0.9	4
1251	Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. Translational Lung Cancer Research, 2021, 10, 878-888.	1.3	4
1252	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer. BMJ Open, 2021, 11, e041345.	0.8	3
1253	The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis. Annals of Palliative Medicine, 2021, 10, 1851-1860.	0.5	1
1254	Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer. Internal Medicine, 2021, 60, 591-594.	0.3	6
1255	Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy. Frontiers in Oncology, 2021, 11, 621992.	1.3	13
1256	Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in nonâ€small cell lung cancer patients: A metaâ€analysis. Thoracic Cancer, 2021, 12, 1096-1105.	0.8	11
1257	Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis. Targeted Oncology, 2021, 16, 207-214.	1.7	9
1258	Clinical impact of rebiopsy among patients with epidermal growth factor receptorâ€mutant lung adenocarcinoma in a realâ€world clinical setting. Thoracic Cancer, 2021, 12, 890-898.	0.8	3
1259	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers, 2021, 13, 804.	1.7	76
1260	Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study. Cancer Management and Research, 2021, Volume 13, 2033-2039.	0.9	8
1261	Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer, 2021, 153, 108-116.	0.9	28
1262	Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology. ELife, 2021, 10, .	2.8	19
1263	Lung adenocarcinoma concomitant with xeroderma pigmentosum: a case report. Journal of Medical Case Reports, 2021, 15, 160.	0.4	2
1264	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of Clinical Oncology, 2021, 39, 1040-1091.	0.8	192

#	Article	IF	Citations
1265	Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases. Frontiers in Oncology, 2021, 11, 622142.	1.3	5
1266	Osimertinib in advanced EGFR-T790MÂmutation-positive non-small cell lung cancer patients treated within the Special Use Medication ProgramÂin Spain: OSIREX-Spanish Lung Cancer Group. BMC Cancer, 2021, 21, 230.	1.1	9
1267	Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis. Frontiers in Oncology, 2021, 11, 600844.	1.3	6
1268	Standard-Dose Osimertinib in EGFR-Mutated Nonâ€“Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. JCO Precision Oncology, 2021, 5, 561-568.	1.5	1
1269	EGFR â€mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib. Thoracic Cancer, 2021, 12, 1441-1444.	0.8	3
1270	Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. Respiratory Investigation, 2021, 59, 240-246.	0.9	3
1271	Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada. Pharmacoeconomics, 2021, 39, 537-548.	1.7	6
1272	HER2-/HER3-Targeting Antibodyâ€”Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors. Cancers, 2021, 13, 1047.	1.7	27
1273	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clinical Cancer Research, 2021, 27, 2920-2927.	3.2	42
1274	Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study. Drugs - Real World Outcomes, 2021, 8, 141-152.	0.7	6
1275	Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 301-317.	0.4	11
1276	The role of <scp>EGFRâ€TKIs</scp> as adjuvant therapy in <scp>EGFR mutationâ€positive earlyâ€stage NSCLC</scp>: A metaâ€analysis. Thoracic Cancer, 2021, 12, 1084-1095.	0.8	12
1277	Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models. EMBO Molecular Medicine, 2021, 13, e13144.	3.3	13
1278	A Case Report of EGFR-mutated Metastatic Lung Adenocarcinoma with Long-term Survival on Systemic Treatment. Journal of Medical & Radiation Oncology, 2021, 1, 51-58.	0.0	0
1279	Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP). Journal of Clinical Pathology, 2022, 75, 193-200.	1.0	12
1280	PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment. OncoTargets and Therapy, 2021, Volume 14, 2301-2309.	1.0	6
1281	Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective. Critical Reviews in Oncology/Hematology, 2021, 159, 103225.	2.0	10
1282	Exceptional Response of a Large and Symptomatic EGFR-Mutant Brain Metastasis to Osimertinib: Case Report and Review of the Literature. JCO Precision Oncology, 2021, 5, 585-588.	1.5	4

#	Article	IF	Citations
1283	Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancerâ€”an option for overcoming EGFR-TKI resistance. Translational Lung Cancer Research, 2021, 10, 1277-1291.	1.3	15
1284	Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC. Advances in Therapy, 2021, 38, 1843-1859.	1.3	24
1285	Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. Nature Reviews Clinical Oncology, 2021, 18, 454-467.	12.5	11
1286	Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies. Molecular Diagnosis and Therapy, 2021, 25, 239-250.	1.6	6
1287	Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790Mâ€“Mutated Nonâ€“Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitor. JAMA Oncology, 2021, 7, 386.	3.4	108
1288	Genetic and non-genetic clonal diversity in cancer evolution. Nature Reviews Cancer, 2021, 21, 379-392.	12.8	155
1289	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nature Communications, 2021, 12, 1780.	5.8	39
1290	Recent Trends of Lung Cancer in Korea. Tuberculosis and Respiratory Diseases, 2021, 84, 89-95.	0.7	31
1291	Long-Term Survival of Over 6ÂYears with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report. Clinical Drug Investigation, 2021, 41, 483-488.	1.1	0
1292	Targeting pan-essential genes in cancer: Challenges and opportunities. Cancer Cell, 2021, 39, 466-479.	7.7	88
1293	Overcoming therapy resistance in EGFR-mutant lung cancer. Nature Cancer, 2021, 2, 377-391.	5.7	198
1294	Personalized and targeted therapies. ChemistrySelect, 2023, 8, 2103-2126.	0.7	0
1295	Survival analysis for older patients with epidermal growth factor receptor mutationâ€positive advanced nonâ€small cell lung cancer after progression of firstâ€line gefitinib. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 150-155.	0.7	1
1296	SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer. Frontiers in Pharmacology, 2021, 12, 665253.	1.6	13
1297	Pharmacogenomics in the era of next generation sequencing â€“ from byte to bedside. Drug Metabolism Reviews, 2021, 53, 253-278.	1.5	19
1298	Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 160, 103305.	2.0	25
1299	Brain metastases: An update on the multi-disciplinary approach of clinical management. Neurochirurgie, 2022, 68, 69-85.	0.6	16
1300	Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review. Frontiers in Oncology, 2021, 11, 642190.	1.3	26

#	Article	IF	Citations
1301	Systemic Therapy for Mutation-Driven NSCLC. Seminars in Radiation Oncology, 2021, 31, 140-148.	1.0	4
1302	VPS34 suppression reverses osimertinib resistance via simultaneously inhibiting glycolysis and autophagy. Carcinogenesis, 2021, 42, 880-890.	1.3	9
1303	Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients. Biomolecules, 2021, 11, 618.	1.8	7
1304	Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. Cancer Discovery, 2021, 11, 874-899.	7.7	107
1305	EGFR L718V (+)/T790M (â€“) as a Mechanism of Resistance in Patients with Metastatic Nonâ€“small-cell Lung Cancer with EGFR L858R Mutations. Clinical Lung Cancer, 2021, 22, e817-e819.	1.1	4
1306	Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling. International Journal of Molecular Sciences, 2021, 22, 4005.	1.8	24
1307	Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment. Frontiers in Oncology, 2021, 11, 649843.	1.3	8
1308	Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer. Current Pharmaceutical Biotechnology, 2021, 22, 389-399.	0.9	5
1309	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. Critical Reviews in Oncology/Hematology, 2021, 160, 103300.	2.0	6
1310	The Use of Traditional Chinese Medicine in Relieving EGFR-TKI-Associated Diarrhea Based on Network Pharmacology and Data Mining. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-16.	0.5	3
1311	Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. Cancers, 2021, 13, 1861.	1.7	4
1312	Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. Translational Lung Cancer Research, 2021, 10, 1623-1634.	1.3	5
1313	Circulating Biomarkers for Early Stage Non-Small Cell Lung Carcinoma Detection: Supplementation to Lowâ€Dose Computed Tomography. Frontiers in Oncology, 2021, 11, 555331.	1.3	10
1314	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. Japanese Journal of Clinical Oncology, 2021, 51, 956-965.	0.6	6
1315	Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review. Internal Medicine, 2021, 60, 1067-1071.	0.3	5
1316	Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans. Acta Pharmacologica Sinica, 2022, 43, 494-503.	2.8	7
1317	Savolitinib Â± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. Targeted Oncology, 2021, 16, 339-355.	1.7	6
1318	Liquid biopsy in non-small cell lung cancerâ€”current status and future outlookâ€”a narrative review. Translational Lung Cancer Research, 2021, 10, 2237-2251.	1.3	8

#	Article	IF	Citations
1319	Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers. Scientific Reports, 2021, 11, 10470.	1.6	7
1320	Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China. Annals of Translational Medicine, 2021, 9, 760-760.	0.7	2
1321	EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2301-2307.	1.2	0
1322	Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clinical Lung Cancer, 2021, 22, 201-209.	1.1	24
1323	Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. European Journal of Cancer, 2021, 148, 202-210.	1.3	9
1324	Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptorâ€“positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. European Journal of Cancer, 2021, 149, 61-72.	1.3	21
1325	The role of comprehensive analysis with circulating tumor DNA in advanced nonâ€small cell lung cancer patients considered for osimertinib treatment. Cancer Medicine, 2021, 10, 3873-3885.	1.3	8
1326	High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content. JCO Precision Oncology, 2021, 5, 921-930.	1.5	4
1327	Overall survival after initial radiotherapy for brain metastases; a population based study of 2140 patients with non-small cell lung cancer. Acta OncolÃ³gica, 2021, 60, 1054-1060.	0.8	6
1328	The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. Scientific Reports, 2021, 11, 9629.	1.6	3
1329	Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 602924.	1.3	4
1330	Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study. Lung Cancer, 2021, 155, 20-27.	0.9	32
1331	A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy. Oncology and Therapy, 2021, 9, 489-503.	1.0	5
1332	EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacological Research, 2021, 167, 105583.	3.1	78
1333	Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review. International Journal of Molecular Sciences, 2021, 22, 4852.	1.8	17
1334	Unveiling mutational dynamics in nonâ€small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA. Molecular Oncology, 2021, 15, 2423-2438.	2.1	10
1335	Exosomeâ€derived <scp>miR</scp>â€210 involved in resistance to osimertinib and epithelialâ€“mesenchymal transition in <scp>EGFR</scp> mutant nonâ€small cell lung cancer cells. Thoracic Cancer, 2021, 12, 1690-1698.	0.8	29
1336	Individualized Nomogram for Predicting Survival in Patients with Brain Metastases After Stereotactic Radiosurgery Utilizing Driver Gene Mutations and Volumetric Surrogates. Frontiers in Oncology, 2021, 11, 659538.	1.3	5

#	Article	IF	Citations
1337	Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer. Cancer Management and Research, 2021, Volume 13, 4263-4270.	0.9	6
1338	Heart Failure With Targeted Cancer Therapies. Circulation Research, 2021, 128, 1576-1593.	2.0	33
1339	Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations. Medicina (Lithuania), 2021, 57, 508.	0.8	2
1340	Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. Cells, 2021, 10, 1206.	1.8	17
1341	Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. Respiratory Research, 2021, 22, 145.	1.4	5
1342	ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelialâ€“mesenchymal transition. BMC Pulmonary Medicine, 2021, 21, 163.	0.8	6
1343	Sputum cellâ€free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFRâ€TKIs. Cancer Medicine, 2021, 10, 3323-3331.	1.3	6
1344	Monitoring epidermal growth factor receptor C797S mutation in Japanese nonâ€“small cell lung cancer patients with serial cellâ€free DNA evaluation using digital droplet PCR. Cancer Science, 2021, 112, 2371-2380.	1.7	7
1345	Targeting the <scp>EMT</scp> transcription factor Snail overcomes resistance to osimertinib in <scp>EGFR</scp>â€mutant nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 1708-1715.	0.8	24
1346	Efficacy and Safety of EGFR Inhibitors in the Treatment of EGFRPositive NSCLC Patients: A Meta-Analysis. Reviews on Recent Clinical Trials, 2021, 16, 193-201.	0.4	3
1347	Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations. JCO Oncology Practice, 2021, 17, 228-236.	1.4	38
1348	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinomaâ€”A Retrospective Analysis of a Multicenter Clinical Study. Frontiers in Molecular Biosciences, 2021, 8, 639892.	1.6	7
1349	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Nonâ€“Small Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e859-e869.	1.1	23
1350	Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice. Journal of Clinical Medicine, 2021, 10, 2236.	1.0	4
1351	Osimertinib versus osimertinib plus chemotherapy for nonâ€“small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. European Journal of Cancer, 2021, 149, 14-22.	1.3	30
1352	Evaluation of Drugâ€”Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. Journal of Personalized Medicine, 2021, 11, 424.	1.1	6
1353	Pearls and Pitfalls in the Imaging of Targeted Therapy and Immunotherapy in Lung Cancer. Seminars in Ultrasound, CT and MRI, 2021, 42, 552-562.	0.7	0
1354	Fully Automated <scp>MR</scp> Detection and Segmentation of Brain Metastases in Nonâ€small Cell Lung Cancer Using Deep Learning. Journal of Magnetic Resonance Imaging, 2021, 54, 1608-1622.	1.9	25

#	Article	IF	Citations
1355	Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting. BMC Cancer, 2021, 21, 602.	1.1	7
1356	Precision Oncology. Advances in Oncology, 2021, 1, 97-112.	0.1	0
1357	Kinase drug discovery 20 years after imatinib: progress and future directions. Nature Reviews Drug Discovery, 2021, 20, 551-569.	21.5	497
1358	Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer. ELife, 2021, 10, .	2.8	16
1359	Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review. Annals of Translational Medicine, 2021, 9, 950-950.	0.7	8
1360	Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model. Frontiers in Cell and Developmental Biology, 2021, 9, 688062.	1.8	12
1361	Re-use of erlotinib in a patient using osimertinib after erlotinib, case report. Journal of Oncology Pharmacy Practice, 2022, 28, 211-214.	0.5	1
1362	CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790Mâ€“positive lung cancer after osimertinib. International Journal of Clinical Oncology, 2021, 26, 1628-1639.	1.0	11
1363	The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. Expert Opinion on Drug Discovery, 2021, 16, 1091-1103.	2.5	6
1364	Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. Current Treatment Options in Oncology, 2021, 22, 71.	1.3	3
1365	Is Osimertinib-Induced Cardiotoxicity Really Harmless?. Journal of Clinical Oncology, 2021, 39, 2050-2051.	0.8	5
1366	Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases. JAMA Oncology, 2021, 7, 845.	3.4	56
1367	Immunotherapy in oncogene addicted non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2736-2751.	1.3	7
1368	A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903. ESMO Open, 2021, 6, 100115.	2.0	30
1369	Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study. Acta OncolÃ³gica, 2021, 60, 1100-1105.	0.8	1
1370	EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 2021, 13, 2748.	1.7	148
1371	Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review). Medicni Perspektivi, 2021, 26, 4-11.	0.1	0
1372	Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M. Global Medical Genetics, 2021, 08, 133-134.	0.4	0

#	Article	IF	Citations
1373	Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis. Clinical Lung Cancer, 2022, 23, 159-169.	1.1	3
1374	The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Scientific Reports, 2021, 11, 12084.	1.6	7
1375	Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset. JTO Clinical and Research Reports, 2021, 2, 100171.	0.6	5
1376	Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancers, 2021, 13, 3096.	1.7	7
1377	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. Journal of Personalized Medicine, 2021, 11, 518.	1.1	8
1378	A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study. Journal of Oncology Pharmacy Practice, 2022, 28, 1140-1151.	0.5	7
1379	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 4807-4813.	3.2	9
1380	PKCÎ´-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs. Oncogene, 2021, 40, 4796-4808.	2.6	9
1381	A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report. OncoTargets and Therapy, 2021, Volume 14, 3739-3744.	1.0	6
1382	Nextâ€Generation Kinase Inhibitors Targeting Specific Biomarkers in Nonâ€Small Cell Lung Cancer (NSCLC): A Recent Overview. ChemMedChem, 2021, 16, 2459-2479.	1.6	12
1383	EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncology, 2021, 17, 2395-2408.	1.1	17
1384	Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinomaâ€”A Systematic Review. Cancers, 2021, 13, 3144.	1.7	5
1385	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naÃ¯ve ALK-, ROS1-, or EGFR-altered Nonâ€“small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 1653-1662.	1.9	7
1386	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. Frontiers in Medicine, 2021, 8, 570921.	1.2	2
1387	Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 2987.	1.7	10
1388	Concurrent chemotherapy and firstâ€generation epidermal growth factor receptor (EGFR)â€tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as firstâ€line treatment in advanced lung adenocarcinoma harboring an EGFR mutation. Thoracic Cancer, 2021, 12, 2233-2240.	0.8	1
1389	Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions. Cancers, 2021, 13, 2798.	1.7	20
1390	Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2021, 22, 72.	1.3	9

#	Article	IF	Citations
1391	Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-NaÃ¯ve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial. Journal of Inflammation Research, 2021, Volume 14, 2557-2567.	1.6	2
1392	Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations. Cells, 2021, 10, 1590.	1.8	16
1393	An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naÃ¯ve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. BMC Cancer, 2021, 21, 802.	1.1	5
1394	Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncology, 2021, 17, 4045-4055.	1.1	76
1395	Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. European Journal of Pharmaceutical Sciences, 2021, 162, 105815.	1.9	5
1396	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. Pharmacological Research, 2021, 169, 105643.	3.1	13
1397	Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance. Cancers, 2021, 13, 3441.	1.7	8
1398	The role of EGFR mutation testing in the choice for surgical tactics in NSCLC treatment. Voprosy Onkologii, 2021, 67, 315-322.	0.1	1
1399	Triple therapy with osimertinib, bevacizumab and cetuximab in EGFRâ€‘mutant lung cancer with HIFâ€‘1Î±/TGFâ€Î± expression. Oncology Letters, 2021, 22, 639.	0.8	1
1400	SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness. Cancer Cell International, 2021, 21, 337.	1.8	9
1401	Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors. Annals of Translational Medicine, 2021, 9, 1150-1150.	0.7	5
1402	Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. European Respiratory Review, 2021, 30, 200294.	3.0	7
1403	Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis. Ecological Management and Restoration, 2022, 35, .	0.2	14
1404	The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1501-1508.	1.2	3
1405	CÃC Yáº¾U Tá»•TIÃŠN LÆ¯á»¢NG Hlá»†U QUáº¢ Cá»¦A PHÃC Äá»' PEMETREXED â€“ CARBOPLATIN Äá»€U TRá»Š UNG THÆ¯ PHá»"I KHÃNG THUá»C á»¨C CHáº¾ EGFR TYROSINE KINASE. Y Hoc Viet Nam, 2021, 502, .	0.0	0
1406	High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib. JTO Clinical and Research Reports, 2021, 2, 100191.	0.6	5
1407	Province-Wide Analysis of Patient-Reported Outcomes for Stage IV Non-Small Cell Lung Cancer. Oncologist, 2021, 26, e1800-e1811.	1.9	13
1408	Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer. Journal of Molecular Pathology, 2021, 2, 241-254.	0.5	6

#	Article	IF	Citations
1409	Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report. Annals of Palliative Medicine, 2021, 10, 8413-8419.	0.5	9
1410	Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014. Clinical Lung Cancer, 2021, 22, e602-e611.	1.1	5
1411	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. Future Oncology, 2021, 17, 2513-2527.	1.1	7
1412	Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. British Journal of Anaesthesia, 2021, 127, 75-84.	1.5	33
1413	TargetingEGFRExon 20 Insertions in Nonâ€“Small Cell Lung Cancer: Recent Advances and Clinical Updates. Cancer Discovery, 2021, 11, 2145-2157.	7.7	54
1414	Circulating tumor DNA in cancer: Predictive molecular pathology meets mathematics. Critical Reviews in Oncology/Hematology, 2021, 163, 103394.	2.0	7
1415	The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report. Journal of Thoracic Disease, 2021, 13, 4554-4559.	0.6	8
1416	The treatment of advanced lung adenocarcinoma with activating EGFR mutations. Expert Opinion on Pharmacotherapy, 2021, 22, 2475-2482.	0.9	5
1417	TÃ€ Dá»NG KHÃ”NG MONG MUá»N Cá»¦A PHÃ€ Äá»' PEMETREXED â€“ CARBOPLATIN Äá»€U TRá»Š UNG THÆ¯ PHá»”I KHÃ”NG Táº¾ SAU KHÃNG THá»¨ PHÃ Vá»šI THUá»€C á»¨C CHáº¾ EGFR TYROSINE KINASE. Y Hoc Viet Nam, 2021, 502, .	0.0	0
1418	Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Clinical and Translational Oncology, 2021, 23, 2560-2567.	1.2	7
1419	The bloodâ€“tumour barrier in cancer biology and therapy. Nature Reviews Clinical Oncology, 2021, 18, 696-714.	12.5	112
1420	Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Nonâ€“small-cell Lung Cancer: LAURA Trial in Progress. Clinical Lung Cancer, 2021, 22, 371-375.	1.1	44
1421	Low-Dosage Apatinib in Treating Advanced Pulmonary Adenocarcinoma Patient With Kras Mutation After Osimertinib Resistance. American Journal of Therapeutics, 2021, Publish Ahead of Print, .	0.5	0
1422	Paradigm shift in the management of metastatic nonsmall cell lung cancer. International Journal of Clinical Practice, 2021, 75, e14533.	0.8	0
1423	Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities. Clinical Cancer Research, 2021, 27, 5939-5950.	3.2	21
1425	Update on recent key publications in lung oncology: picking up speed. European Respiratory Review, 2021, 30, 200300.	3.0	1
1426	Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer. Oncologist, 2021, 26, e1812-e1821.	1.9	15
1427	Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced nonâ€smallâ€cell lung cancer harboring EGFR mutations: Results from a realâ€world study in South Korea. Cancer Medicine, 2021, 10, 5809-5822.	1.3	13

#	Article	IF	Citations
1428	Can Quantitative Measures of T790M Allelic Fraction Predict Survival Outcomes in Patients Receiving Osimertinib? Observations From an Early Access Programme. Clinical Oncology, 2021, 33, e305-e314.	0.6	1
1429	Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes. Biomolecules, 2021, 11, 1252.	1.8	5
1430	First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly. Current Oncology Reports, 2021, 23, 119.	1.8	4
1431	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. Scientific Reports, 2021, 11, 16122.	1.6	13
1432	Lung cancer. Lancet, The, 2021, 398, 535-554.	6.3	896
1433	Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease. JAMA Oncology, 2021, 7, 1220.	3.4	5
1434	Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data. OncoTargets and Therapy, 2021, Volume 14, 4579-4597.	1.0	21
1435	Amivantamab: TreatingEGFRExon 20â€“Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation. Journal of Clinical Oncology, 2021, 39, 3403-3406.	0.8	8
1436	Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma. Frontiers in Pharmacology, 2021, 12, 672233.	1.6	9
1437	The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments. Cancers, 2021, 13, 3923.	1.7	33
1438	Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. Biochemical Pharmacology, 2021, 190, 114643.	2.0	11
1439	How specific molecularâ€‘targeted agents canÂmake obsolete a â€˜one size fits allâ€™ approach inÂEGFRâ€‘mutated NSCLC treatment (Review). Experimental and Therapeutic Medicine, 2021, 22, 1150.	0.8	3
1440	Association of Exosomal miR-210 with Signaling Pathways Implicated in Lung Cancer. Genes, 2021, 12, 1248.	1.0	8
1441	Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment. Lung Cancer, 2021, 158, 137-145.	0.9	6
1442	Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in nonâ€“small cell lung cancer patients treated with osimertinib. Lung Cancer, 2021, 158, 156-161.	0.9	4
1443	Erlotinib: How to increase the duration of effective use of tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation. Meditsinskiy Sovet, 2021, , 42-47.	0.1	0
1444	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. Clinical Lung Cancer, 2021, , .	1.1	4
1445	A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L). Journal of Thoracic Oncology, 2021, 16, 2121-2132.	0.5	36

#	Article	IF	Citations
1446	Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respiratory Medicine,the, 2021, 9, 829-839.	5.2	66
1447	Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 698371.	1.6	11
1448	Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study. World Journal of Surgical Oncology, 2021, 19, 231.	0.8	6
1449	EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 8522.	1.8	7
1450	Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. Nature Communications, 2021, 12, 4789.	5.8	21
1451	Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	3
1452	Molecular follow-up of first-line treatment by osimertinib in lung cancer: Importance of using appropriate tools for detecting EGFR resistance mutation C797S. Cancer Genetics, 2021, 256-257, 158-161.	0.2	4
1453	Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer. Cancer Cell International, 2021, 21, 428.	1.8	28
1454	Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis. American Journal of Case Reports, 2021, 22, e932252.	0.3	4
1455	Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis. Lung Cancer, 2021, 158, 74-84.	0.9	8
1456	Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC. Current Problems in Cancer, 2022, 46, 100787.	1.0	5
1457	The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer. Cureus, 2021, 13, e16919.	0.2	2
1458	Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer: Case Report and Literature Review. Clinical Lung Cancer, 2021, , .	1.1	6
1459	A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood. JTO Clinical and Research Reports, 2021, 2, 100212.	0.6	2
1460	Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs. Cancer Biomarkers, 2021, 32, 1-13.	0.8	2
1461	The Association of Annexin A1 and Chemosensitivity to Osimertinib in Lung Cancer Cells. Cancers, 2021, 13, 4106.	1.7	5
1462	The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 987-996.	0.4	1
1463	What management for epidermal growth factor receptor-mutated nonâ€“small-cell lung cancer, with squamous cell transformation and T790M-acquired resistance mechanisms? A Case report and review of literature. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	3

#	Article	IF	Citations
1464	Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo. Archives of Toxicology, 2021, 95, 3575-3587.	1.9	7
1465	Medication guide for the perioperative management of oral antineoplastic agents in cancer patients. Expert Opinion on Drug Safety, 2022, 21, 107-119.	1.0	2
1466	The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2021, 21, 1071-1080.	1.1	3
1467	Development and validation of an HPLCâ€“MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run. Biomedical Chromatography, 2021, 35, e5224.	0.8	9
1468	Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitors. Oncoscience, 2021, 8, 80-81.	0.9	1
1469	IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer. Biochemical and Biophysical Research Communications, 2021, 571, 38-45.	1.0	7
1470	A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Investigational New Drugs, 2021, , 1.	1.2	0
1471	Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Annals of Oncology, 2021, 32, 1597-1607.	0.6	47
1472	ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC. Cancer Cell, 2021, 39, 1178-1180.	7.7	6
1473	Treatment Patterns in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: Analysis of US Insurance Claims Databases. Drugs - Real World Outcomes, 2021, , 1.	0.7	3
1474	Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies. JTO Clinical and Research Reports, 2021, 2, 100224.	0.6	6
1475	EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibodyâ€“Drug Conjugate HER3â€“DXd. Cancer Research, 2022, 82, 130-141.	0.4	29
1476	Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin. Anticancer Research, 2021, 41, 4321-4331.	0.5	5
1477	Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy. Translational Lung Cancer Research, 2021, 10, 3782-3792.	1.3	11
1478	Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib. Tumori, 2022, 108, 592-599.	0.6	5
1479	Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis. Anticancer Research, 2021, 41, 5137-5145.	0.5	6
1480	Outcomes of salvage lung resections in advanced <scp>EGFR</scp>â€mutant lung adenocarcinomas under <scp>EGFR TKIs</scp>. Thoracic Cancer, 2021, 12, 2655-2665.	0.8	10
1481	Frequency of actionable molecular drivers in lung cancer patients with precocious brain metastases. Clinical Neurology and Neurosurgery, 2021, 208, 106841.	0.6	0

#	Article	IF	Citations
1482	Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. Advanced Drug Delivery Reviews, 2021, 176, 113854.	6.6	12
1483	Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure. Lung Cancer, 2021, 159, 18-26.	0.9	46
1484	Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations. Medicina (Lithuania), 2021, 57, 929.	0.8	3
1485	Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers, 2021, 13, 4705.	1.7	86
1486	Risk of tract recurrence with stereotactic biopsy of brain metastases: an 18-year cancer center experience. Journal of Neurosurgery, 2022, 136, 1045-1051.	0.9	7
1487	Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. Acta OncolÃ³gica, 2021, 60, 1565-1571.	0.8	2
1488	A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2475-2486.	1.2	2
1489	Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective. Pharmaceutics, 2021, 13, 1500.	2.0	10
1490	Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation. Clinical Lung Cancer, 2021, 22, e712-e715.	1.1	3
1491	Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience. Biomedicines, 2021, 9, 1299.	1.4	10
1492	Microfluidic Single-Cell Proteomics Assay Chip: Lung Cancer Cell Line Case Study. Micromachines, 2021, 12, 1147.	1.4	1
1493	Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment. Frontiers in Oncology, 2021, 11, 719919.	1.3	18
1494	Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis. Cancer Management and Research, 2021, Volume 13, 6901-6910.	0.9	2
1495	Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. Frontiers in Cell and Developmental Biology, 2021, 9, 694363.	1.8	42
1496	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist, 2022, 27, 87-e115.	1.9	25
1497	Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). Lung Cancer, 2021, 162, 9-15.	0.9	18
1498	Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 4215-4228.	0.5	7
1499	A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance. Anti-Cancer Drugs, 2022, 33, e76-e83.	0.7	9

#	Article	IF	Citations
1500	Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 4651.	1.7	5
1501	Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies. Cancer Research, 2021, 81, 5589-5595.	0.4	24
1502	Impact of angiogenesis inhibitor eligibility on the prognosis of patients with nonâ€small cell lung cancer harboring EGFR mutation. Cancer Medicine, 2021, 10, 7503-7513.	1.3	4
1503	Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities. Genes and Diseases, 2022, 9, 1181-1193.	1.5	8
1504	TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib. Translational Oncology, 2021, 14, 101163.	1.7	11
1505	In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions. Toxicology Letters, 2021, 348, 10-17.	0.4	6
1506	Mechanisms and management of 3rdâ€‘generation EGFRâ€‘TKI resistance in advanced nonâ€‘small cell lung cancer (Review). International Journal of Oncology, 2021, 59, .	1.4	99
1507	Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?. Expert Review of Anticancer Therapy, 2021, 21, 1229-1235.	1.1	5
1508	Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. Translational Lung Cancer Research, 2021, 10, 3823-3839.	1.3	13
1509	Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Imaging, 2021, Publish Ahead of Print, .	0.8	0
1510	Clinical outcomes of patients taking firstâ€generation EGFRâ€TKIs may predict the benefits afforded by osimertinib in EGFR T790Mâ€mutant NSCLC patients. International Journal of Clinical Practice, 2021, 75, e14877.	0.8	0
1511	Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm⁺ non-small cell lung cancer. Current Medical Research and Opinion, 2022, 38, 91-99.	0.9	3
1512	Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA. Experimental and Molecular Pathology, 2021, 123, 104685.	0.9	3
1513	European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review. Drugs - Real World Outcomes, 2021, 8, 537-545.	0.7	10
1514	A meta-analysis of front-line therapy of osimertinib in treating non-small cell lung cancer. Food Science and Technology, 0, , .	0.8	1
1515	Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer. Pharmaceutics, 2021, 13, 1478.	2.0	9
1516	Progress and application of circulating tumor cells in non-small cell lung cancer. Molecular Therapy - Oncolytics, 2021, 22, 72-84.	2.0	17
1517	Reasonable Timing of Radiotherapy for Stage IV Non-Small-Cell Lung Cancer During Targeted Therapy Based on Tumour Volume Change. Frontiers in Oncology, 2021, 11, 705303.	1.3	3

#	Article	IF	Citations
1518	Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. Cancers, 2021, 13, 4926.	1.7	52
1519	Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 166, 103460.	2.0	3
1520	Osimertinib plus platinumâ€“pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open, 2021, 6, 100271.	2.0	40
1521	Hype or hope â€“ Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?. Critical Reviews in Oncology/Hematology, 2021, 166, 103454.	2.0	15
1522	Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer. Clinical Oncology, 2021, 33, 619-626.	0.6	4
1523	Instant Oncology: FLAURA. Clinical Oncology, 2021, 33, 617-618.	0.6	0
1524	The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC. Lung Cancer, 2021, 160, 118-126.	0.9	5
1525	Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1291-1302.	0.4	0
1526	Under-recognized toxicities of cranial irradiation. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2021, 25, 713-722.	0.6	2
1527	Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ove		6
1528	Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptorâ€“Mutant Non-Small Cell Lung Cancer With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2021, 111, 804-815.	0.4	22
1529	Exhaled breath condensate confirming T790M mutation in EGFR-mutated Non-Small Cell Lung Cancer. Current Problems in Cancer Case Reports, 2021, 4, 100114.	0.1	0
1530	Management of Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC). , 2022, , 825-843.		0
1531	Molecular Targetable Pathways â€“ EGFR. , 2022, , 844-852.		0
1532	<scp>ALK</scp> rearrangements as mechanisms of acquired resistance to osimertinib in <scp>EGFR</scp> mutant nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 962-969.	0.8	13
1533	Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110180.	1.4	10
1534	The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small-cell lung cancer. Translational Cancer Research, 2021, 10, 0-0.	0.4	2
1535	Breakthrough in targeted therapy for non-small cell lung cancer. Biomedicine and Pharmacotherapy, 2021, 133, 111079.	2.5	59

#	Article	IF	Citations
1536	Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. International Journal of Molecular Sciences, 2021, 22, 593.	1.8	35
1537	Targeting metastatic cancer. Nature Medicine, 2021, 27, 34-44.	15.2	447
1539	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort. Frontiers in Oncology, 2020, 10, 590356.	1.3	4
1540	Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors. Cancer Chemotherapy and Pharmacology, 2021, 87, 269-276.	1.1	5
1541	Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury. International Journal of Molecular Sciences, 2021, 22, 792.	1.8	43
1542	Osimertinib-induced rapid regression of large metastatic tumor to the pituitary in a patient with lung adenocarcinoma. , 2021, 12, 13.		3
1543	Crizotinib for recurring nonâ€smallâ€cell lung cancer with EML4â€ALK fusion genes previously treated with alectinib: A phase II trial. Thoracic Cancer, 2021, 12, 643-649.	0.8	5
1544	Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790Mâ€“Positive NSCLC. JTO Clinical and Research Reports, 2021, 2, 100099.	0.6	0
1545	Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients. Clinical Medicine Insights: Oncology, 2021, 15, 117955492199307.	0.6	8
1546	Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation. Anticancer Research, 2021, 41, 911-917.	0.5	4
1547	Engineering nanomedicine for glutathione depletion-augmented cancer therapy. Chemical Society Reviews, 2021, 50, 6013-6041.	18.7	342
1548	Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation <scp>EGFRâ€TKIs</scp>. Thoracic Cancer, 2021, 12, 746-751.	0.8	7
1549	Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Advances in Experimental Medicine and Biology, 2019, 1168, 9-30.	0.8	114
1550	Role of Next-Generation Sequencing Technologies in Personalized Medicine. , 2020, , 125-154.		13
1551	Progress on treatment of MET signaling pathway in non-small cell lung cancer. International Journal of Clinical Oncology, 2020, 25, 1450-1458.	1.0	4
1552	Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. Lung Cancer, 2020, 145, 1-9.	0.9	18
1554	An umbrella approach to test lung cancer therapies. Nature, 2020, 583, 688-689.	13.7	3
1555	Facile preparation of cancer cell membrane vehicle loaded with indocyanine green for effective photothermal therapy of cancer. Micro and Nano Letters, 2020, 15, 784-787.	0.6	2

#	Article	IF	Citations
1556	Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line. Journal of the Chinese Medical Association, 2021, 84, 248-254.	0.6	9
1558	Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in nonâ€“small cell lung cancer. Cancer Science, 2020, 111, 2736-2746.	1.7	12
1559	Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. Cancer Research, 2019, 79, 689-698.	0.4	153
1560	Osimertinib plus Ramucirumab: The Best of Both Worlds?. Clinical Cancer Research, 2021, 27, 905-907.	3.2	2
1561	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clinical Cancer Research, 2021, 27, 1604-1611.	3.2	18
1562	Epidemiology, Treatment, and Complications of Central Nervous System Metastases. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1580-1600.	0.4	12
1563	Recent advances in managing brain metastasis. F1000Research, 2018, 7, 1772.	0.8	63
1564	Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report. World Journal of Clinical Cases, 2019, 7, 1221-1229.	0.3	3
1565	Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients. PLoS ONE, 2017, 12, e0181867.	1.1	9
1566	Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS ONE, 2018, 13, e0194630.	1.1	117
1567	Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer. PLoS ONE, 2020, 15, e0242544.	1.1	10
1568	AR-dependent phosphorylation and phospho-proteome targets in prostate cancer. Endocrine-Related Cancer, 2020, 27, R193-R210.	1.6	7
1569	Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. Oncologist, 2020, 25, e130-e137.	1.9	19
1570	Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis. Aging, 2020, 12, 7129-7162.	1.4	6
1571	Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses. Aging, 2020, 12, 14244-14270.	1.4	23
1572	NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors. Genes and Cancer, 2017, 8, 497-504.	0.6	47
1573	Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature. Oncotarget, 2017, 8, 55760-55765.	0.8	1
1574	Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. Oncotarget, 2017, 8, 77897-77914.	0.8	19

#	Article	IF	Citations
1575	Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment. Oncotarget, 2017, 8, 86056-86065.	0.8	13
1576	Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study. Oncotarget, 2017, 8, 87980-87996.	0.8	30
1577	Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. Oncotarget, 2017, 8, 107630-107639.	0.8	16
1578	Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis. Oncotarget, 2017, 8, 110133-110144.	0.8	18
1579	T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer. Oncotarget, 2018, 9, 27929-27939.	0.8	16
1580	Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer. Oncotarget, 2018, 9, 27074-27086.	0.8	8
1581	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. Oncotarget, 2018, 9, 29525-29531.	0.8	28
1582	Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?. Oncotarget, 2018, 9, 34765-34771.	0.8	7
1583	Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients. Oncotarget, 2019, 10, 2911-2920.	0.8	35
1584	Development, validation, and comparison of gene analysis methods for detecting EGFR mutation from non-small cell lung cancer patients-derived circulating free DNA. Oncotarget, 2019, 10, 3654-3666.	0.8	6
1585	Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance. Annals of Translational Medicine, 2017, 5, 377-377.	0.7	15
1586	Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer. Annals of Translational Medicine, 2017, 5, 380-380.	0.7	12
1587	Osimertinib in first-line treatmentâ€"is a comparison not proof?. Annals of Translational Medicine, 2018, 6, 57-57.	0.7	3
1588	First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer. Annals of Translational Medicine, 2018, 6, 62-62.	0.7	2
1589	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. Annals of Translational Medicine, 2018, 6, 143-143.	0.7	13
1590	Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. Annals of Translational Medicine, 2018, 6, 160-160.	0.7	22
1591	VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story?. Annals of Translational Medicine, 2018, 6, 446-446.	0.7	10
1592	Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?. Annals of Translational Medicine, 2018, 6, S110-S110.	0.7	7

#	Article	IF	Citations
1593	Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer. Annals of Translational Medicine, 2019, 7, 61-61.	0.7	16
1594	Systemic therapy of elderly patients with advanced non-small cell lung cancerâ€"individualized treatment is key. Annals of Translational Medicine, 2019, 7, S48-S48.	0.7	3
1595	A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Translational Cancer Research, 2017, 6, S78-S82.	0.4	8
1596	EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review. Translational Cancer Research, 2018, 8, S64-S69.	0.4	15
1597	Targeting the reversible drug-tolerant state: aurora kinase A, is that the final answer?. Translational Cancer Research, 2019, 8, S564-S568.	0.4	1
1598	Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma. Translational Cancer Research, 2019, 8, 2151-2163.	0.4	8
1599	Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study. Translational Lung Cancer Research, 2020, 9, 2401-2410.	1.3	2
1600	HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 2178-2183.	1.3	3
1601	Treatment tactics of non-small-cell lung cancer with erlotinib: literature review and description of a clinical case. Meditsinskiy Sovet, 2019, , 38-43.	0.1	2
1602	Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases. Current Cancer Drug Targets, 2019, 19, 666-673.	0.8	11
1603	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2019, 19, 595-630.	0.8	61
1604	From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 1235-1240.	0.9	9
1605	Establishment and Characterization of Pemetrexed-resistant NCI-H460/PMT Cells. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 731-739.	0.9	5
1606	Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases. Anticancer Research, 2019, 39, 923-931.	0.5	6
1607	Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study. Future Oncology, 2020, 16, 1115-1124.	1.1	4
1608	Knockout of lncRNA UCA1 inhibits drug resistance to gefitinib via targeting STAT3 signaling in NSCLC. Minerva Medica, 2019, 110, 273-275.	0.3	14
1610	Results of liquid biopsy studies by next generation sequencing in patients with advanced stage non-small cell lung cancer: Single center experience from Turkey. Balkan Journal of Medical Genetics, 2019, 22, 17-24.	0.5	7
1611	A Case of Small Cell Lung Cancer with an Epidermal Growth Factor Receptor T790M Mutation That Responded to Osimertinib. Japanese Journal of Lung Cancer, 2019, 59, 151-157.	0.0	1

#	Article	IF	Citations
1612	A Case of Lung Adenocarcinoma with an Organizing Pneumonia Appearance Which Demonstrated a Spontaneous Resolution After the Administration of Osimertinib. Japanese Journal of Lung Cancer, 2020, 60, 202-206.	0.0	3
1613	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. Frontiers in Oncology, 2019, 9, 263.	1.3	62
1614	Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 593831.	1.3	25
1615	Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib. Cancers, 2021, 13, 6.	1.7	30
1616	Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer. Cancers, 2021, 13, 111.	1.7	11
1617	Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals, 2020, 13, 273.	1.7	28
1618	Non-small cell lung cancer. Vnitrni Lekarstvi, 2017, 63, 861-874.	0.1	10
1620	Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study. Radiation Oncology Journal, 2017, 35, 153-162.	0.7	5
1621	Clinical importance of long nonâ€‘coding RNA LINC00460 expression in EGFRâ€‘mutant lung adenocarcinoma. International Journal of Oncology, 2020, 56, 243-257.	1.4	19
1622	Predictive value of tumor genetic alteration profiling for chemotherapy and EGFRâ€TKI treatment in advanced NSCLC. Oncology Letters, 2020, 19, 3859-3870.	0.8	1
1623	Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction. Oncology Letters, 2020, 20, 1-1.	0.8	4
1624	Targeted Therapy for Non-Small Cell Lung Cancer. Korean Journal of Medicine, 2020, 95, 78-88.	0.1	3
1625	Saudi lung cancer management guidelines 2017. Annals of Thoracic Medicine, 2017, 12, 221.	0.7	16
1626	Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management. Cancer Research Statistics and Treatment, 2019, 2, 36.	0.1	23
1627	Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients. Indian Journal of Cancer, 2017, 54, 280.	0.2	8
1628	Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors. Indian Journal of Cancer, 2019, 56, 23.	0.2	6
1629	Management of CNS metastases in patients with EGFR mutation-positive NSCLC. Indian Journal of Cancer, 2019, 56, 31.	0.2	6
1630	T790M mutation and clinical outcomes with osimertinib in patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 73-78.	0.1	3

#	Article	IF	Citations
1631	Erlotinib in Patients with Advanced Non-small Cell Lung Cancer in Middle Eastern Population. Journal of Immunotherapy and Precision Oncology, 2018, 1, 19-25.	0.6	1
1632	Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer. South Asian Journal of Cancer, 2017, 06, 143-146.	0.2	4
1633	Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment. Cancer Research and Treatment, 2018, 50, 1164-1174.	1.3	5
1634	The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. Cancer Research and Treatment, 2018, 50, 1294-1303.	1.3	49
1635	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. Cancer Research and Treatment, 2019, 51, 493-501.	1.3	30
1636	A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Cancer Research and Treatment, 2019, 51, 718-726.	1.3	10
1637	A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. Cancer Research and Treatment, 2019, 51, 777-787.	1.3	46
1638	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Research and Treatment, 2020, 52, 284-291.	1.3	4
1639	Biomarker Testing Rates in Patients with Advanced Non-Small Cell Lung Cancer Treated in the Community. Journal of Cancer Therapy, 2019, 10, 971-984.	0.1	9
1640	Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non- Small-Cell Lung Cancer. Turkish Thoracic Journal, 2017, 18, 66-71.	0.2	7
1641	Management of Central Nervous System Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 579-582.	2.3	2
1642	Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 36-43.	2.3	21
1643	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1537-1570.	2.3	253
1644	Potential Applications of Circulating Tumor DNA Technology as a Cancer Diagnostic Tool. Cureus, 2019, 11, e4907.	0.2	9
1645	Liquid Biopsy. UNIPA Springer Series, 2021, , 99-122.	0.1	0
1646	Biomarkers. UNIPA Springer Series, 2021, , 43-64.	0.1	0
1647	Brain metastases: increasingly precision medicineâ€"a narrative review. Annals of Translational Medicine, 2021, 9, 1629-1629.	0.7	10
1648	A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients. Translational Lung Cancer Research, 2021, 10, 3888-3901.	1.3	7

#	Article	IF	Citations
1649	High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib. Open Medicine (Poland), 2021, 16, 1602-1607.	0.6	1
1651	Central Nervous System Malignancies. UNIPA Springer Series, 2021, , 731-754.	0.1	0
1654	Systemic Therapy for Lung Cancer Brain Metastases. Current Treatment Options in Oncology, 2021, 22, 110.	1.3	12
1655	A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer, 2021, 162, 140-146.	0.9	32
1656	Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding. Annals of Oncology, 2021, 32, 1463-1465.	0.6	0
1657	Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis. BioMed Research International, 2021, 2021, 1-13.	0.9	3
1658	Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value. Frontiers in Oncology, 2021, 11, 692788.	1.3	16
1659	Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Nonâ€“Small Cell Lung Cancer. Clinical Lung Cancer, 2022, 23, 72-81.	1.1	17
1660	The Sequence of Intracranial Radiotherapy and Systemic Treatment With Tyrosine Kinase Inhibitors for Gene-Driven Non-Small Cell Lung Cancer Brain Metastases in the Targeted Treatment Era: A 10-Year Single-Center Experience. Frontiers in Oncology, 2021, 11, 732883.	1.3	3
1661	Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer. Cancer Medicine, 2021, 10, 8595-8603.	1.3	3
1662	Possibility of brigatinibâ€based therapy, or chemotherapy plus antiâ€angiogenic treatment after resistance of osimertinib harboring EGFR T790Mâ€cisâ€C797S mutations in lung adenocarcinoma patients. Cancer Medicine, 2021, 10, 8328-8337.	1.3	9
1663	Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity. Journal of Medicinal Chemistry, 2021, 64, 15379-15401.	2.9	8
1664	Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway. Frontiers in Oncology, 2021, 11, 741326.	1.3	15
1665	Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Nonâ€“Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). Clinical Lung Cancer, 2022, 23, e257-e263.	1.1	10
1666	Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Nonâ€“Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2021, 5, 1603-1610.	1.5	4
1667	Diverse landscape of dermatologic toxicities from smallâ€molecule inhibitor cancer therapy. Journal of Cutaneous Pathology, 2022, 49, 61-81.	0.7	5
1668	A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes. Targeted Oncology, 2021, 16, 801-811.	1.7	13
1669	Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Clinical Lung Cancer, 2022, 23, e69-e82.	1.1	31

#	Article	IF	Citations
1670	Elevated serum creatine kinase levels due to osimertinib: A case report and review of the literature. Journal of Oncology Pharmacy Practice, 2021, , 107815522110422.	0.5	2
1671	Cost-effectiveness analysis of the firstâ€line EGFRâ€TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 637-646.	0.7	3
1672	Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer. Nature Communications, 2021, 12, 6068.	5.8	31
1673	Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). International Journal of Clinical Oncology, 2022, 27, 112-120.	1.0	9
1674	Comparing survival and treatment response of patients with acquired <scp>T790M</scp> mutation secondâ€line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A realâ€world study. Thoracic Cancer, 2021, 12, 3263-3272.	0.8	2
1675	The Role of Kinase Inhibitors in Cancer Therapies. Biochemistry, 0, , .	0.8	0
1676	Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial. Signal Transduction and Targeted Therapy, 2021, 6, 355.	7.1	45
1677	Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer. Current Opinion in Oncology, 2022, 34, 54-65.	1.1	18
1678	Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment. Thoracic Surgery Clinics, 2021, 31, 399-406.	0.4	1
1679	EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 1793-1797.	0.5	5
1680	Thoracic surgery improved overall survival in patients with stage IIIBâ€“IV epidermal growth factor receptor-mutant lung adenocarcinoma who received and responded to tyrosine kinase inhibitor treatment. Lung Cancer, 2021, 162, 29-35.	0.9	3
1681	The History and Current State of EGFR-TKIs. Japanese Journal of Lung Cancer, 2017, 57, 69-74.	0.0	1
1682	Neue Arzneimittel 2016. , 2017, , 55-135.		0
1683	What Can We Save for the First-Line Treatment of NSCLC in 2016?. World Journal of Oncology, 2017, 8, 31-33.	0.6	4
1684	Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. Translational Cancer Research, 2017, 6, S151-S157.	0.4	2
1685	Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Nonâ€“Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2017, 8, 196-201.	0.2	1
1687	Osimertinib - a new treatment option for patients with EGFR mutation T790M. Onkologie (Czech) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.0	0
1688	Nicht-kleinzelliges Lungenkarzinom. Pharma-Kritik (discontinued), 2017, 39, .	0.0	0

#	Article	IF	Citations
1689	2. State of the Art of EGFR-TKI and Future Perspectives. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1096-1100.	0.0	0
1690	The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients â€“ single centre experience. OnCOReview, 2017, 7, 92-97.	0.1	0
1691	Targeted Therapies for Lung Cancer. Molecular Pathology Library, 2018, , 239-255.	0.1	0
1692	Mutations as Predictive Biomarkers for Adenocarcinoma. Molecular Pathology Library, 2018, , 147-158.	0.1	0
1693	TYROSINE KINASE INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER. Russian Journal of Oncology, 2018, 23, 50-54.	0.1	0
1694	Osimertinib, the winner, but cannot yet take it all. Annals of Translational Medicine, 2018, 6, 61-61.	0.7	1
1696	New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors. Journal of Modern Oncology, 2018, 20, 50-54.	0.1	0
1697	Analysis of Adverse Drug Reactions on Osimertinib in T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2018, 44, 355-362.	0.0	0
1699	Treatment of patients with non-small cell cancer and EGFR mutations. Onkologie (Czech Republic), 2018, 12, 175-181.	0.0	0
1700	Adenocarcinoma of the Lung with Miliary Metastases and Primary Resistance Exon 20 Mutations. Cureus, 2018, 10, e3533.	0.2	2
1701	Molecular Targeted Therapy of Lung Cancer. Nihon Ika Daigaku Igakkai Zasshi, 2018, 14, 177-179.	0.0	0
1702	EGFR Tyrosine kinase inhibitors in the treatment of metastases of non-small cell lung cancer in the brain. , 2018, 17, 22-30.	0.3	0
1703	Phenotypic transformation as a cause of secondary drug resistance to osimetinib clinical observation. Meditsinskiy Sovet, 2018, , 130-135.	0.1	0
1704	Non-small Cell Lung Cancer. , 2019, , 143-192.		0
1705	Editorial - T790M mutation and clinical outcomes with genuine osimertinib. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 7-8.	0.1	1
1706	Central Nervous System Cancers. , 2019, , 83-131.		1
1708	Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines. Cancer Drug Resistance (Alhambra, Calif), 2019, 2, 539-549.	0.9	0
1709	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0

#	Article	IF	Citations
1711	Successful Dose-reduction Therapy for Osimertinib-induced Neutropenia in EGFR-mutant Lung Adenocarcinoma: a Report of Two Cases. Japanese Journal of Lung Cancer, 2019, 59, 46-52.	0.0	0
1713	Les avancÃ©es dans la prise en charge des cancers bronchopulmonaires : ce qui change pour le rÃ©animateur. Medecine Intensive Reanimation, 2019, 28, 290-299.	0.1	0
1714	Experiencia Con Erlotinib Y Gefitinib En Pacientes Con CÃ¡ncer De PulmÃ³n Avanzado Con MutaciÃ³n Positiva En El Receptor De Factor De Crecimiento EpidÃ©rmico.. Revista Medica De Panama, 2019, 38, .	0.0	0
1715	æ•´å½¢å–ç§'ã'å'ˆè¨ºã•–è,‰è…«ä»¥å–ã®æ,ªæ€§è…«ç˜ã•è¨ºæ–ã•ã,Œãÿç—‡ä¾‹ã®æœè¨Ž. Orthopedics & Traumatology, 2019, 68, 435-4	0.0	0
1716	Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?. Translational Cancer Research, 2019, 8, 2223-2229.	0.4	2
1717	Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial. Chinese Clinical Oncology, 2019, 8, S2-S2.	0.4	2
1718	Traitement des cancers bronchiques non Ã petites cellules de stades avancÃ©s mutÃ©s EGFR: quelle(s) sÃ©quence(s) ?. Revue Des Maladies Respiratoires Actualites, 2019, 11, 364-379.	0.0	0
1719	Brain Metastases from Lung Tumors. , 2020, , 259-266.		0
1720	Neurological Complications of Targeted Therapies. , 2020, , 341-363.		0
1722	Rational approach to the treatment of EGFR-positive lung cancer. Meditsinskiy Sovet, 2019, , 51-56.	0.1	0
1723	Systemic Therapy of Brain Metastases: Lung Cancer. , 2020, , 207-217.		0
1724	Prognostic factors affecting survival in third-line treatment of advanced non-small cell lung cancer: Retrospective cohort study. Journal of Surgery and Medicine, 0, , 1-1.	0.0	1
1725	Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer. , 2020, 1, 117-130.		1
1726	The biology of Epidermal Growth Factor Receptor (EGFR) from regulating cell cycle to promoting carcinogenesis: the state of art including treatment options. Annals of Cytology and Pathology, 2020, 5, 048-053.	0.3	3
1727	EV-based EGFR genotyping in bronchoalveolar lavage fluidâ€"a step forward from blood?. Translational Lung Cancer Research, 2020, 9, 427-429.	1.3	0
1728	Role of imaging biomarkers in mutation-driven non-small cell lung cancer. World Journal of Clinical Oncology, 2020, 11, 412-427.	0.9	4
1730	Progress in individualized treatment for <i>EGFR</i>-mutated advanced non-small cell lung cancer. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2020, 96, 266-272.	1.6	4
1731	Future directions and management of liquid biopsy in non-small cell lung cancer. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 239-252.	0.5	3

#	Article	IF	Citations
1732	Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature. Cancers, 2021, 13, 5403.	1.7	7
1733	EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. Communications Biology, 2021, 4, 1237.	2.0	20
1734	Real world approach for molecular analysis of acquired EGFR TKI resistance mechanisms in non-small cell lung carcinoma. JTO Clinical and Research Reports, 2021, 2, 100252.	0.6	3
1735	Research Progress of TCMCombined with EGFR-TKI Drugs in the Treatment of Advanced Non-Small Cell Lung Cancer. Advances in Clinical Medicine, 2020, 10, 664-669.	0.0	0
1736	Testing for Driver Oncogenes is Essential for the Optimal Treatment of Advanced Non-small-cell Lung Cancer. Juntendo Medical Journal, 2020, 66, 403-409.	0.1	0
1737	Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study. World Journal of Clinical Oncology, 2020, 11, 983-989.	0.9	3
1738	OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS. Siberian Journal of Oncology, 2020, 19, 119-125.	0.1	0
1740	Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?. Translational Lung Cancer Research, 2020, 9, 2599-2617.	1.3	10
1741	Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy. Meditsinskiy Sovet, 2020, , 194-198.	0.1	0
1742	Direct digital polymerase chain reaction chip for the detection of EGFR T790M mutation in plasma. Talanta, 2022, 237, 122977.	2.9	5
1743	Development of Molecularly Targeted Agents in Early Phase Clinical Trials. , 2020, , 199-220.		0
1744	Gastrointestinal Toxicities of Targeted Therapy. , 2020, , 119-132.		0
1745	Leptomeningeal Disease in Solid Cancers. , 2020, , 409-427.		0
1746	The importance of repeated biopsies for the detection of T790M resistance mutation in non-small cell lung cancer â€“ case report. Oncolog-Hematolog Ro, 2020, 4, 7.	0.0	0
1747	Dermatological Toxicities of Targeted Therapy. , 2020, , 147-164.		1
1749	Indications for Whole-Brain Radiation Therapy. , 2020, , 165-184.		1
1750	Using Multiple Machine Learning Algorithms for Cancer Prognosis in Lung Adenocarcinoma. , 2020, , .		0
1751	Chemical Probes for Kinases. Chemical Biology, 2020, , 182-213.	0.1	0

#	Article	IF	Citations
1753	Serum C-Reactive Protein Level Predicts Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. Cancer Investigation, 2020, 38, 122-129.	0.6	0
1754	PREDICTIVE VALUE OF THE DYNAMIC DETERMINATION OF CIRCULATING TUMOR DNA ON PFS IN PATIENTS WITH EGFR MUTATED NSCLC, WITH OSIMERTINIB THERAPY. Voprosy Onkologii, 2020, 66, 135-142.	0.1	0
1755	Critical Review of EGFR-Mutated NSCLC: What We Do and Do Not Know. Healthbook TIMES Oncology Hematology, 2020, , 20-35.	0.1	3
1756	Resection of symptomatic nonâ€“small cell lung cancer brain metastasis in the setting of multiple brain metastases. Journal of Neurosurgery, 2022, 136, 1576-1582.	0.9	7
1757	The pathological tissue expression pattern and clinical significance of m6Aâ€regulatory genes in nonâ€small cell lung cancer. Journal of Gene Medicine, 2022, 24, e3397.	1.4	3
1758	A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Nonâ€“Small Cell Lung Cancer: a Multicenter Phase I/II Study. Clinical Cancer Research, 2022, 28, 1127-1135.	3.2	9
1759	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal of Thoracic Oncology, 2022, 17, 423-433.	0.5	89
1760	Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial. Medical Oncology, 2022, 39, 4.	1.2	3
1761	Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutationâ€“positive nonâ€“small-cell lung cancer in a real-world setting (OSI-FACT). European Journal of Cancer, 2021, 159, 144-153.	1.3	33
1762	First-line osimertinib in patients with epidermal growth factor receptorâ€“mutant nonâ€“small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. European Journal of Cancer, 2021, 159, 174-181.	1.3	5
1763	ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. Revista Espanola De Patologia, 2020, 53, 140-148.	0.6	0
1764	Sequencing Therapy for Patients With Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 945-948.	2.3	0
1765	Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists. Current Respiratory Medicine Reviews, 2020, 16, 5-10.	0.1	0
1766	New lung-cancer drugs extend survival times. Nature, 2020, 587, S10-S12.	13.7	14
1769	Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 391-400.	0.5	2
1770	Current achievements and future perspectives with liquid biopsy. Personalized Medicine Universe, 2020, 9, 3-9.	0.1	0
1771	Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFRâ€“Mutated Lung Cancer. JTO Clinical and Research Reports, 2020, 1, 100085.	0.6	6
1772	Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?. Lung India, 2017, 34, 405-408.	0.3	1

#	Article	IF	Citations
1773	Molecular Targets in Non-Small Cell Lung Cancer. Ochsner Journal, 2017, 17, 388-392.	0.5	20
1783	Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer. International Journal of Clinical and Experimental Pathology, 2019, 12, 1723-1730.	0.5	0
1784	Upregulated lncRNA H19 promotes non-small cell lung cancer cell proliferation through miR-138/PDK1 axis. International Journal of Clinical and Experimental Pathology, 2017, 10, 9012-9020.	0.5	5
1785	Cell-Free Circulating Tumour DNA Blood Testing to Detect T790M Mutation in People With Advanced Non-Small Cell Lung Cancer: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2020, 20, 1-176.	3.0	7
1787	Effect of Whole-Brain and Intensity-Modulated Radiotherapy on Serum Levels of miR-21 and Prognosis for Lung Cancer Metastatic to the Brain. Medical Science Monitor, 2020, 26, e924640.	0.5	0
1788	Does the natural product, honokiol, have value in the battle against osimertinib resistance?. Oncoscience, 2020, 7, 73-75.	0.9	0
1789	A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients. Journal of Thoracic Disease, 2020, 12, 6107-6111.	0.6	1
1792	Multidisciplinary brain metastasis clinic: is it effective and worthwhile?. Ecancermedicalscience, 2020, 14, 1136.	0.6	0
1795	Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant Brain Metastasis and Spinal Cord Metastasis Models. Frontiers in Pharmacology, 2021, 12, 750031.	1.6	2
1796	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2022, 52, 53-64.	0.6	0
1797	Recent advances in lung cancer genomics: Application in targeted therapy. Advances in Genetics, 2021, 108, 201-275.	0.8	5
1798	Target Therapy, from its Initial Clinical Breakthroughs to Current Hot Spot. , 2021, 1, 11.		0
1799	Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 751209.	1.3	10
1800	A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. Cancer Management and Research, 2021, Volume 13, 8695-8705.	0.9	8
1801	A review on the role of epidermal growth factor signaling in the development, progression and treatment of cervical cancer. International Journal of Biological Macromolecules, 2022, 194, 179-187.	3.6	13
1802	A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Annals of Oncology, 2022, 33, 181-192.	0.6	51
1803	A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 105-115.	1.1	10
1804	First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. Investigational New Drugs, 2022, 40, 430-437.	1.2	8

#	Article	IF	Citations
1805	Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Nonâ€“Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study. International Journal of General Medicine, 2021, Volume 14, 8903-8918.	0.8	3
1806	Animal models of brain metastasis. Neuro-Oncology Advances, 2021, 3, v144-v156.	0.4	8
1807	Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation. Frontiers in Oncology, 2021, 11, 739090.	1.3	19
1808	Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance. Cells, 2021, 10, 3192.	1.8	17
1809	Brain metastases: nanomedicine-boosted diagnosis and treatment. Medicine in Drug Discovery, 2021, 13, 100111.	2.3	1
1810	Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 394-403.	0.7	7
1811	Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model. Acta Pharmacologica Sinica, 2022, 43, 1865-1874.	2.8	3
1812	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. Journal of Thoracic Oncology, 2022, 17, 411-422.	0.5	70
1813	Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report. Journal of Medical Case Reports, 2021, 15, 562.	0.4	4
1814	Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. Current Oncology, 2021, 28, 4552-4576.	0.9	4
1815	EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome. Translational Lung Cancer Research, 2021, 10, 4084-4094.	1.3	5
1816	Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications, 2022, 30, 100497.	0.7	4
1817	Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial. Lung Cancer, 2022, 166, 255-264.	0.9	13
1818	LSâ€106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Science, 2022, 113, 709-720.	1.7	19
1819	Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lungÂcancer. ESMO Open, 2021, 6, 100319.	2.0	47
1820	Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea. Translational Lung Cancer Research, 2021, 10, 4353-4367.	1.3	7
1821	The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110563.	1.4	6
1822	Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110598.	1.4	6

#	Article	IF	Citations
1823	Impact of epidermal growth factor receptor T790M testing in relapsed non-small cell lung cancer: A narrative review of the T790M reflex testing algorithm. Cancer Research Statistics and Treatment, 2021, 4, 692.	0.1	3
1824	Tumors: Non-small Cell Lung Cancer. , 2021, , 5270-5279.		0
1825	Practical Management of Oligometastatic Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 635-641.	0.8	33
1826	Utility of the Ba/F3 cell system for exploring onâ€target mechanisms of resistance to targeted therapies for lung cancer. Cancer Science, 2022, 113, 815-827.	1.7	11
1827	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptorâ€“Mutated Nonâ€“Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical Cancer Research, 2022, 28, 2286-2296.	3.2	14
1828	Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities. ESMO Open, 2022, 7, 100308.	2.0	5
1829	Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry. Clinica Chimica Acta, 2022, 527, 1-10.	0.5	8
1830	Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors. Journal of Molecular Graphics and Modelling, 2022, 112, 108114.	1.3	7
1831	Lungenkarzinom: Mehr Optionen fÃ¼r Patienten im fortgeschrittenen Stadium. , 0, , .		0
1832	Does the natural product, honokiol, have value in the battle against osimertinib resistance?. Oncoscience, 2020, 7, 73-75.	0.9	0
1833	Effect of Whole-Brain and Intensity-Modulated Radiotherapy on Serum Levels of miR-21 and Prognosis for Lung Cancer Metastatic to the Brain. Medical Science Monitor, 2020, 26, e924640.	0.5	5
1834	A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients. Journal of Thoracic Disease, 2020, 12, 6107-6111.	0.6	2
1835	Multidisciplinary brain metastasis clinic: is it effective and worthwhile?. Ecancermedicalscience, 2020, 14, 1136.	0.6	4
1836	Biomarkers for respiratory diseases: Present applications and future discoveries. Clinical and Translational Discovery, 2021, 1, .	0.2	3
1837	Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib. Thoracic Cancer, 2022, 13, 394-403.	0.8	7
1838	Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Nonâ€“Small Cell Lung Cancer Patients Treated with Osimertinib. Tuberculosis and Respiratory Diseases, 2022, 85, 155-164.	0.7	5
1839	Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance. Biomedicines, 2022, 10, 277.	1.4	4
1840	UncommonEGFRmutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901). Future Oncology, 2022, 18, 523-531.	1.1	7

#	Article	IF	Citations
1841	Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimerâ€™s disease. Neural Regeneration Research, 2022, 17, 1913.	1.6	21
1842	TP53 co-mutations as an independent prognostic factor in 2nd and further line therapyâ€”EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Translational Lung Cancer Research, 2022, 11, 4-13.	1.3	13
1843	Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790Mâ€positive NSCLC:ÂA retrospective study. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 643-651.	0.7	5
1844	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFRâ€T790M mutation in nonâ€small cell lung cancer cells. Cancer Medicine, 2022, 11, 944-955.	1.3	5
1845	Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients. Clinical Drug Investigation, 2022, 42, 185-192.	1.1	7
1846	Complications following novel therapies for nonâ€small cell lung cancer. Journal of Internal Medicine, 2022, 291, 732-754.	2.7	6
1847	A realâ€world study of dacomitinib in laterâ€line settings for advanced nonâ€small cell lung cancer patients harboring EGFR mutations. Cancer Medicine, 2022, 11, 1026-1036.	1.3	4
1848	Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study. BMJ Open, 2022, 12, e046451.	0.8	2
1849	Should We Target OligometastaticEGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?. Journal of the National Cancer Institute, 2023, 115, 605-607.	3.0	2
1850	Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion. Cancer Research and Treatment, 2022, 54, 985-995.	1.3	2
1851	Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nature Biomedical Engineering, 2022, 6, 232-245.	11.6	56
1852	Successful desensitization under antihistamine suppression in a case with urticaria due to osimertinib. Journal of Oncology Pharmacy Practice, 2022, , 107815522210758.	0.5	1
1853	Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. European Journal of Hospital Pharmacy, 2023, 30, 328-332.	0.5	4
1854	Targeting S100A9â€“ALDH1A1â€“Retinoic Acid Signaling to Suppress Brain Relapse inEGFR-Mutant Lung Cancer. Cancer Discovery, 2022, 12, 1002-1021.	7.7	22
1855	OUP accepted manuscript. Oncologist, 2022, 27, 163-e213.	1.9	6
1857	Functions of lncRNA DUXAP8 in non-small cell lung cancer. Molecular Biology Reports, 2022, 49, 2531-2542.	1.0	7
1858	Multiple Primary Malignant Neoplasms in African Americans: A Case Series and Literature Review. Cureus, 2022, 14, e21585.	0.2	2
1859	Therapeutic potential of pyrrole and pyrrolidine analogs: an update. Molecular Diversity, 2022, 26, 2915-2937.	2.1	65

#	Article	IF	Citations
1860	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. Journal of Clinical Oncology, 2022, 40, 611-625.	0.8	242
1861	Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network. Cancer Treatment and Research Communications, 2022, 31, 100522.	0.7	10
1862	Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report. Translational Cancer Research, 2022, 11, 295-298.	0.4	1
1863	Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance. Frontiers in Pharmacology, 2021, 12, 746707.	1.6	9
1864	First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study. Japanese Journal of Clinical Oncology, 2022, 52, 405-410.	0.6	5
1865	Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma. Cancers, 2022, 14, 674.	1.7	10
1866	Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002. Investigational New Drugs, 2022, 40, 361-369.	1.2	3
1867	Survival Outcomes of Patients With Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis. Frontiers in Oncology, 2021, 11, 723562.	1.3	5
1868	Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma. Journal of Oncology Pharmacy Practice, 2022, 28, 989-994.	0.5	5
1869	Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF). Cancers, 2022, 14, 769.	1.7	9
1870	Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. Cancer Treatment Reviews, 2022, 104, 102354.	3.4	2
1871	The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC. Journal of Inflammation Research, 2022, Volume 15, 649-667.	1.6	11
1872	Liquid biopsy: the value of different bodily fluids. Biomarkers in Medicine, 2022, 16, 127-145.	0.6	12
1873	Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study. Lung Cancer, 2022, 165, 145-151.	0.9	6
1874	Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations. Cancers, 2022, 14, 832.	1.7	7
1875	Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer. Future Oncology, 2022, 18, 1485-1497.	1.1	0
1876	A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. Lung Cancer, 2022, 166, 98-106.	0.9	1
1877	Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities. Tumori, 2022, , 030089162110694.	0.6	0

#	Article	IF	Citations
1878	Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report. Thoracic Cancer, 2022, , .	0.8	3
1879	Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis. PLoS ONE, 2022, 17, e0263629.	1.1	11
1880	Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/Î²-Catenin activity and cancer stemness. Cancer Letters, 2022, 531, 83-97.	3.2	27
1881	Current therapy and development of therapeutic agents for lung cancer. , 2022, 1, 100015.		8
1882	Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer. Cells, 2021, 10, 3553.	1.8	5
1883	Cancer gene mutation frequencies for the U.S. population. Nature Communications, 2021, 12, 5961.	5.8	78
1884	A Randomized Phase II Study Comparing Nivolumab with Carboplatinâ€“Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clinical Cancer Research, 2022, 28, 893-902.	3.2	35
1885	INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Future Oncology, 2022, 18, 1039-1054.	1.1	30
1886	A Case of Metastatic Non-small Cell Lung Adenocarcinoma and Metachronous Primary Hepatocellular Carcinoma. Cureus, 2021, 13, e20185.	0.2	1
1887	The management of postoperative recurrence of non-small cell lung cancer harboring EGFR mutation: what is the best way?. Journal of Thoracic Disease, 2021, 14, 0-0.	0.6	0
1888	Future prospects of EGFR-TKIs and surgery for non-small-cell lung cancer. Journal of Thoracic Disease, 2021, 14, 0-0.	0.6	0
1889	Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions. Expert Review of Precision Medicine and Drug Development, 2022, 7, 29-38.	0.4	0
1890	Synthetic Migrastatic: A New Class of Anticancer Drug. , 2022, , 1-24.		0
1892	Neurological complications of lung cancer. , 2022, , 243-276.		0
1893	Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial. Integrative Cancer Therapies, 2022, 21, 153473542210866.	0.8	4
1894	Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210791.	1.4	10
1895	ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Annals of Oncology, 2022, 33, 466-487.	0.6	67
1896	Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study. Journal of Thoracic Oncology, 2022, 17, 708-717.	0.5	11

#	Article	IF	Citations
1897	Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience. Frontiers in Immunology, 2022, 13, 832419.	2.2	11
1898	Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Frontiers in Molecular Biosciences, 2022, 9, 847835.	1.6	41
1899	Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. Journal of Thoracic Oncology, 2022, 17, 718-723.	0.5	29
1900	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. Molecular Cancer, 2022, 21, 61.	7.9	6
1901	Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer. Cancer Cell International, 2022, 22, 82.	1.8	8
1902	Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to firstâ€‘generation EGFRâ€TKIs in a realâ€‘world clinical setting. Molecular and Clinical Oncology, 2022, 16, 88.	0.4	1
1903	Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?. Journal of Oncology Pharmacy Practice, 2023, 29, 646-662.	0.5	2
1904	Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment. Acta Pharmaceutica Sinica B, 2022, 12, 1825-1839.	5.7	9
1905	Challenges in the Use of Targeted Therapies in Nonâ€“Small Cell Lung Cancer. Cancer Research and Treatment, 2022, 54, 315-329.	1.3	17
1906	Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy. Current Oncology Reports, 2022, 24, 475-491.	1.8	4
1908	The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. Cancers, 2022, 14, 1143.	1.7	23
1909	Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial). Japanese Journal of Clinical Oncology, 2022, , .	0.6	2
1910	Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands. Journal of Medicinal Chemistry, 2022, 65, 4709-4726.	2.9	32
1911	Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. British Journal of Cancer, 2022, 127, 592-602.	2.9	36
1912	Real-world Afatinib Outcomes in Advanced Nonâ€“small Cell Lung Cancer Harboring EGFR Mutations. Anticancer Research, 2022, 42, 2145-2157.	0.5	10
1913	Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis. Cancers, 2022, 14, 1682.	1.7	2
1914	Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRÎ± re-expression. Molecular Cancer, 2022, 21, 77.	7.9	40
1915	Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients. Cancer Management and Research, 2022, Volume 14, 863-873.	0.9	4

#	Article	IF	Citations
1916	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. British Journal of Cancer, 2022, 127, 383-393.	2.9	36
1917	Potential treatment strategy for the rare osimertinib resistant EGFR L718Q mutation. Journal of Thoracic Disease, 2022, 14, 599-601.	0.6	0
1918	Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated with First-Line EGFR-TKIs: A Large Population-Based Study and Literature Review. International Journal of General Medicine, 2022, Volume 15, 3405-3416.	0.8	3
1919	Intracranial Metastatic Disease: Present Challenges, Future Opportunities. Frontiers in Oncology, 2022, 12, 855182.	1.3	4
1920	A concise review on tyrosine kinase targeted cancer therapy. Current Drug Therapy, 2022, 17, .	0.2	1
1921	Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. International Journal of Molecular Sciences, 2022, 23, 2815.	1.8	15
1922	Characterization of the Different Subtypes of Immune Cell Infiltration to Aid Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 758479.	1.8	1
1923	An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2022, 23, 647-652.	0.9	8
1924	ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer. Oncology and Therapy, 2022, 10, 13-22.	1.0	2
1925	Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer. Frontiers in Pharmacology, 2022, 13, 847906.	1.6	6
1926	Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations. Oncotarget, 2022, 13, 456-463.	0.8	0
1927	Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer. Egyptian Journal of Bronchology, 2022, 16, .	0.3	0
1928	Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma. Frontiers in Immunology, 2022, 13, 746869.	2.2	2
1929	Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials. BMC Cancer, 2022, 22, 328.	1.1	16
1930	Treatment strategy of EGFR-mutated non-small cell lung cancer. Journal of Thoracic Disease, 2022, 14, 602-606.	0.6	0
1931	Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Nonâ€“Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. Cancer Research and Treatment, 2023, 55, 344-349.	1.3	2
1932	Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity. Current Oncology, 2022, 29, 2530-2538.	0.9	1
1933	Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports. Frontiers in Pharmacology, 2022, 13, 838247.	1.6	2

#	Article	IF	Citations
1934	An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib. Value in Health, 2022, , .	0.1	2
1935	The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC. Journal of Thoracic Oncology, 2022, 17, 481-486.	0.5	7
1936	Novel targeted therapies for advanced non-small lung cancer. Seminars in Oncology, 2022, 49, 326-336.	0.8	9
1937	Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials. Expert Opinion on Emerging Drugs, 2022, 27, 111-126.	1.0	2
1938	The optimal therapy strategy for epidermal growth factor receptor<scp>â€mutated nonâ€small cell</scp> lung cancer patients with brain metastasis: A <scp>realâ€world</scp> study from Taiwan. Thoracic Cancer, 2022, 13, 1505-1512.	0.8	8
1939	Acetyltanshinone IIA reduces the synthesis of cell cycle-related proteins by degrading p70S6K and subsequently inhibits drug-resistant lung cancer cell growth. Pharmacological Research, 2022, 179, 106209.	3.1	7
1940	Developing Economic Models for Assessing the Cost-Effectiveness of Multiple Diagnostic Tests: Methods and Applications. Medical Decision Making, 2022, 42, 861-871.	1.2	1
1941	Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer. American Journal of Ophthalmology Case Reports, 2022, 26, 101459.	0.4	3
1942	Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review. Current Problems in Cancer Case Reports, 2022, 6, 100153.	0.1	7
1943	Role of HMGB1 in Cisplatin-Persistent Lung Adenocarcinoma Cell Lines. Frontiers in Oncology, 2021, 11, 750677.	1.3	7
1944	Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report. Frontiers in Pharmacology, 2021, 12, 809467.	1.6	3
1945	Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, S1-S11.	2.3	3
1946	Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. Neuro-Oncology Advances, 2022, 4, vdab188.	0.4	9
1947	Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study. Radiation Oncology, 2021, 16, 233.	1.2	8
1948	Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 787585.	1.3	20
1949	Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec. Current Oncology, 2021, 28, 5179-5191.	0.9	5
1950	The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. Cancer Cell International, 2021, 21, 675.	1.8	9
1951	Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice. Targeted Oncology, 2022, 17, 53-59.	1.7	1

#	Article	IF	Citations
1952	A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC. Frontiers in Oncology, 2021, 11, 722106.	1.3	2
1953	Amivantamab for the treatment ofEGFRexon 20 insertion mutant non-small cell lung cancer. Expert Review of Anticancer Therapy, 2022, 22, 3-16.	1.1	9
1954	Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2022, 23, 311-319.	1.1	7
1955	Biomedical Applications of Non-Small Cell Lung Cancer Spheroids. Frontiers in Oncology, 2021, 11, 791069.	1.3	12
1956	Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models. Frontiers in Pharmacology, 2021, 12, 750031.	1.6	26
1957	Circulating tumor DNA in non-small-cell lung cancer: A step beyond blood. Cancer Research Statistics and Treatment, 2020, 3, 577.	0.1	1
1958	Chinese contribution to NEJM, Lancet, JAMA, and BMJ from 2011 to 2020: a 10-year bibliometric study. Annals of Translational Medicine, 2022, 10, 505-505.	0.7	1
1960	Treatment of Metastatic Brain Lesion Using Osimertinib: A Case Report. I P Pavlov Russian Medical Biological Herald, 2022, 30, 101-107.	0.2	0
1961	Acquired Mechanisms of Resistance to Osimertinibâ€"The Next Challenge. Cancers, 2022, 14, 1931.	1.7	16
1962	Airway Microbiota in Patients With Synchronous Multiple Primary Lung Cancer: The Bacterial Topography of the Respiratory Tract. Frontiers in Oncology, 2022, 12, 811279.	1.3	2
1963	Resistance is futile with fourth-generation EGFR inhibitors. Nature Cancer, 2022, 3, 381-383.	5.7	6
1964	Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC. Scientific Reports, 2022, 12, 6367.	1.6	7
1965	Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer. OncoTargets and Therapy, 2022, Volume 15, 407-410.	1.0	3
1966	EGFR signaling pathway as therapeutic target in human cancers. Seminars in Cancer Biology, 2022, 85, 253-275.	4.3	61
1967	Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Nonâ€"Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L). Lung Cancer, 2022, 168, 38-45.	0.9	5
1968	Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. Nature Medicine, 2022, 28, 620-626.	15.2	13
1969	Targeting mutations in cancer. Journal of Clinical Investigation, 2022, 132, .	3.9	56
1970	An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nature Cancer, 2022, 3, 402-417.	5.7	65

#	Article	IF	Citations
1971	Impact of preâ€€existing interstitial lung abnormal shadow on lung injury development and severity in patients of nonâ€€small cell lung cancer treated with osimertinib. Cancer Medicine, 2022, , .	1.3	4
1972	Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report. Frontiers in Pharmacology, 2022, 13, 854277.	1.6	4
1973	Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors. Cancer Epidemiology, 2022, 78, 102149.	0.8	3
1974	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. Lung Cancer, 2022, 168, 10-20.	0.9	6
1996	The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan. Targeted Oncology, 2022, 17, 295-306.	1.7	7
1997	Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. Archives of Pharmacal Research, 2022, 45, 263-279.	2.7	11
1998	Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care. American Journal of the Medical Sciences, 2022, 364, 371-378.	0.4	2
1999	Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences. Cancer Investigation, 2022, 40, 590-603.	0.6	5
2000	Osimertinib and chemotherapy combination to treat brain metastasis flare and osimertinib resistance by EGFR C797S. Journal of Chemotherapy, 2023, 35, 168-172.	0.7	1
2001	Publishing inconvenient data. Japanese Journal of Clinical Oncology, 2022, 52, 403-404.	0.6	1
2002	Individualized comprehensive treatment for lung adenocarcinoma with multiple skin and bilateral breast metastasis: A case report. Journal of Central South University (Medical Sciences), 2020, 45, 102-108.	0.1	0
2018	Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as â€œROS1â€•as it appears?. Lung India, 2017, 34, 405.	0.3	3
2019	EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?. Cancers, 2022, 14, 2257.	1.7	6
2020	Development of a Nomogram Based on 3D CT Radiomics Signature to Predict the Mutation Status of EGFR Molecular Subtypes in Lung Adenocarcinoma: A Multicenter Study. Frontiers in Oncology, 2022, 12, 889293.	1.3	2
2021	Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 2157.	1.7	7
2022	Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutationâ€“Case Report and a Literature Review. Current Oncology, 2022, 29, 3531-3539.	0.9	6
2023	The efficacy of T790M mutation testing in liquid biopsyâ€”Real clinic data. PLoS ONE, 2022, 17, e0267846.	1.1	2
2024	Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer. Science Advances, 2022, 8, eabn1229.	4.7	9

#	Article	IF	Citations
2025	Nonâ€“Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 497-530.	2.3	530
2026	Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer. Ecancermedicalscience, 0, 16, .	0.6	3
2027	Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Cancer Diagnosis & Prognosis, 2022, 2, 324-329.	0.3	5
2028	Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report. Journal of Geriatric Oncology, 2022, 13, 1071-1083.	0.5	2
2029	Dynamic monitoring serum tumor markers to predict molecular features of <scp>EGFR</scp> â€mutated lung cancer during targeted therapy. Cancer Medicine, 2022, , .	1.3	5
2030	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nature Reviews Clinical Oncology, 2022, 19, 499-514.	12.5	140
2031	Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer. Clinical Drug Investigation, 2022, 42, 459-464.	1.1	3
2032	Optimize Local Therapy for Oligometastatic and Oligoprogressive Nonâ€“Small Cell Lung Cancer to Enhance Survival. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 531-539.	2.3	10
2033	Statistical considerations for outcomes in clinical research: A review of common data types and methodology. Experimental Biology and Medicine, 2022, 247, 734-742.	1.1	0
2034	Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study. ESMO Open, 2022, 7, 100473.	2.0	0
2035	Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study. Clinical Lung Cancer, 2022, 23, e353-e361.	1.1	1
2036	Natural therapeutics and nutraceuticalsÂfor lung diseases: Traditional significance, phytochemistry, and pharmacology. Biomedicine and Pharmacotherapy, 2022, 150, 113041.	2.5	61
2037	The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinomaâ€”successes and challenges. Journal of Thoracic Disease, 2021, .	0.6	0
2038	Diagnosis and treatment of non-small cell lung cancer: current advances and challenges. Journal of Thoracic Disease, 2022, 14, 1753-1757.	0.6	4
2039	A randomized phase <scp>II</scp> study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with nonâ€small cell lung cancer harboring <scp>EGFR</scp> mutations (<scp>JMTO LC12</scp>â€01). Thoracic Cancer, 2022, 13, 1827-1836.	0.8	2
2041	Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England. Clinical Oncology, 2022, 34, 497-507.	0.6	2
2042	Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation. Journal of Cardiology, 2023, 81, 253-259.	0.8	2
2043	AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNonâ€“Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. Journal of Clinical Oncology, 2022, 40, 3162-3171.	0.8	76

#	Article	IF	Citations
2044	A Novel Framework for the Next Generation of Precision Oncology Targets. JAMA Oncology, 2022, 8, 974.	3.4	1
2045	Altered splicing of <scp>ATG16â€L1</scp> mediates acquired resistance to tyrosine kinase inhibitors of <scp>EGFR</scp> by blocking autophagy in nonâ€small cell lung cancer. Molecular Oncology, 2022, 16, 3490-3508.	2.1	2
2046	Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events. Clinical Trials, 2022, 19, 267-273.	0.7	5
2047	EGFRC797S mutation and fourth-generation EGFR tyrosine kinase inhibitors. , 2022, , 689-709.		1
2048	Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer, 2022, 170, 41-51.	0.9	33
2049	Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. Cancers, 2022, 14, 2519.	1.7	8
2050	Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent <i>EGFR</i> T790M Mutated NSCLC: A Phase IIb Study. SSRN Electronic Journal, 0, , .	0.4	0
2051	Epidermal growth factor receptor tyrosine kinase inhibitors for de novo <scp>T790M</scp> mutation: A retrospective study of 44 patients. Thoracic Cancer, 2022, 13, 1888-1897.	0.8	8
2052	Liquid biopsy in nonâ€small cell lung cancer: Is it ready for prime time yet?. Asia-Pacific Journal of Clinical Oncology, 2023, 19, .	0.7	0
2053	The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study. Translational Lung Cancer Research, 2022, 11, 776-785.	1.3	1
2054	Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib. BMC Cancer, 2022, 22, .	1.1	2
2055	Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report. Diagnostics, 2022, 12, 1266.	1.3	2
2056	When to add anti-angiogenesis drugs to EGFR-mutated metastatic nonâ€“small cell lung cancer patients: a real-world study from Taiwan. BMC Cancer, 2022, 22, .	1.1	5
2057	Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer. Translational Cancer Research, 2022, 11, 1245-1254.	0.4	6
2058	An integrated biomarker of <scp>PDâ€L1</scp> expression and intraepithelial <scp>CD8</scp> ⁺ T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastases. Thoracic Cancer, 0, , .	0.8	3
2059	Case Report: Torsade de Pointes Induced by the Third-Generation Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitor Osimertinib Combined With Litsea Cubeba. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	3
2060	Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review. Frontiers in Endocrinology, 2022, 13, .	1.5	6
2061	Molecular relation between biological stress and carcinogenesis. Molecular Biology Reports, 2022, 49, 9929-9945.	1.0	1

#	Article	IF	Citations
2062	Antiproliferative Activity of a New Quinazolin-4(3H)-One Derivative via Targeting Aurora Kinase A in Non-Small Cell Lung Cancer. Pharmaceuticals, 2022, 15, 698.	1.7	3
2063	Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data. Drugs - Real World Outcomes, 2022, 9, 333-345.	0.7	4
2064	Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer. Korean Journal of Internal Medicine, 0, , .	0.7	0
2065	KIT Mutations Correlate with Higher Galectin Levels and Brain Metastasis in Breast and Non-Small Cell Lung Cancer. Cancers, 2022, 14, 2781.	1.7	12
2066	A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2022, 31, 747-757.	1.9	6
2067	Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion. BMC Cancer, 2022, 22, .	1.1	1
2068	Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China. Frontiers in Oncology, 2022, 12, .	1.3	3
2069	Radiotherapy with continued EGFRâ€TKIs for oligoprogressive disease in EGFRâ€mutated nonâ€small cell lung cancer: A realâ€world study. Cancer Medicine, 2023, 12, 266-273.	1.3	5
2070	Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22. Translational Lung Cancer Research, 2022, 11, 1369-1379.	1.3	9
2071	Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials. Translational Lung Cancer Research, 2022, 11, 953-963.	1.3	7
2072	PD-1 Blockade Plus Chemotherapy for EGFR-Mutant, EGFR Tyrosine Kinase Inhibitor-Pretreated Non-Small Cell Lung Cancer: A Multicenter Retrospective Study on Efficacy and Biomarker Exploration. SSRN Electronic Journal, 0, , .	0.4	0
2073	Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211032.	0.6	2
2074	Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study. Journal of Thoracic Oncology, 2022, 17, 1192-1204.	0.5	7
2075	Distribution and favorable prognostic implication of genomic <scp>EGFR</scp> alterations in <scp>IDH</scp>â€wildtype glioblastoma. Cancer Medicine, 2023, 12, 49-60.	1.3	7
2076	Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	1
2077	High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial. Lung Cancer, 2022, 170, 133-140.	0.9	20
2078	Targeting molecular alterations in non-small-cell lung cancer: what's next?. Personalized Medicine, 0, , .	0.8	4
2079	PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naÃ¯ve advanced EGFR-mutant non-small cell lung cancer patients. Scientific Reports, 2022, 12, .	1.6	13

#	Article	IF	Citations
2080	Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib. OncoTargets and Therapy, 0, Volume 15, 659-667.	1.0	2
2081	Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia. Cancer Management and Research, 0, Volume 14, 1995-2005.	0.9	2
2082	Osimertinib plus Selumetinib in EGFR-Mutated Nonâ€“Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). Clinical Cancer Research, 2022, 28, 4222-4231.	3.2	6
2083	Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Nonâ€“Small Cell Lung Cancer. Frontiers in Pharmacology, 0, 13, .	1.6	3
2084	Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLCâ€”a systematic review and meta-analysis. ESMO Open, 2022, 7, 100507.	2.0	5
2085	Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?. International Journal of Molecular Sciences, 2022, 23, 6936.	1.8	8
2087	Computed Tomography Image under Artificial Intelligence Algorithm to Evaluate the Nursing and Treatment Effect of Pemetrexed Combined Platinum-Based Chemotherapy on Elderly Lung Cancer. Contrast Media and Molecular Imaging, 2022, 2022, 1-9.	0.4	0
2088	Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis. Future Oncology, 2022, 18, 2695-2707.	1.1	1
2089	CCDC65, a Gene Knockout that leads to Early Death of Mice, acts as a potentially Novel Tumor Suppressor in Lung Adenocarcinoma. International Journal of Biological Sciences, 2022, 18, 4171-4186.	2.6	10
2091	Brain metastases from non-small cell lung carcinoma: an overview of classical and novel treatment strategies. Reports of Practical Oncology and Radiotherapy, 0, , .	0.3	2
2093	The Synergistic Effect of Ruthenium Complex Î”-Ru1 and Doxorubicin in a Mouse Breast Cancer Model. Recent Patents on Anti-Cancer Drug Discovery, 2023, 18, 174-186.	0.8	2
2094	Costâ€effectiveness of osimertinib versus placebo in resected <scp>EGFR</scp> â€mutated nonâ€small cell lung cancer in China. Cancer Medicine, 0, , .	1.3	2
2095	Two case reports of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy. Annals of Translational Medicine, 2022, 10, 719-719.	0.7	3
2096	Comparison of T790M Acquisition After Treatment With First- and Second-Generation Tyrosine-Kinase Inhibitors: A Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 0, 12, .	1.3	3
2098	Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Clinical Oncology, 2022, 34, e451-e462.	0.6	6
2099	Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation. Cells, 2022, 11, 2201.	1.8	5
2100	Tyrosine Kinase Inhibitors In Reduction Of Mortality Of Non-Small Cell Lung Cancer: A Meta-Analysis. Combinatorial Chemistry and High Throughput Screening, 2022, 25, .	0.6	0
2101	Treating advanced lung cancer in older veterans with comorbid conditions and frailty. Seminars in Oncology, 2022, , .	0.8	0

#	Article	IF	Citations
2102	Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program. Seminars in Oncology, 2022, , .	0.8	1
2103	Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer. BMC Cancer, 2022, 22, .	1.1	1
2104	The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nature Reviews Clinical Oncology, 2022, 19, 585-599.	12.5	39
2105	Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer. Cancers, 2022, 14, 3430.	1.7	4
2106	Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2022, 65, 9662-9677.	2.9	50
2107	Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. International Journal of Molecular Sciences, 2022, 23, 7774.	1.8	3
2108	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. Cancers, 2022, 14, 3337.	1.7	21
2109	Efficacy and Safety of EGFR Tyrosine Kinase Inhibitors Combined with Cranial Radiotherapy for Brain Metastases from Non-Small-Cell Lung Cancer: A Protocol for a Systematic Review and Meta-Analysis. BioMed Research International, 2022, 2022, 1-7.	0.9	0
2110	Case Report: Heterogeneity of Resistance Mechanisms in Different Lesions Co-Mediate Acquired Resistance to First-Line Icotinib in EGFR Mutant Non-Small Cell Lung Cancer. Frontiers in Medicine, 0, 9, .	1.2	1
2111	Discovery of novel 4-arylamino-quinazoline derivatives as EGFRL858R/T790M inhibitors with the potential to inhibit the non-small cell lung cancers. Bioorganic Chemistry, 2022, 127, 105994.	2.0	8
2112	Activation of the integrated stress response is a vulnerability for multidrugâ€resistant <scp>FBXW7</scp> â€deficient cells. EMBO Molecular Medicine, 2022, 14, .	3.3	12
2113	Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study. Radiology and Oncology, 2022, 56, 371-379.	0.6	1
2114	Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?. Frontiers in Oncology, 0, 12, .	1.3	4
2115	Unarranged territory in uncommon EGFR mutations. Translational Lung Cancer Research, 2022, 11, 1233-1236.	1.3	0
2116	Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation. Frontiers in Oncology, 0, 12, .	1.3	1
2117	Osimertinibâ€related liver injury with successful osimertinib rechallenge: A case report. Thoracic Cancer, 0, , .	0.8	3
2118	Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report. World Journal of Clinical Cases, 2022, 10, 7968-7972.	0.3	1
2119	EGFR T790M Site-Mutated Non-Small Cell Lung Cancer Drug Resistance Mechanism and Comprehensive Treatment after Drug Resistance. Advances in Clinical Medicine, 2022, 12, 6872-6881.	0.0	0

#	Article	IF	Citations
2120	Lazertinib: on the Way to Its Throne. Yonsei Medical Journal, 2022, 63, 799.	0.9	7
2121	Liquid Biopsy â€" A Novel Diagnostic Tool for Management of Early-Stage Peripheral Lung Cancer. Proceedings of the Latvian Academy of Sciences, 2022, 76, 325-332.	0.0	0
2122	Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2022, 23, 1167-1179.	5.1	79
2123	Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion. Frontiers in Oncology, 0, 12, .	1.3	5
2124	PO2RDF: representation of real-world data for precision oncology using resource description framework. BMC Medical Genomics, 2022, 15, .	0.7	0
2125	Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 8526.	1.8	2
2126	Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. Frontiers in Immunology, 0, 13, .	2.2	5
2127	Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT). Current Oncology, 2022, 29, 5833-5845.	0.9	2
2128	Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies. Anti-Cancer Drugs, 0, Publish Ahead of Print, .	0.7	2
2129	Cutting-Edge AI Technologies Meet Precision Medicine to Improve Cancer Care. Biomolecules, 2022, 12, 1133.	1.8	1
2130	The exploration of three different treatment models of osimertinib plus antiangiogenic agents in nonâ€small cell lung cancer: A realâ€world study. Thoracic Cancer, 2022, 13, 2641-2649.	0.8	2
2131	Heart Failure With Reduced Ejection Fraction Caused by Osimertinib in a Patient With Lung Cancer: A Case Report and Literature Review. Cureus, 2022, , .	0.2	3
2132	A Case of Osimertinib-Induced Eosinophilic Pneumonia. Clinical Lung Cancer, 2022, , .	1.1	1
2133	Retrospective analysis of independent predictors of progressionâ€free survival in patients with <scp>EGFR mutationâ€positive</scp> advanced nonâ€small cell lung cancer receiving firstâ€line osimertinib. Thoracic Cancer, 2022, 13, 2741-2750.	0.8	5
2134	Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment. Clinical Lung Cancer, 2022, 23, e473-e477.	1.1	1
2135	Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2022, 23, 9006.	1.8	9
2136	L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment. Discover Oncology, 2022, 13, .	0.8	3
2137	Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies. OncoTargets and Therapy, 0, Volume 15, 873-882.	1.0	6

#	Article	IF	Citations
2138	Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece. Future Oncology, 0, , .	1.1	0
2139	T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock		
2140	EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022. Expert Review of Anticancer Therapy, 2022, 22, 1115-1125.	1.1	2
2141	Advances in covalent drug discovery. Nature Reviews Drug Discovery, 2022, 21, 881-898.	21.5	187
2142	Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation. Frontiers in Pharmacology, 0, 13, .	1.6	0
2143	Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report. JTO Clinical and Research Reports, 2022, 3, 100396.	0.6	1
2144	A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC. JTO Clinical and Research Reports, 2022, 3, 100388.	0.6	4
2145	Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC. Scientific Reports, 2022, 12, .	1.6	5
2146	P21-activated kinase 2-mediated Î²-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer. Oncogene, 0, , .	2.6	5
2147	An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	1.3	4
2148	Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	2
2149	Targeting KRAS: Crossroads of Signaling and Immune Inhibition. Journal of Immunotherapy and Precision Oncology, 2022, 5, 68-78.	0.6	6
2150	Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial. Lung Cancer, 2022, 171, 97-102.	0.9	7
2151	Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization. EBioMedicine, 2022, 83, 104200.	2.7	10
2152	Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells. Biochemical and Biophysical Research Communications, 2022, 626, 156-166.	1.0	4
2153	Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients. Lung Cancer, 2022, 172, 86-93.	0.9	4
2154	Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs. Bioorganic Chemistry, 2022, 128, 106057.	2.0	10
2155	Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors. Supportive Care in Cancer, 0, , .	1.0	0

#	Article	IF	Citations
2156	Association between EGFR gene mutant protein expression and T790M mutation after first-generation EGFR-TKI treatment resistance: a retrospective, single-arm clinical study. Annals of Translational Medicine, 2022, 10, 935-935.	0.7	1
2158	EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil. Oncologist, 0, , .	1.9	1
2159	Overview of pathology and treatment of metastatic brain tumors. , 2022, , 25-37.		0
2160	Synthetic Migrastatic: A New Class of Anticancer Drug. , 2022, , 3157-3179.		0
2161	Targeted Therapies in Non-small Cell Lung Cancer. Medical Radiology, 2022, , .	0.0	1
2162	Temporal Pattern of Cardiac Adverse Events Associated with EGFR-TKIs in Lung Cancer Patients: A Pharmacovigilance Analysis. SSRN Electronic Journal, 0, , .	0.4	0
2164	Combined procedure with radial probe and convex probe endobronchial ultrasound. Thoracic Cancer, 0, , .	0.8	2
2165	A Study of the Relationship Between Interstitial Lung Abnormalities and Osimertinib-induced Lung Injury. Japanese Journal of Lung Cancer, 2022, 62, 292-298.	0.0	1
2166	High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. Biomedicines, 2022, 10, 2109.	1.4	0
2167	Clinical trial design in the era of precision medicine. Genome Medicine, 2022, 14, .	3.6	68
2168	A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11). Clinical Lung Cancer, 2022, 23, e536-e539.	1.1	7
2169	Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study. Journal of Thoracic Oncology, 2022, 17, 1306-1317.	0.5	5
2170	Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer. Cancer Research and Treatment, 2023, 55, 112-122.	1.3	1
2171	RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer. Journal of Translational Medicine, 2022, 20, .	1.8	5
2172	Drug resistance mechanisms and progress in the treatment of EGFRâ€˜mutated lung adenocarcinoma (Review). Oncology Letters, 2022, 24, .	0.8	16
2173	EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy. Investigational New Drugs, 2022, 40, 1342-1349.	1.2	3
2174	Quality of Life and Cognitive Function Evaluations and Interventions for Patients with Brain Metastases in the Radiation Oncology Clinic. Cancers, 2022, 14, 4301.	1.7	3
2175	Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study. International Journal of Molecular Sciences, 2022, 23, 10661.	1.8	2

#	Article	IF	Citations
2176	Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangementâ€"Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors. JTO Clinical and Research Reports, 2022, 3, 100405.	0.6	2
2177	Nonâ€small cell lung cancer in China. Cancer Communications, 2022, 42, 937-970.	3.7	129
2178	TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma. International Journal of Molecular Sciences, 2022, 23, 10415.	1.8	10
2179	EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience. Journal of Thoracic Disease, 2022, 14, 3364-3375.	0.6	1
2180	Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China. Frontiers in Pharmacology, 0, 13, .	1.6	4
2181	Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors. Nature Communications, 2022, 13, .	5.8	7
2182	The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study. Frontiers in Immunology, 0, 13, .	2.2	3
2183	Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board. Cancers, 2022, 14, 4430.	1.7	7
2184	Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation. Cancers, 2022, 14, 4709.	1.7	2
2185	High levels of <scp>AXL</scp> expression in untreated <scp>EGFR</scp>â€mutated nonâ€small cell lung cancer negatively impacts the use of osimertinib. Cancer Science, 2023, 114, 606-618.	1.7	9
2186	A miRâ€15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinumâ€based chemotherapy. Journal of Cellular and Molecular Medicine, 2022, 26, 5439-5451.	1.6	5
2187	Exposureâ€"Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer. Pharmaceutics, 2022, 14, 1844.	2.0	12
2188	Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer. Investigational New Drugs, 2022, 40, 1254-1262.	1.2	4
2189	Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs. International Journal of Molecular Sciences, 2022, 23, 11353.	1.8	6
2190	And Still They Come Over Troubled Waters: Can Asiaâ€™s Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC. Journal of Thoracic Oncology, 2022, 17, 1144-1154.	0.5	8
2191	A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study. Oncologist, 2022, 27, 903-e834.	1.9	4
2192	A case report: Response to Osimertinib in non-small cell lung cancer patient with uncommon EGFR mutation. Current Problems in Cancer Case Reports, 2022, 8, 100188.	0.1	0
2193	Histologic transformation in lung cancer: when one door shuts, another opens. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211305.	1.4	3

#	Article	IF	Citations
2194	The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them. Cancer Drug Resistance (Alhambra, Calif), 0, 5, 1016-24.	0.9	1
2195	Sequential treatment in advanced nonâ€“small cell lung cancer harboring EGFR mutations. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662211327.	1.0	6
2196	Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. , 2022, , .		0
2197	Emerging genetic biomarkers in lung adenocarcinoma. SAGE Open Medicine, 2022, 10, 205031212211323.	0.7	1
2198	Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center. Journal of Personalized Medicine, 2022, 12, 1746.	1.1	5
2199	Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. Acta OncolÃ³gica, 2022, 61, 1347-1353.	0.8	2
2200	UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN). Journal of Thoracic Oncology, 2023, 18, 169-180.	0.5	30
2201	New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer. Current Treatment Options in Oncology, 2022, 23, 1626-1644.	1.3	10
2203	A Detouring Experience Not Recommended: Lessons Learned from PF00299804. Cancer Research, 2022, 82, 3662-3664.	0.4	0
2204	Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptorâ€“Mutated, <i>MET</i>-Amplified Nonâ€“Small Cell Lung Cancer: TATTON. Cancer Discovery, 2023, 13, 98-113.	7.7	35
2206	Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis. Frontiers in Oncology, 0, 12, .	1.3	1
2207	Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients. Cancers, 2022, 14, 5095.	1.7	5
2209	The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer. Life, 2022, 12, 1640.	1.1	5
2211	Metaâ€'analysis of the efficacy and safety of sintilimab for treating advanced nonâ€'small cell lung cancer. Oncology Letters, 2022, 24, .	0.8	0
2212	Biomarker-Targeted Therapies in Nonâ€“Small Cell Lung Cancer: Current Status and Perspectives. Cells, 2022, 11, 3200.	1.8	15
2213	Advanced Lung Cancer Patientsâ€™ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada. Current Oncology, 2022, 29, 8043-8073.	0.9	1
2214	Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): AÂSingle-Arm, Open-Label, Phase 2 Clinical Trial. JTO Clinical and Research Reports, 2022, 3, 100424.	0.6	1
2215	Äáº¶C Äiá»‚M LÃ‚M SÃ€NG, Cáº¬N LÃ‚M SÃ€NG VÃ€ Káº¾T QUáº¢ BÆ¯á»šC Äáº¦U Äiá»€U TRá»Š UNG THÆ¯ PHá»”I KHÃ”NG Táº¾ BÃ€ GEN T790M THá»¨ PHÃT Báº°NG THUá»C á»¨C CHáº¾ TYROSINE KINASE THáº¾ Há»† 3 - OSIMERTINIB. Y Hoc Viet Nam, 2022, 519, .	0.0	1

#	Article	IF	Citations
2216	Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation. Frontiers in Oncology, 0, 12, .	1.3	4
2217	Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients â€“ an overview. Frontiers in Oncology, 0, 12, .	1.3	2
2218	Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an <scp>EGFR</scp> â€mutant <scp>NSCLC</scp> patient with acquired <scp>LMNAâ€NTRK1</scp> fusion following osimertinib resistance. Respirology Case Reports, 2022, 10, .	0.3	2
2219	Effects of voriconazole and fluconazole on the pharmacokinetics of almonertinib in rats by UPLCâ€“MS/MS. Biomedical Chromatography, 2023, 37, .	0.8	3
2221	Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients. Translational Lung Cancer Research, 2022, 11, 2064-2078.	1.3	3
2222	Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20) Tj ETQq1 1 0.784314 rgBT /Ove Targets and Therapy, 0, Volume 13, 67-73.	1.3	3
2224	Exploring histopathological and serum biomarkers in lung adenocarcinoma: Clinical applications and translational opportunities (Review). International Journal of Oncology, 2022, 61, .	1.4	7
2225	Predicting anaplastic lymphoma kinase rearrangement status in patients with non-small cell lung cancer using a machine learning algorithm that combines clinical features and CT images. Frontiers in Oncology, 0, 12, .	1.3	2
2226	Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience. Current Oncology, 2022, 29, 8374-8389.	0.9	8
2227	EGFR testing in paraffin-embedded cell block cytology material is reliable with increased detection for effusion fluid. Lung Cancer, 2022, 174, 97-103.	0.9	5
2228	TARGET National: A UK-wide Liquid-based Molecular Profiling Programme. Clinical Oncology, 2022, , .	0.6	0
2229	Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5-14.	1.2	3
2230	Durable clinical response to immunotherapy in EGFR-mutated lung adenocarcinoma with squamous cell carcinoma transformation and high expression of PD-L1 after resistance development: A case report. Current Problems in Cancer Case Reports, 2022, 8, 100199.	0.1	0
2231	State of Art of LM Therapies: Intrathecal and Systemic Approaches. , 2022, , 101-124.		0
2232	Construction of IMMS containing multi-site liposomes for Dynamic Monitoring of Blood CTC in Patients with Osimertinib-resistant Non-small-cell Lung Cancer and Its Mechanism. Anti-Cancer Agents in Medicinal Chemistry, 2022, 23, .	0.9	1
2233	The effect of <scp>EGFRâ€TKIs</scp> on survival in advanced nonâ€smallâ€cell lung cancer with <scp>EGFR</scp> mutations: A realâ€world study. Cancer Medicine, 0, , .	1.3	2
2234	Singleâ€cell RNA sequencing reveals cellular and molecular reprograming landscape of gliomas and lung cancer brain metastases. Clinical and Translational Medicine, 2022, 12, .	1.7	12
2235	Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	1

#	Article	IF	Citations
2236	Targeting exon 20 insertion mutations in lung cancer. Current Opinion in Oncology, 0, Publish Ahead of Print, .	1.1	1
2237	Anlotinib plus chemotherapy for <scp>T790M</scp>â€negative <scp>EGFR</scp>â€mutant <scp>nonâ€sqNSCLC</scp> resistant to <scp>TKIs</scp>: A multicenter phase 1b/2 trial. Thoracic Cancer, 2022, 13, 3496-3503.	0.8	1
2238	Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study. European Journal of Cancer, 2023, 179, 15-24.	1.3	5
2239	The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC. Biomedicine and Pharmacotherapy, 2022, 156, 113959.	2.5	4
2240	<scp>Pyroleâ€based EGFR</scp> inhibitors for the treatment of <scp>NCSLC</scp>: Binding modes and <scp>SARs</scp> investigations. Chemical Biology and Drug Design, 2023, 101, 195-217.	1.5	2
2241	BeitrÃge zu Kombination von Immun-Checkpoint-Inhibitoren und Chemotherapie beim nicht-kleinzelligen Bronchialkarzinom. Karger Kompass Pneumologie, 2017, 5, 233-234.	0.0	0
2242	Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in nonâ€“small cell lung cancer. Bioorganic and Medicinal Chemistry Letters, 2023, 80, 129084.	1.0	3
2243	Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. , 2022, , 153-172.		1
2244	Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211440.	1.4	7
2245	ASTRIS, estudio de mundo real con osimertinib en pacientes EGFR mutados, progresados con T790M. , 2018, 23, .		0
2246	Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples. Cancers, 2022, 14, 5859.	1.7	0
2247	Identification of super-enhancer-driven peptidyl arginine deiminases as potential biomarkers and therapeutic targets for osimertinib-resistant non-small cell lung cancer. Frontiers in Pharmacology, 0, 13, .	1.6	0
2248	Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS). International Journal of Clinical Oncology, 0, , .	1.0	0
2249	Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer. Genes, 2022, 13, 2183.	1.0	3
2250	Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma. Cancer Biomarkers, 2022, , 1-12.	0.8	0
2251	Possible heart failure caused by osimertinib in a lung cancer patient. Journal of Oncology Pharmacy Practice, 2023, 29, 1015-1020.	0.5	1
2252	Notch pathway regulates osimertinib drugâ€tolerant persistence in <scp>EGFR</scp>â€mutated nonâ€“smallâ€cell lung cancer. Cancer Science, 2023, 114, 1635-1650.	1.7	9
2253	EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives. European Medical Journal (Chelmsford, England), 0, , .	3.0	0

#	Article	IF	Citations
2254	Endobronchial ultrasoundâ€guided reâ€biopsy of nonâ€“small cell lung cancer with acquired resistance after <scp>EGFR</scp> tyrosine kinase inhibitor treatment. Thoracic Cancer, 0, , .	0.8	1
2255	Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy. European Journal of Cancer, 2023, 181, 53-61.	1.3	5
2256	Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAEÂ® to Provide Two Distinct and Complementary Perspectives. Patient Related Outcome Measures, 0, Volume 13, 249-258.	0.7	5
2257	Clinical case of long-term disease control in a patient with <i>EGFR</i>-positive non-small cell lung cancer. Meditsinskiy Sovet, 2022, , 154-159.	0.1	1
2258	The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells. Npj Precision Oncology, 2022, 6, .	2.3	5
2259	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Molecular Biomedicine, 2022, 3, .	1.7	8
2260	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. Journal of Hematology and Oncology, 2022, 15, .	6.9	46
2261	Cardiac toxicity of EGFR â€“ 3rd generation TKI in patients with metastatic non-small cell lung cancer. Case report and literature data update. Technium BioChemMed, 2022, 4, 10-16.	0.2	0
2263	Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. International Journal of Molecular Sciences, 2022, 23, 15056.	1.8	32
2264	Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer. Cancers, 2023, 15, 504.	1.7	14
2265	Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	1.3	2
2266	Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study. JTO Clinical and Research Reports, 2023, 4, 100459.	0.6	4
2267	Unravelling the genetic links between Parkinsonâ€™s disease and lung cancer. Biological Chemistry, 2023, 404, 551-567.	1.2	1
2268	Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies. Targeted Oncology, 2023, 18, 9-24.	1.7	6
2269	Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy. Molecular Pharmaceutics, 2023, 20, 829-852.	2.3	13
2270	Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Nonâ€“Small-Cell Lung Cancer in the United States. JCO Precision Oncology, 2023, , .	1.5	2
2271	The metabolism and pharmacokinetic study of deuterated osimertinib. Biopharmaceutics and Drug Disposition, 0, , .	1.1	0
2272	Circulating immune response proteins predict the outcome following disease progression of osimertinib treated epidermal growth factor receptor-positive non-small-cell lung cancer patients. Translational Lung Cancer Research, 2023, 12, 14-26.	1.3	1

#	Article	IF	Citations
2273	Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer. Journal of Personalized Medicine, 2023, 13, 167.	1.1	5
2274	Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery. International Journal of Nanomedicine, 0, Volume 18, 263-276.	3.3	3
2275	Updates in pathology and molecular diagnostics to inform the evolving landscape of thoracic surgery and oncology. Journal of Surgical Oncology, 2023, 127, 244-257.	0.8	1
2276	Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2023, 9, 261.	3.4	4
2277	Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Nonâ€“small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2023, 24, 278-286.	1.1	3
2278	The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study. Scientific Reports, 2022, 12, .	1.6	0
2279	Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Nonâ€“Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. Journal of Clinical Oncology, 2023, 41, 1830-1840.	0.8	84
2280	FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC. Pathology and Oncology Research, 0, 29, .	0.9	4
2281	Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021. JAMA Network Open, 2023, 6, e2252562.	2.8	8
2282	Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options. Cancers, 2023, 15, 841.	1.7	15
2283	Current clinically validated applications of liquid biopsy. , 2023, , 63-81.		0
2284	Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance. Expert Review of Anticancer Therapy, 2023, 23, 187-198.	1.1	3
2285	Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer. Anticancer Research, 2023, 43, 725-732.	0.5	1
2286	Historical development of EGFR-targeted therapy. , 2023, , 1-11.		0
2288	CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	5
2289	Upfront and repeated stereotactic radiosurgery in patients with brain metastases from NSCLC. Clinical Lung Cancer, 2023, , .	1.1	0
2290	A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data. Future Oncology, 2023, 19, 61-75.	1.1	1
2291	Pharmacokinetic and doseâ€finding study of osimertinib in patients with impaired renal function and low body weight. Cancer Science, 2023, 114, 2087-2097.	1.7	6

#	Article	IF	Citations
2292	Káº¿t quáº£ sá»‘ng thÃªm vÃ yáº¿u tá»‘ tiÃªn lÆ°á»£ng trÃªn bá»‡nh nhÃ¢n ung thÆ° phá»•i khÃ´ng táº¿ bÃo nhá»giai Ä‘oáº¡n muá»™n k tyrosine kinase tháº¿ há»‡ 1, 2 Ä‘iá»u trá»‹ phÃ¡c Ä‘á»“ paclitaxel - carboplatin. Tap Chi Nghien Cuu Y Hoc, 2023, 160, 266-274.	0.0	0
2293	Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2023, 34, 339-357.	0.6	118
2294	Adjuvant therapies in stages Iâ€“III epidermal growth factor receptor-mutated lung cancer: current and future perspectives. Translational Lung Cancer Research, 2023, 12, 824-836.	1.3	2
2295	Realâ€world data on efficacy and safety of osimertinib in nonâ€small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy. Asia-Pacific Journal of Clinical Oncology, 2023, 19, 715-722.	0.7	0
2296	Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. Current Cardiology Reports, 2023, 25, 269-280.	1.3	6
2297	Multiple cardiotoxicities during osimertinib therapy. Journal of Oncology Pharmacy Practice, 0, , 107815522311643.	0.5	1
2298	Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study. Investigational New Drugs, 2023, 41, 306-316.	1.2	3
2299	Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. Cell Communication and Signaling, 2023, 21, .	2.7	7
2300	Effects of Ephedra Herb extract on the expression of EGFR-activating mutations and c-Met in non-small-cell lung cancer cell line, H1975, and its combined effects with osimertinib. Journal of Natural Medicines, 0, , .	1.1	0
2301	Noninvasive genomic profiling of somatic mutations in oral cavity cancers. Oral Oncology, 2023, 140, 106372.	0.8	1
2302	Acquired resistance mechanisms to osimertinib: The constant battle. Cancer Treatment Reviews, 2023, 116, 102557.	3.4	1
2303	NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature. Current Problems in Cancer Case Reports, 2023, 10, 100232.	0.1	0
2304	Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer. Oncologie, 2022, 24, 613-648.	0.2	8
2305	A Wnt/β-catenin signaling inhibitor, IMU1003, suppresses the emergence of osimertinib-resistant colonies from gefitinib-resistant non-small cell lung cancer cells. Biochemical and Biophysical Research Communications, 2023, 645, 24-29.	1.0	2
2306	Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. Cancers, 2023, 15, 629.	1.7	7
2307	Is There a Unicorn Among the Uncommon EGFR Mutations?. Journal of Thoracic Oncology, 2023, 18, 129-132.	0.5	1
2308	Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients. Frontiers in Oncology, 0, 12, .	1.3	3
2309	Molekulare Diagnostik und molekulares Tumorboard. , 2022, , 359-376.		2

#	Article	IF	Citations
2310	A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. Lung Cancer, 2023, 177, 44-50.	0.9	2
2311	Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. European Journal of Cancer, 2023, 183, 38-48.	1.3	8
2312	Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report. Anti-Cancer Drugs, 0, Publish Ahead of Print, .	0.7	2
2313	Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry, 2023, 66, 2566-2588.	2.9	5
2314	Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2â€“IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer, 2023, 24, 376-380.	1.1	10
2315	The development and implementation of EGFR inhibitors in advanced NSCLC. , 2023, , 13-36.		0
2316	Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelialâ€“Mesenchymal Transition. Cancers, 2023, 15, 1092.	1.7	1
2317	The safety profile of EGFR/ALK-TKIs administered immediately before or after ICIs in advanced NSCLC. International Immunopharmacology, 2023, 116, 109787.	1.7	1
2318	CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell, 2023, 41, 340-355.e6.	7.7	23
2319	Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?. Journal of Clinical Medicine, 2023, 12, 1438.	1.0	6
2320	The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study. Annals of Translational Medicine, 2023, 11, 157-157.	0.7	2
2321	Kết QUả¢ Äá»€U TRá»Š BỆNH UNG THƯ PHá»”I KHÔNG Tế BÀO NHỎ CÃ“ Äá»˜T Blá»‹ Hoc Viet Nam, 2023, 521, .	0.0	1
2322	Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. Journal of Biochemical and Molecular Toxicology, 2023, 37, .	1.4	2
2324	Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer. PharmacoEconomics - Open, 0, , .	0.9	1
2325	Development and validation of an LC-MS/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics. Xenobiotica, 0, , 1-9.	0.5	0
2326	Safety, efficacy, and pharmacokinetics of SHâ€1028 in EGFR T790Mâ€positive advanced nonâ€“small cell lung cancer patients: A doseâ€escalation phase 1 study. Cancer, 2023, 129, 1513-1522.	2.0	3
2327	Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions. Frontiers of Medicine, 2023, 17, 18-42.	1.5	8
2328	Efficacy and safety of osimertinib plus anlotinib in advanced nonâ€smallâ€cell lung cancer patients after drug resistance. Thoracic Cancer, 2023, 14, 873-880.	0.8	3

#	Article	IF	Citations
2329	Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications, 2023, 14, .	5.8	38
2331	Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature Communications, 2023, 14, .	5.8	24
2332	Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 102-138.	0.5	14
2333	Precision Surgery in NSCLC. Cancers, 2023, 15, 1571.	1.7	5
2334	Intracranial efficacy and safety of furmonertinib 160â€‰mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy. BMC Cancer, 2023, 23, .	1.1	4
2335	Realâ€world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multiâ€center study. Cancer Science, 2023, 114, 2552-2559.	1.7	1
2336	Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. Critical Reviews in Oncology/Hematology, 2023, 184, 103954.	2.0	3
2337	Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutationâ€“Positive, MET-Amplified Nonâ€“Small Cell Lung Cancer Model. Molecular Cancer Therapeutics, 2023, 22, 679-690.	1.9	0
2338	A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. ESMO Open, 2023, 8, 101183.	2.0	7
2339	Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. BMC Cancer, 2023, 23, .	1.1	5
2340	Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research, 2023, 29, 2123-2130.	3.2	6
2341	Acquired L718V/TP53 co-mutation and discordant molecular pattern between plasmatic and cerebrospinal fluid in a bone and meningeal metastatic L858R+ non-small cell lung cancer: a case report. Annals of Translational Medicine, 2023, 11, 223-223.	0.7	0
2342	Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance. Translational Lung Cancer Research, 2023, .	1.3	0
2343	Plasma-derived immune-related factors as biomarkers of osimertinib resistance in EGFR-mutant non-small cell lung cancer patients. Translational Lung Cancer Research, 2023, 12, 405-407.	1.3	0
2344	CT Radiomics Predict EGFR-T790M Resistance Mutation in Advanced Non-Small Cell Lung Cancer Patients After Progression on First-line EGFR-TKI. Academic Radiology, 2023, 30, 2574-2587.	1.3	3
2345	Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma. International Journal of Molecular Sciences, 2023, 24, 6410.	1.8	3
2346	New targeted therapies for non-small cell lung cancer. Journal of the Korean Medical Association, 2023, 66, 180-190.	0.1	0
2347	Recent trends of characteristics and treatments in adults with newly diagnosed brain metastases. Japanese Journal of Clinical Oncology, 0, , .	0.6	2

#	Article	IF	Citations
2348	Incidence of bone metastases and skeletal related events in patients with epidermal growth factor receptor mutated non-small cell lung cancer treated with osimertinib. JTO Clinical and Research Reports, 2023, , 100513.	0.6	0
2349	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39.		0
2350	Treatment failure shortcomings, possible causes and upcoming phyto-optimism in oral cancer. The Applied Biology & Chemistry Journal, 0, , 4-27.	0.0	0
2351	Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. EClinicalMedicine, 2023, 59, 101955.	3.2	1
2352	Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting. BMC Cancer, 2023, 23, .	1.1	1
2353	Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies. Lung Cancer, 2023, 180, 107194.	0.9	0
2354	Simultaneous Quantitation of Anlotinib and Osimertinib by Isotope-Labeled UHPLCâ€“MS/MS in Human Plasma: Application in NSCLC Patients. Journal of Chromatographic Science, 0, , .	0.7	1
2355	Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines. ACS Medicinal Chemistry Letters, 0, , .	1.3	0
2356	Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer. JCO Oncology Practice, 2023, 19, 345-351.	1.4	2
2357	Personalized treatment for patients with lung cancer. Deutsches Ärzteblatt International, 0, , .	0.6	0
2358	Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis. PharmacoEconomics - Open, 2023, 7, 617-626.	0.9	1
2359	Growth Factors and Cancer. , 2023, , 187-241.		0
2360	Role of molecular testing for malignant pleural effusion in targeted therapy for advanced nonâ€small cell lung cancer. Diagnostic Cytopathology, 2023, 51, 397-405.	0.5	0
2361	Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer. Technology in Cancer Research and Treatment, 2023, 22, 153303382311684.	0.8	0
2363	Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study. Lung Cancer, 2023, 180, 107213.	0.9	1
2364	Fatal ventricular arrhythmias after osimertinib treatment for lung adenocarcinoma: a case report. Journal of Geriatric Cardiology, 2023, 20, 242-246.	0.2	3
2370	Genetic and Epigenetic Dysregulation in Environmental Disease. , 2024, , 465-492.		0
2398	Iatrogenic Conditions. , 2023, , 871-905.		0

#	Article	IF	Citations
2424	Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges. Journal of Medicinal Chemistry, 2023, 66, 8339-8381.	2.9	13
2437	Health Care Management: Cancer Prediction and Diagnosis Using Artificial Intelligence (AI). Lecture Notes in Mechanical Engineering, 2023, , 99-108.	0.3	0
2450	Recent advances in targeting the â€œundruggableâ€•proteins: from drug discovery to clinical trials. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	11
2490	Epidermal growth factor receptorâ€“mutated nonâ€“small cell lung cancer: a clinical approach. , 2024, , 217-252.		0
2496	Treatment of Stage IV Non-small Cell Lung Cancer. Respiratory Medicine, 2023, , 165-186.	0.1	0
2579	Somatic mutation: Pharmacogenomics in oncology care. , 2024, , 329-356.		0
2581	Case report: Acute pancreatitis in lung adenocarcinoma with small cell transformation after multiple line targeted therapy. Frontiers in Oncology, 0, 14, .	1.3	0
2607	Advancing Precision Medicine. , 2024, , 1-31.		0